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General introduction
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Myotonic dystrophies
The myotonic dystrophies (DM) are dominantly inherited muscle disorders, and are the most 
common of the genetic muscle diseases with a worldwide prevalence of 5 -  12 / 100,000 
(Table 1.1). There are presently two types of DM. The clinical features include myotonia, 
progressive muscle weakness and atrophy. Besides being muscle disorders, myotonic 
dystrophies are multisystem diseases, characterised by cataracts, cardiac conduction 
defects, gastrointestinal features, insulin resistance and cognitive impairment.
Table 1.1 Inherited muscle disorders and their prevalence.1
Disorder Point prevalence / 100,000
Myotonic dystrophies 10.6
Duchenne muscular dystrophy 8.3 (excluding female carriers)
Becker muscular dystrophy 7.3 (males only)
Facioscapulohumeral muscular dystrophy 4.0
Limb girdle muscular dystrophies 2.3
Spinal muscular atrophies 1.9
Oculopharyngeal muscular dystrophy 0.1
Myotonic dystrophy type 1
Historical notes
The first descriptions that mark the clear delineation of myotonic dystrophy type 1 (DM1) as a 
disorder date from 1909.23 Dr. Hans Steinert published a paper on a clinical entity that was 
new at that time; an autosomal dominant myotonic dystrophy. Steinert already emphasized 
the multisystem aspect of the disease:
Sehr auffallend ist das rasche Nachlassen der Fähigkeit, zu schlucken. (p 62)
Zunächst ein Kuriosum, das zu der grossen äusseren Ähnlichkeit, die viele der Fälle unter 
einander zeigen, immerhin beiträgt: die partielle Kahlköpfigkeit. (p 81)
Eine Reihe mehr oder minder häufiger Einzelzüge und Begleiterscheinungen heben die 
Eigenart des Bildes noch schärfer hervor. Nur an die verhältnismässig häufige Impotenz und 
Atrophie der Hoden möchte ich hier noch einmal besonders erinnern. (p 103)
In the decades to come the field of DM1 (OMIM 160900) research was mainly characterised 
by detailed clinical studies expanding the phenotype. The involvement of organs aside from 
skeletal muscle, such as the eyes, the endocrine system, and the skin became evident. The 
occurrence of mental changes and cardiorespiratory problems appeared to be of main
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importance. The severe congenital form was recognized in I960.4 After several decades of 
research and discussion Howeler provided convincing evidence for the existence of 
anticipation (progressively younger onset of the disease with increasing severity in 
successive generations within a family) in DM1 in 1986.5 Although the presence of 
gastrointestinal dysfunction, notably swallowing, was already recognized by Steinert, interest 
in this feature of DM1 and the mechanisms behind gastrointestinal symptoms has been 
resurrected seventy years later.6-8
A milestone in DM research was the discovery in 1992 of the first gene that was associated 
with DM. This gene was designated DMPK gene (dystrophica myotonica protein kinase) and 
the mutation consisted of an expanded trinucleotide (CTG) repeat in a noncoding part of the 
gene on chromosome 19q.9-11 Myotonic dystrophy type 1 was the third of what is now a list of 
over 30 trinucleotide repeat expansion disorders, which at that time included fragile X 
syndrome and spinobulbar muscular atrophy.
Figure 1.1 A 31-year old patient with adult-onset myotonic dystrophy type 1, showing weakness and 
atrophy of the facial muscles, wasting of the temporalis muscle and frontal balding.
Clinical aspects of myotonic dystrophy type 1
From a clinical point of view DM1 is classified in four different (pheno)types: the mild, adult, 
childhood and congenital type.12 The mild type, with onset after the age of 50, is 
characterised by early-onset of cataracts (before 50 years of age), and a late-onset 
myopathy may develop. In the adult-onset type, age of onset is typically in the second 
decade of life, but may vary between 12 and 50 years. The most frequent symptoms are 
slowly progressive weakness and myotonia. The childhood-onset type, with age at onset 
between 1 and 12 years, is clearly associated with cognitive and behavioural abnormalities, 
e.g. difficulties in learning and socialization at school. Muscle involvement may be minimal in 
the childhood presentation. In the congenital type polyhydramnios and poor fetal movements 
precede the birth of an infant with this severe type of DM1. The infant is typically a floppy 
newborn with failure to thrive and severe respiratory distress. Facial and jaw muscles are
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weak and produce a tented upper lip that causes feeding and sucking difficulties. Clubfeet 
and joint contractures are common, as well as mental retardation and development delay 
(Table 1.2).
Table 1.2 The four phenotypes of DM1, age at onset, symptoms and size ranges of CTG repeats in 
the DMPK  gene.
Phenotype Age at onset Symptoms Number of repeats
Mild >50 years cataract 51 -  80
Adult 12-50 years myotonia, 
muscle weakness, 
cataract, fatigue
100 -  1000
Childhood 1-12 years learning difficulties, 
speech difficulties, 
hypotonia
500 -  2000
Congenital birth hypotonia, respiratory and 
swallowing problems, 
club feet, mental retardation
1000 -  5000
Figure 1.2 A 47 year-old patient with severe adult-onset myotonic dystrophy type 1. Typical facial 
appearance showing atrophy of the facial muscles and ptosis, and distal limb atrophy.
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Myotonic dystrophy type 2
History
In 1994, Ricker described a new disorder, similar to but distinct from DM1, characterised by 
mainly proximal muscle weakness, myotonia, cataracts, and autosomal dominant 
inheritance. In contrast to DM1, no abnormal CTG-repeat expansion of the DMPK gene in 
DNA from blood or muscle was identified.13 He coined the term proximal myotonic myopathy 
(PROMM) as a phenotype description. In the same year, Thornton described a DM-like 
disorder in three patients from two families with myotonia and muscle weakness, cataracts, 
cardiac conduction abnormalities, frontal balding and testicular atrophy, which did not show 
an abnormal expansion of CTG-repeats within the DMPK gene.14
In 1997, Udd described proximal myotonic dystrophy (PMD) in a family with an autosomal 
dominant, multisystem disorder, consisting of late-onset proximal muscular dystrophy, 
electrophysiological myotonia, cataracts, late-onset deafness and male hypogonadism.15 The 
clinical findings differ from those described in PROMM, in terms of the more severe muscle 
involvement with atrophy of affected muscles and the hearing loss. Molecular examination of 
genomic DNA showed no expansion of the CTG-repeat on chromosome 19q 13.3 and linkage 
to the muscle chloride channel (CLCN1) gene, and the muscle sodium channel (SCN4A) 
gene was assessed and excluded.
One year later, Day identified a five-generation family in which affected individuals exhibited 
remarkable clinical similarity to DM1 including myotonia, proximal and distal limb weakness, 
frontal balding, cataracts, infertility and cardiac arrhythmias but did not have the CTG-repeat 
expansion of the DMPK gene. They designated the disorder as myotonic dystrophy type 2 
(DM2) and mapped the disease locus of the family to a 10-cM region of chromosome 3q.16,17
Figure 1.3 Atrophy of the proximal arm muscles in a patient with myotonic dystrophy type 2.
A second milestone in DM research was the discovery in 2001 of the genetic defect 
responsible for this recent form of multisystem myotonic disorder. The mutation was 
identified as a tetranucleotide (CCTG) expansion in intron 1 of the ZNF9 gene located on 
chromosome 3q.18 Expanded allele sizes ranges from 75 to approximately 11,000 CCTG-
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repeats, with a mean of 5,000 repeats. The three phenotypes (PROMM, PMD and DM2) 
were found to rely on the same mutation in the ZNF9 gene on chromosome 3q21.
DM2 is the only tetranucleotide repeat expansion disorder, which makes DM2 unique among 
the repeat-associated disorders.
Clinical aspects of myotonic dystrophy type 2
Myotonic dystrophy type 2 (OMIM 602668) is a clinically heterogeneous multisystem disorder. 
Patients with DM2 may be asymptomatic, mildly affected, or considerably disabled and 
wheelchair dependant. Clinical onset of DM2 is usually between 20 and 60 years of age.19,20 
Day reported a mean age of onset of 37 years with a range of 13-67 years.21 Symptoms and 
severity vary greatly among family members and between generations.
The core clinical features are proximal muscle weakness, myotonia, muscle pain and 
cataracts. The characteristic pattern of muscle weakness involves hip flexors and extensors, 
neck flexors, elbow extensors, and deep finger and thumb flexors. Diabetes mellitus, gonadal 
atrophy, cardiac conduction defects, hypothyroidism and reduced levels of immunoglobulin G 
and M can also be present.21 Contrary to DM1 there is minimal cognitive impairment or 
respiratory insufficiency and no or only mild involvement of the facial muscles (Figure 1.4). 
DM2 is associated with deafness in one or two cases.22 Notably absent is a congenital form 
of DM2. Although there is evidence of anticipation, it is clearly less striking than in DM1.21 
Progression of the disease is slow and the prognosis and life expectancy are more 
favourable than in DM1.19 Life expectancy may be reduced in some DM2 cases, mainly if 
there is severe cardiac involvement with malignant rhythm abnormalities.23-25
{
V
fit
Figure 1.4 DM2 patients; no or only mild involvement of the facial muscles is demonstrated.
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The following cases illustrate the variability of symptoms of DM2, and the difficulty in 
identifying them.
Case 1
A 30-year old man presented with painful muscle cramps, fatigue and muscle stiffness in rest as well 
as after physical activity. Symptoms started at the age of 25. Clinical neurological examination 
revealed mild action myotonia in thenar muscles. No evident weakness or muscle atrophy was found. 
Laboratory screening revealed an abnormal elevated CK (322 U/L). Nerve conduction studies were 
normal, electromyography showed myopathic changes in the deltoid muscle. Muscle biopsy showed 
unspecific myopathic changes, and myophosphorylase staining was normal. Myotonic dystrophy type
1, Pompe disease, facioscapulohumeral disease were excluded by genetic testing and McArdle’s 
disease was excluded histological. Symptoms progressed and expanded. Climbing stairs and lifting of 
the arms above the head became a problem and tremor of the hands developed. He furthermore 
suffered from dysphagia, reflux and diarrhea. Despite a desire for children that he shared with his wife 
they had had no children. Patient’s concentration diminished and his bilingualism decreased. 
Neuropsychological testing demonstrated a diminished attention and frontal executive dysfunction. He 
had to stop working as a nurse because of the high physical demands and because of his cognitive 
impairment. Twelve years after the first medical consultation, at the age of 42, the diagnosis myotonic 
dystrophy type 2 was made on genetic analysis.
Case 2
A 27-year old man complained of stomach fullness, bloating and regurgitation of liquids, which did not 
improve essentially after a nissen fundoplication surgery. A year later he was diagnosed with having 
hypothyroidism after complaints of feeling constant malaise and continued stomach complaints. 
Gallbladder removal did not improve the abdominal pain. He was referred to a neurologist at the age 
of 34 because of oesophageal dysmotility, fatigue, muscle pain and constipation. Neurological 
examination only revealed mild weakness in the sternocleidomastoid muscles. Laboratory screening 
revealed only slightly elevated CK (204 U/L). Electromyography showed increased insertional activity 
in the left opponens pollicis muscle, fibrillation potentials in the left biceps, and tibialis anterior 
muscles, and short runs of myotonic discharges in the left deltoid, biceps brachii and T9 paraspinal 
muscles. Slit lamp eye examination demonstrated posterior, subcapsular, iridescent, lens opacities. 
DNA analysis verified the myotonic dystrophy type 2 mutation. He has since also been diagnosed with 
diabetes insipidus and episodic immunodeficiency.
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Prevalence of myotonic dystrophy type 2
The exact prevalence and incidence of DM2 are unclear, and vary geographically. The 
condition is not described in comparable population study papers. The estimate of 1 in 
100,000 in Germany as discussed in the report of the 115th European Neuromuscular Centre 
workshop was considered to be the minimum prevalence.26 Ricker considered DM2 to have 
a prevalence similar to that of DM1, thus 1 in 8,000 worldwide.19 The apparently high 
prevalence in some countries (Germany) and low prevalence in others (e.g. United Kingdom) 
may possibly be due to a founder effect, but may also relate to availability of molecular tests 
and particular research interests.27,1 In Finland, an overall DM2 mutation frequency of 1 in 
2,250 was recently estimated on the basis of DNA samples obtained from blood donors.28
Differential diagnosis
Diagnosis of DM2 is suspected clinically and confirmed by DNA analysis. Genetically 
unconfirmed DM2 patients may have DM1 or other neuromuscular disorders, like 
facioscapulohumeral disease, limb-girdle muscular dystrophy, polymyositis, inclusion body 
myositis, mitochondriopathy, or late-onset glycogen storage disease, e.g. acid maltase 
deficiency.29 Furthermore, the non-dystrophic myotonias (myotonia congenita, paramyotonia 
congenita, hyperkalemic periodic paralysis and potassium aggravated myotonia) and thyroid 
diseases need to be considered in the differential diagnosis of DM2 (Table 1.3).30
Table 1.3 Differential diagnosis of myotonic dystrophy type 2.
Motor neuron disorders spinal muscular atrophy type 3b and 4 
adult-onset progressive muscular atrophy
Dystrophies myotonic dystrophy type 1 
limb-girdle muscular dystrophies
Myopathies facioscapulohumeral disease 
steroid-induced myopathy 
sarcoid myopathy 
polymyositis 
inclusion body myositis 
necrotizing autoimmune myositis
Non-dystrophic myotonias myotonia congenita 
paramyotonia congenita 
hyperkalemic periodic paralysis 
potassium-aggravated myotonia
Metabolic disorders hypo- and hyperthyroidism 
hypopotassemia 
hyperparathyroidism 
vitamin D deficiency
late-onset glycogen storage disease, e.g. acid maltase deficiency 
mitochondriopathy
Rheumatic disorders fibromyalgia
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Molecular pathogenesis of the myotonic dystrophies
The molecular basis of both DM1 and DM2 is a repeat instability in a noncoding part of a 
gene. DM1 is caused by a trinucleotide (CTG) repeat within the DMPK on chromosome 
19q13.3. DM2 is caused by a tetranucleotide (CCTG) expansion within intron 1 of the ZNF9 
gene on chromosome 3q21.3 (Figure 1.5). The number of CTG-repeat units in a stable 
nonpathogenic DMPK allele ranges between 5 and 36. DMPK alleles containing over 36 CTG- 
repeat units may be transmitted in an unstable way. Alleles containing a CTG-repeat with a 
length of 51-200 may be asymptomatic or may give rise to mild or adult-onset DM1. A more 
severe DM1 phenotype is associated with DMPK alleles with sizes >200 CTG-repeat units. 
Thus, the severity of the disease and the age of onset is correlated with the number of CTG- 
repeat units within the expanded DNA sequence, although the individual variability is high.31-33 
In general an increasing number of CTG-repeat units within the DMPK gene in subsequent 
generations in a family corresponds with an earlier onset of the disorder (anticipation). The 
DM1 parental sex plays an important role in determining the level of intergenerational 
instability. The increase of CTG-repeat units is on average higher by maternal transmission 
compared to paternal transmission.34 Severe expansions are transmitted almost exclusively 
through female meioses, explaining why congenital DM1 is virtually exclusively transmitted by 
the mother.
The ZNF9 CCTG-repeat tract is part of a complex motif that may contain up to 26 repeat 
units in nonpathogenic alleles. In DM2 patients, the range of repeat units in the expanded 
CCTG-tract is extremely wide, ranging from 75 to over 11,000 units, with a mean of 5,000.18 
The CCTG-repeat tract in affected children is often smaller compared to their affected parent, 
a phenomenon called retraction. However, the age-related somatic increase that 
characterizes each patient complicates the interpretation of these data.18 Unlike in DM1, 
there is no significant correlation between the age of onset in DM2 and the number of CCTG- 
repeats.35 It has been demonstrated that CUG- and CCUG-containing transcripts accumulate 
in ribonuclear foci in cells in both DM1 and DM234, altering the regulation and localization of 
the CUG-binding protein (CUG-BP)36 and three different forms of the RNA-binding protein 
Muscleblind-like 1 (MBNL1 ).37,38 Both proteins play a role in affecting alternative splicing 
through antagonistic effects, in which CUG-BP promotes the inclusion of exons that are 
normally expressed during fetal development, whereas MBNL1 favors the adult splicing 
isoform.39 Changes in the regulation of these proteins can cause aberrant splicing of down­
stream genes expressed in DM target tissues. Dysregulation of the insulin receptor, the 
chloride channel 1, the skeletal ryanodine receptor and the sarcoplasmic reticulum Ca2+- 
ATPase mRNAs has been observed in muscle cells from DM patients, confirming the 
hypothesis of a pathogenic role for the expanded DMPK and ZNF9 mRNAs (Figure 1.5).40-44
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Figure 1.5 RNA model of 
pathogenesis in DM1 and 
DM2 showing that a gain-of- 
function RNA mechanism 
underlies the clinical features 
common to both 
(reprinted with permission).
diseases
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Treatment of myotonic dystrophy type 2
Until date, there is no cure for DM2. The disorder can only be treated symptomatically, 
preferable via a multidisciplinary approach by a neurologist, a cardiologist, a pulmonologist, 
an ophthalmologist, and a rehabilitation specialist. Treatment with NSAID, carbamazepine or 
corticosteroids, has been reported to ameliorate myalgia in one or two cases.46 Mexilitine, 
phenytoine, or carbamazepine may be beneficial in patients in whom myotonia persists, but 
no data supporting the effectiveness of these drugs in DM2 are available. Cataracts may 
require surgical treatment. Active management of DM2 patients involves monitoring expected 
complications of the disease. Patients should undergo cardiologic examinations as soon as 
the diagnosis is established. Cardiac therapy, including implantation of pacemakers, may be 
necessary in the case of symptomatic rhythm abnormalities.
The risk of perioperative complications is rather low in DM2, and seems to be predominantly 
related to the minor respiratory involvement in DM2.46 Nevertheless, good clinical 
perioperative practice is strongly recommended and prospective data on general 
anaesthesia and the post-operative period are needed.
Table 1.4 Historical overview of the myotonic dystrophies.
1909 First descriptions of DM1 Steinert, Batten and Gibb
1960 Recognition of congenital DM1 Vanier
1986 Existence of anticipation in DM1 Howeler
1992 CTG-expansion in the DM1-gene Brook, Fu, Mahadevan
1994 Description of PROMM Ricker
2001 CCTG-expansion in the DM2-gene Liquori
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Aims and outline of the Thesis
When routine DNA analysis for proximal myotonic myopathy (PROMM) became available in 
2002 we genetically confirmed the first Dutch DM2 patients in the Neuromuscular Centre 
Nijmegen in collaboration with other Dutch neuromuscular centres.
It was acknowledged that physicians may not be familiar with the disease, particularly in the 
case of a newly described and rare disorder like DM2.48,49 Data on the clinical picture and 
natural course of the disease are essential to reduce considerably delay in the diagnosis and 
management.
We observed for the first time that gastrointestinal complaints such as dysphagia, abdominal 
pain and constipation were frequently mentioned symptoms. We assumed that these 
symptoms suggested the involvement of smooth muscle in this multisystem disorder, as is 
the case in DM1, in which involvement of smooth muscle is prominent and can dominate the 
clinical picture.6-8 Many DM2 patients mentioned apparently non-specific symptoms such as 
fatigue and sleep problems. It is our hypothesis that these extra-muscular symptoms are 
intrinsic to the disease itself which would have a great impact on the quality of life of DM2 
patients.
The research described in this thesis aims to accurately map out the clinical picture in 
greater detail in a nationwide relatively large series of genetically confirmed DM2 patients, 
and was intended to include the patients’ perspective in the assessment of the 
consequences of the disease. These studies lay the groundwork for further studies on the 
natural course of the disease and therapeutic intervention studies.
The first part of this thesis (Chapter 3-6) concerns the clinical studies, while the second part 
(Chapter 7-9) concerns additional investigations. Chapter 2 describes the first reported Dutch 
DM2 family. Chapter 3 and 4 review the literatures regarding what is known about 
gastrointestinal symptoms in DM2 and assess the occurrence of dysphagia, abdominal pain 
and constipation. These Chapters furthermore describe the pathophysiological hypotheses 
and present management. With management in mind the aim of Chapter 5 was to explore 
the presence of sleep disorders, fatigue and excessive daytime sleepiness in DM2. In 
Chapter 6 we describe the impact of DM2 on the patients’ physical, psychological and social 
wellbeing. In Chapter 7 we describe the observation of an association between DM2 and 
autoimmune diseases and possible explanations for this new association are proposed. The 
aim of Chapter 8 was to further objectify muscle involvement of the jaw and limb muscles 
using muscle ultrasound and to correlate the results with quantitative muscle force. The data 
on the genetics of the Dutch DM2 patients are summarised in Chapter 9. A summary and 
implications of the findings presented in this thesis are argued in Chapter 10 and guidelines 
for future research are briefly discussed.
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Abstract
A 41-year-old woman had a 15-year history of pain in her thighs and arms, which also became 
weaker, and a decrease in visual acuity. Her 35-year-old brother, their 38-year-old sister and their 64- 
year-old mother had myalgia, myotonia and proximal muscle weakness, and the women also had 
cataracts. Additional examinations and tests led to a diagnosis of proximal myotonic myopathy 
(PROMM) in all four cases. Neurological and ophthalmological follow-up was provided on a yearly 
basis, including ECG. The clinical features of PROMM display similarities to the adult-onset type of 
myotonic dystrophy (DM) but differ in the proximal localisation of the muscle weakness and the 
frequent occurrence of pain in the affected muscles. PROMM is an autosomal dominant hereditary 
multisystem disorder with a less serious progression than DM and is rarely accompanied by cognitive 
disorders. In most cases, a genetic defect on chromosome 3q21 is the cause of the disease. A 
probable diagnosis can be made based on clinical symptoms and on the results of simple laboratory 
tests, and can be confirmed by means of DNA analysis. As yet, the disorder can only be treated 
symptomatically, preferably via a multidisciplinary approach by a neurologist, an ophthalmologist, a 
cardiologist and a rehabilitation specialist.
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Introduction
Myotonic dystrophy (DM) is the most frequently occurring hereditary neuromuscular disorder: 
the incidence is 5 per 100,000 people per year.1 The disease was initially described almost 
100 years ago by Steinert and was considered the only progressive muscular dystrophy with 
myotonia until around ten years ago.2
The discovery of proximal myotonic myopathy (PROMM) in 1994 was an unexpected and 
important development.3 PROMM, also known as ‘myotonic dystrophy type 2’ and ‘Ricker’s 
disease’, is a disorder similar to DM (type 1) that is also characterised by progressive muscle 
weakness, myotonia, cataract and cardiac conduction defects and that demonstrates an 
autosomally dominant pattern of inheritance (Table 2.1).4 In addition to the clinical 
similarities, there are also differences: PROMM distinguishes itself from DM in terms of the 
mainly proximally located muscle weakness, the sparing of the facial musculature and the 
prominent occurrence of muscular pain. In addition, cognitive disorders are also absent in 
comparison with DM. There is no knowledge of a congenital form. A progressively earlier and 
more severe manifestation of the disease has been found in successive generations 
(anticipation). PROMM has not yet been described in The Netherlands, although the
Table 2.1 Diagnostic criteria for PROMM.4
Mandatory inclusion criteria Muscle weakness, predominantly proximal
Tests supporting the diagnosis Laboratory tests: creatine kinase and y-glutamyltransferase: mildly
Supportive findings
Myotonia on electromyography 
Cataracts, onset is before 50 years of age 
Autosomal dominant inheritance
Normal size of CTG repeat in the gene for myotonic dystrophy 
Muscle pain
Cardiac conduction defects
CNS symptoms: cognitive impairment, hypersomnia, seizures 
Deafness: sensorineural 
Frontal baldness 
Male hypogonadism
Insuline resistence / glucose intolerance / diabetes mellitus
Hypothyroidism
Gastrointestinal symptoms
Hyperhydrosis
of PROMM elevated or normal
Glucose tolerance testing: insulin resistance or diabetes mellitus 
Gonadal function testing: increased follicle stimulating hormone and 
luteinizing hormone, and decreased testosterone levels in males 
ECG: cardiac conduction defects
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incidence of this disease in our neighbouring country Germany is supposed to equal that of 
DM.5 DM was genetically characterised in 1992 and the gene defect that is responsible for 
PROMM in most cases was discovered in 2001, as a result of which it is now possible to 
confirm the clinical diagnosis of both of these similar diseases by means of DNA-research.6 
In cooperation with other neuromuscular centres, we recently diagnosed DM2 both clinically 
and genetically in the first 15 Dutch patients. The purpose of this article is to provide 
information on this relatively unknown disease by describing four family members (Figure 
2.1). It was initially believed that they suffered from DM, but they were eventually diagnosed 
as having PROMM, which had consequences for the treatment and counselling of these 
patients.
Case histories
Patient A (II-1; Figure 2.1), a 41-year-old woman, visited the out-patients’ clinic Neurology in 
connection with pain in her upper legs and arms, which increased with physical strain or cold, 
from which she had suffered for a period of 15 years. It had become increasingly difficult for 
the patient to take the stairs or to bicycle due to the pain and weakness in her upper legs and 
the patient experienced objects slipping from her hands more and more often. After resting, 
her legs and hands felt stiff. The patient had noticed diminishing eyesight from the age of 26; 
subcapsular cataract, for which she recently underwent surgery, was established when the 
patient was 38. The anamnesis stated hyperthyroidism that, following treatment with 
radioactive iodine, was succeeded by hypothyroidism, for which she now used levothyroxine. 
A physical examination showed a reduction in vision (0.3) of the right eye and a delayed 
relaxation after random exertion (action myotonia) of the orbiculares oculi muscles. Atrophy 
of the sternocleidomastoid muscle and the upper leg muscles was visible on both sides. The 
muscle strength had reduced in the neck flexors (degree 4 according to the scale of the 
Medical Research Council (MRC)) and proximal in the arms (MRC 4) and legs (MRC 4); the 
muscle strength was normal distally. Action myotonia could be induced in the hands, but 
percussion myotonia (delayed relaxation following percussion on the muscle belly) was 
absent.
The results of the further examination of the patients A, B, C and D are described following 
the case history of patient D.
Patient B (II-4), the 35-year-old brother of patient A, consulted a doctor in connection with 
stiffness of the upper legs that mainly occurred following a period of rest. Lifting objects was 
difficult due to weakness in the upper arms, and the patient had ceased his sports activities 
due to weakness and muscular pain in the legs. The tractus anamnesis stated complaints of 
fatigue in connected with exercise intolerance, and intestinal cramping. A physical 
examination showed frontal balding, a slight weakness of the neck flexors (MRC 4), and 
proximal muscular weakness of the arms (MRC 4) and the legs (MRC 5-). The strength was
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normal distally. The hands showed action myotonia without percussion myotonia. The other 
findings of the neurological and internal examination did not deviate.
Patient C (I-1), the 64-year-old mother of patients A and B, was examined at our request as 
part of the family examination. At the time, the patient had noticed a slight weakness of the 
muscles of her upper legs, arms and hands for a few years, but had not yet consulted with a 
doctor in that respect. It was found upon further inquiry that she experienced muscular pain 
of the legs, particularly following physical activities. The patient had undergone surgery at the 
age of 50 due to cataract; presurgery blood tests showed mildly elevated liver functions. 
Research into the cause of this, by means of a liver biopsy among other things, did not yield 
any explanation at that time.
Proximal muscular weakness was measured during a physical examination in the arms 
(MRC 3.5) and the legs (MRC 4). A slight action myotonia of the hands could be observed, 
while it was possible to induce percussion myotonia in the thenar. The other findings of the 
neurological and internal examination did not deviate.
Patient D (II-3), a 38-year-old sister of patients A and B, visited the outpatients’ clinic 
Neurology at the same time as her brother. She experienced symptoms similar to those of 
patient A. She too demonstrated no facial muscular weakness; contrary to her sister, the 
muscular strength of the sternocleidomastoid muscle was non-deviant. The further clinical 
description of this patient is not considered here.
1 2
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Q 4
Q O
Figure 2.1 The pedigree of the PROMM family: the Roman numbers represent the generations, the 
Arabic the individual persons per generation; O: female; □ : male; • ■ :  patients with proximal myotonic 
myopathy; ^  proband (patient A).
1 3
23
Figure 2.2 Typical facial weakness in a DM patient (left) is absent in a patient with PROMM (right). 
Additional examination of patients A, B, C and D
Further to the visit to the outpatients’ clinic, all of the patients were subjected to further 
examination in the form of blood tests, EMG and ECG. The findings of the further 
examination of these four patients showed similarities. Repeated laboratory research showed 
an increased creatine kinase (CK) value in all patients and abnormal elevation of liver 
enzymes (Table 2.2) in patients B, C, and D. EMG showed a normal nerve conductions in all 
patients, along with myotonic discharges in all of the proximal and distal muscles of the arms 
and legs that were examined. With the permission of patient A, a biopsy was performed on 
the quadriceps femoris muscle for scientific purposes. Studies showed an increase of type 1 
fibres (Figure 2.3). Most of the fibres had normal to increased diameters and too often 
internal nuclei. There was an increase of angular atrophic fibres (particularly type 2 fibers) 
and an increase of atrophic fibres with solely muscle fibre nuclei (nucleus clots). The ECG 
was assessed as non-deviant in all four patients. As DM was initially presumed, DNA 
diagnostics were conducted in this family. However, no CTG-expansion was found in the 
DM-gene. DNA-research into PROMM showed a strong expansion of the CCTG-repeat in 
the ZNF9-gene on chromosome 3. This confirmed the diagnosis ‘PROMM’. For the purpose 
of monitoring the clinical progression and to ensure the adequate treatment of the patients 
for their pain symptoms, it was agreed to have the patients return to the Neuromuscular 
outpatients’ clinic once a year for a consultation, a check-up by the ophthalmologist and an 
ECG.
Table 2.2 Laboratory values in 4 patients with PROMM.
Enzyme (reference values) A B C D
ASAT (<40 U/l) 25 46 68 23
ALAT (<45 U/l) 25 91 101 70
LDH (<450 U/l) 437 447 581 239
Y-GT (f<35 U/l, m<50 U/l) 41 123 382 276
CK (f< 150 U/l, m<200 U/l) 158 917 490 287
ASAT= aspartate aminotransferase; ALAT= alanine aminotransferase; LDH= lactate dehydrogenase; y-GT= y -  
glutamyltransferase; CK=creatine kinase. Deviating values are in bold.
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Figure 2.3 Muscle biopsy (H&E-staining) of the vastus lateralis of patient A shows increase of 
hypertrophic fibers and central nuclei. In the middle a small angulated atrophic muscle fibre and two 
fibres of which only the nuclei rest (nuclear clumps; arrows).
Discussion
The multisystem disorder PROMM was first described ten years ago by Ricker et al. with 
respect to a small group of German patients.3 This study involved 3 families with complaints 
of slight proximal muscle weakness, myotonia and cataract. Distal weakness was not present 
in the patients, nor was atrophy of the distal muscles and the facial muscles, which are both 
characteristic of DM. Ptosis of the eyelids, weakness of the respiratory muscles and cardiac 
symptoms were also not found in this group of patients. In a later study, Ricker et al. 
described 27 patients from 14 families. Mental retardation had been observed in one of these 
patients from an early age on, but none of the others had experienced any cognitive 
problems.7 DM, myotonia congenita and paramyotonia were excluded by means of genetic 
analysis, and the authors called this variation of DM with proximal weakness ‘PROMM’. 
Nowadays, the term ‘PROMM’ is used to indicate the clinical picture. In cases in which the 
genetic mutation on chromosome 3 (DM2-locus) has been established with respect to this 
phenotype, then this is referred to as ‘DM type 2’ according to the criteria of a recent 
workshop by the European Neuromuscular Centre on PROMM and related disorders.8
Clinical presentation
PROMM, as well as DM, has specific characteristics, such as the occurrence of action 
myotonia and percussion myotonia, muscle weakness, heart rhythm disorders, endocrine 
deviations and deviant liver enzyme values. Slit lamp examination shows subcapsular 
posterior cataract, identical to the type cataract in DM. Still, there are obvious clinical 
differences between the two neuromuscular disorders (Table 2.3).79 A significant difference
-  which also manifests itself in the name ‘PROMM’ -  is that the muscle weakness, and in
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some cases atrophy, starts proximally. Seeing that proximal weakness occurs in PROMM 
patients, they become wheelchair-dependent sooner and more often than do DM1 patients; 
no specific data on this subject can be found in literature.10 Another remarkable difference is 
that pain in the affected muscles plays a prominent role in PROMM patients, whereas this 
seems to be less the case in DM1 patients. A third difference between both multisystem 
diseases concerns the cognitive functioning. Patients with the adult-onset type of DM1 
frequently show cognitive deterioration.1 So far, cognitive disorders are only rarely found in 
PROMM patients and these were minor.11 Finally, no congenital form is described in 
PROMM, whereas there may be a slight anticipation, as appears to be the case in the family 
described here.
Diagnostics
If a patient has limb-girdle weakness and cataract before the age of 50, if myotonia is 
demonstrable on electromyography and autosomal dominant inheritance applies, then a 
diagnosis of ‘PROMM’ can be established, provided that a CTG-repeat expansion of the DM- 
gene has been excluded (Table 2.1).4 The findings of histological research in patient A 
correspond to those in earlier publications.12 However, the diagnosis of ‘PROMM’ is not only 
made based on exclusion, as it is nowadays possible to genetically establish the disease. A 
gene defect, a CCTG-repeat in intron 1 of the ZNF9-gene on chromosome 3q21, is in most 
cases responsible for PROMM.6,13 As of recently, it is also possible to establish this gene 
mutation in The Netherlands (Radboud University Medical Centre Nijmegen, University 
Medical Centre Maastricht and the University Medical Centre Utrecht), making it possible to 
genetically confirm the clinical diagnosis.
Prognosis
It is as yet not known whether PROMM patients have a shorter life expectancy, as is 
described in patients with the adult-onset type of DM.1,14 Life-threatening heart rhythm 
disorders, namely conduction defects and ventricular arrhythmia, have also only been 
occasionally described in PROMM.15
Treatment
For now, the treatment of PROMM is symptomatic; drugs such as NSAIDs, carbamazepine 
or corticosteroids favourably influence the pain in some cases.16 Treatment is not generally 
necessary where it concerns the myotonia; fenytoine can ease the symptoms, but may also 
cause cardiac side effects. Cataract can be treated surgically if the disorder has seriously 
affected the patient’s vision. The cardiac state of a PROMM patient is to be initially 
determined by means of an ECG, Holter-registration and echocardiography.16 If the family 
case history shows cardiac conduction defects or sudden death, or if there are complaints of 
tachycardia or syncope, then the patient should be referred to a cardiologist. Medication or 
pacemaker treatment are generally proposed in cases of severe rhythm disorders.15 Although 
no data can be found in literature concerning the effects of administering anaesthetics to
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PROMM patients, it seems advisable to observe the same guidelines that apply to DM type 
1; muscle relaxing agents are to be avoided and the postsurgery monitoring should be longer 
than is normally the case.
Prenatal analysis can be offered. No use has been made of this possibility so far in The 
Netherlands and there are no data available on this from abroad. The reason for this may be 
unfamiliarity with this type of research -  compared to research into DM - , that a congenital 
form of PROMM is lacking and that the progression of the disease is less severe.
PROMM appears to be rare in The Netherlands. Although patients with PROMM have been 
described in America, Italy, Spain, Sweden, Norway, Finland, Great-Britain and France, the 
incidence of the disorder is not known in any of these countries.17-24 The incidence is 
presumed to be relatively high in Germany, namely 5 per 100,000 per year, and therefore 
equal to that of DM.5 The precise incidence in The Netherlands and that of other countries 
bordering along Germany is not known, but PROMM seems to occur less frequently in The 
Netherlands. It is however highly probable that this is also due to underdiagnostics; until 
recently, PROMM patients were diagnosed as having ‘atypical’ DM or ‘DNA-negative DM’.
Conclusion
The clinical picture of the multisystem disorder PROMM shows similarities with DM, but the 
differences between the two have become more evident in the past few years. Although both 
disorders are characterised by an autosomally dominant inheritance pattern, a gradual 
progression and both cannot be treated causally, it is important to distinguish between the 
two in connection with the different prognosis, progression and proper supervision. Ever 
since the discovery of the gene mutation in PROMM, it is possible to confirm the clinically 
determined diagnosis by means of DNA-analysis. The reason why PROMM has so far only 
been diagnosed in a small number of patients in The Netherlands is not known; the relative 
unfamiliarity with this disorder may play a role in this respect. PROMM should be considered 
in all cases in which DM is presumed based on the clinical picture, yet the DNA-analysis is 
negative. This requires further research and DNA-analysis. The disease can only be treated 
symptomatically, preferably by means of a multidisciplinary approach by a neurologist, 
ophthalmologist, cardiologist and a rehabilitation specialist.
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Table 2.3 Clinical characteristics of myotonic dystrophy type 1 (DM1) and proximal myotonic 
myopathy (PROMM).9
DM1 PROMM
Clinical features
myotonia + +
cataracts + +
weakness + +
Localization of muscle weakness
facial muscles, jaw muscles ++ -
distal muscles ++ -
proximal leg muscles +/- ++
Muscle symptoms
atrophy ++ +
muscle pain +/- ++
elevated CK + +
Heart
cardiac conduction arrhythmias ++ +
Liver
Elevated y-GT + +
Endocrine
diabetes mellitus / insulin resistance + +
hypogonadism + +
Brain
hypersomnia ++ +
mental retardation + -
Genetic characteristics
CTG-repeat chromosome 19q13.3 + -
CCTG-repeat chromosome 3q21.3 - +
anticipation + +/-
congenital form + -
CTG = cytosine, thymine and guanine.
Symbols: ++ finding is present and prominent; + finding is present; +/- finding is 
present but only to a minor degree; - finding is not present.
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Abstract
Background and aim
The phenotype of DM2 shows similarities as well as differences to that of myotonic dystrophy type 1 
(DM1). Gastrointestinal dysfunction is common in DM1 and 25% of the patients consider this to be the 
most disabling consequence of the disease.1 Little is known about gastrointestinal involvement in 
myotonic dystrophy type 2 (DM2). The aim of the study was to explore the occurrence and 
characteristics of gastrointestinal symptoms in patients with DM2. This was compared to symptoms in 
adult-onset DM1 patients, and to age- and sex-matched healthy controls.
Methods
Twenty-nine genetically proven DM2 patients filled out two standardized questionnaires about 
gastrointestinal symptoms; most important outcome measures were answers to questions about 
dysphagia, abdominal pain, and constipation. The results were compared to those of 29 adult-onset 
DM1 patients, and to 87 age- and sex-matched healthy controls. Radiological measurement of colon 
transit time was investigated in 18 DM2 patients.
Results
Dysphagia for liquids (38%) and solid food (41%), abdominal pain (62%), and constipation (62%) were 
all significantly more common among DM2 patients than among healthy controls, and comparable to 
their occurrence in DM1. Colon transit time was increased in 24% of the DM2 patients.
Conclusion
Our results show that gastrointestinal symptoms are highly prevalent in DM2 patients. Gastrointestinal 
dysfunction may be attributed to any part of the gastrointestinal tract. The results provide new insight 
into the clinical picture of DM2.
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Introduction
Myotonic dystrophy type 2 (DM2, OMIM 602668) is a dominantly inherited multisystem 
disorder characterised by progressive proximal muscle weakness, myotonia, cataracts, 
cardiac arrhythmia, and muscle pain.1,2 The disease was first described by Ricker in 1994, 
who coined the term proximal myotonic myopathy (PROMM).3 In 2001, the mutation 
responsible for DM2 was identified as a CCTG expansion located in the intron 1 of the zinc 
finger protein 9 (ZNF9) gene on chromosome 3q21.3.4 The clinical picture of DM2 shows 
similarities as well as differences to that of myotonic dystrophy type 1 (DM1).2 Shared core 
features are autosomal dominant inheritance, muscle weakness, myotonia, cataracts, and 
multiorgan involvement with cardiac conduction defects, insulin resistance, hypothyroidism 
and gonadal atrophy. Notably absent is a congenital form of DM2, and evidence of 
anticipation is less striking than in DM1, while muscle pain is more prominent in DM2.5 
Gastrointestinal dysfunction, a predominant feature in DM16, has not yet been examined in 
DM2. However, dysphagia, vomiting due to pyloric stenosis, and constipation were described 
in PROMM and DM2 case reports.3,7"10 Dysphagia and constipation were already mentioned 
in the first ENMC International Workshop Report about PROMM as supportive findings to 
establish the diagnosis11, but so far the expert opinion has not been corroborated by clinical 
research.
We performed a nationwide study to explore the presence and characteristics of 
gastrointestinal dysfunction in genetically proven DM2 patients and compared them to adult" 
onset DM1 patients and healthy controls.
Patients and methods
Patients
In The Netherlands, 32 patients from 12 families are known with genetically proven DM2. All 
were retrieved from CRAMP, the Dutch neuromuscular database12 and approached for 
participation with the consent of their treating physician, according to the Helsinki criteria. 
Two age- and sex-matched control groups were selected, one from known adult-onset DM1 
patients, the other from healthy spouses of patients visiting our outpatient department. The 
local ethics committee approved the study. All patients and controls gave written informed 
consent. The exclusion criteria for participating were untreated hypothyroidism or other co 
morbidity with influence on the gastrointestinal tract.
Methods
Participants were asked to fill out two questionnaires about gastrointestinal symptoms.
The first questionnaire, the Dutch Gastrointestinal Symptoms Questionnaire, covers 
symptoms from all parts of the gastrointestinal tract.13 It contains questions about the severity 
of gastrointestinal symptoms during the last 4 weeks. Symptoms are rated from 0 to 6, 0
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meaning ‘no complaints’ and 6 representing ‘the worst imaginable severity of that symptom’. 
Answers to questions about dysphagia, abdominal pain, and constipation were considered 
the most important outcome measures, since those symptoms are known to be highly 
prevalent in DM1, relevant in clinical practice, and probably all the result of impaired motility. 
A cut-off between 0 and 1 was used to estimate the frequencies of these symptoms.
The second questionnaire contains questions about defecation frequency (rated 1-6), feeling 
of incomplete evacuation (rated 1-4), difficult evacuation (rated 1-4), and pain during 
defecation straining (rated 1-4). Answers to these four questions were used to calculate the 
constipation score, which has reliability (Cronbach’s a) of 0.82. The mean constipation score 
for healthy controls is 6, while the mean constipation score for patients with defecation 
complaints visiting a surgeon is 8.14
All DM2 patients were also asked to undergo radiological measurement of colon transit time. 
The procedure was performed as described earlier.15 In short, ten radiopaque markers were 
ingested daily for 10 consecutive days. On the eleventh day an abdominal X-ray was 
performed. The markers were counted in total. According to a validated formula the total 
colon transit time in hours was calculated by multiplying the number of markers by 2.4.16 
Increased colon transit time was defined as more than 72 hours.17,18
Statistical analyses
Relative risks were used to compare the frequencies of gastrointestinal symptoms. In order 
to be able to determine the confidence interval and estimate when the frequency of a 
symptom was 0 in one of the groups, one additional observation was added to that group 
with the symptom present. This leads to a slightly conservative estimate of the risk ratio and 
its confidence interval. Differences in mean constipation score were tested using the t-test. 
Ninety-five percent confidence intervals were calculated.
Table 3.1 Characteristics of DM2 patients, DM1 patients and controls.
Characteristic DM2 DM1 Controls
N 29 29 87
Female sex (%) 23 (79%) 20 (69%) 69 (79%)
Mean age in years (range) 56 (27-75) 54 (29-75) 55 (24-80)
Results
Questionnaires
Of the 32 known genetically proven Dutch DM2 patients, two patients were excluded 
because they had co morbidity that could have influenced gastrointestinal motility, namely 
Sjogren’s syndrome and HIV infection. One DM2 patient refused to participate due to 
psychological problems with the diagnosis. The average age of the remaining 29 DM2
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patients was 55.5 years (range 27-75) and 23 (79%) were female. Twenty-nine adult-onset 
DM1 patients and 87 healthy volunteers, both matched for age and sex, also filled out the 
questionnaires (Table 3.1).
Concerning dysphagia, abdominal pain, and constipation, there was a statistically significant 
higher frequency of these symptoms among DM2 patients compared to the healthy controls, 
as shown in Table 3.2. Moreover, the frequencies of these symptoms in DM2 were 
comparable to or even higher than in DM1, although not statistically significant. Mean 
constipation score for healthy controls was 6.1 (men: 5.6, women: 6.2), which corresponds to 
the mean of healthy controls of 6.0, published earlier.14 Mean constipation score in DM2 was 
9.1 (men: 8.8, women 9.2), significantly higher than in healthy controls, which means a 
higher presence of constipation in DM2 (Table 3.2). In general, gastrointestinal dysfunction 
was considered among the most disabling symptoms by 45% of DM2 patients. Use of 
laxatives was reported in six DM2 patients. Mean ages of DM2 patients using laxatives and 
non-users were comparable (54.7 vs 55.7 years). The constipation score was higher in DM2 
patients using laxatives (mean constipation score 12.2) than in DM2 patients not using them 
(mean constipation score 8.3).
Colon transit time
Colon transit time was measured in 18 DM2 patients. There was no significant difference in 
frequencies of gastrointestinal symptoms between DM2 patients who underwent colon transit 
time measurement and DM2 patients who did not. One of the 18 DM2 patients continuously 
used laxatives during the study because of the severity of her constipation, and was 
excluded from further analysis. Colon transit time was delayed in 24% of the DM2 patients. 
The four DM2 patients (one man, three women, mean age 61.0 years) with increased colon 
transit time all belonged to different DM2 families. Mean age of the DM2 patients with normal 
colon transit time was 56.0 years.
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Table 3.2 Prevalence of gastrointestinal symptoms in DM2 patients, DM1 patients and controls.
Symptom DM2
(N=29)
DM1
(N=29)
Controls
(N=87)
RR
DM2-DM1
RR
DM2-Controls
Dysphagia 52% (15) 62% (18) 2% (2) 0.8 (0.5-1.3) 22.5 (5.5-92.9)
Dysphagia for liquids 38% (11) 35% (10) 0% (0) 1.1 (0.6-2.2) 33.5 (4.5-248)
Dysphagia for solid food 41% (12) 62% (18) 2% (2) 0.7 (0.4-1.1) 18.0 (4.3-75.7)
Abdominal pain 62% (18) 45% (13) 21% (18) 1.4 (0.8-2.3) 3.0 (1.8-4.9)
Postprandial 41% (12) 17% (5) 8% (7) 2.3 (0.9-5.7) 5.1 (2.2-11.8)
During fasting 31% (9) 17% (5) 3% (3) 1.7 (0.7-4.5) 9.0 (2.6-31.0)
No decline after defecation 41% (12) 35% (10) 3% (3) 1.2 (0.6-2.2) 12.0 (3.6-39.6)
Epigastric pain 55% (16) 38% (11) 18% (16) 1.5 (0.8-2.6) 3.0 (1.7-5.2)
Epigastric pain at day 55% (16) 35% (10) 16% (14) 1.6 (0.9-2.9) 4.3 (1.9-6.4)
Epigastric pain at night 48% (14) 24% (7) 8% (7) 2.0 (0.9-4.2) 6.0 (2.7-13.4)
Constipation 62% (18) 55% (16) 15% (13) 1.1 (0.7-1.7) 4.2 (2.3-7.4)
DM2 DM1 Controls DM2-DM1 DM2-Controls
(N=29) (N=29) (N=87)
Constipation score 9.1 (3.0) 8.1 (2.9) 6.1 (1.5) 1.0 (-0.6-2.5) 3.0 (2.2-3.9)
RR = relative risk for differences between DM2-DM1 and DM2-controls (95% confidence interval).
Constipation score (standard deviation) in DM2 patients, DM1 patients and controls, and differences (95% confidence interval) between 
DM2-DM1 and DM2-controls.
Symptoms in bold are symptoms we defined as most important outcome measures.
Discussion
In this nationwide cross-sectional study, gastrointestinal symptoms were found to be highly 
prevalent in genetically proven DM2 patients. Their prevalence was comparable to that of 
DM1 patients. Dysphagia was present in about 40% of the 29 DM2 patients from 12 families, 
which is more than in a previous study of a DM2 family, where complaints of dysphagia and 
aspiration were described in three of the 22 DM2 patients (14%).9 Other reports contained 
only single case observations.3,8 Since the major complication of dysphagia is aspiration, 
dysphagia may be a problem that can lead to pneumonia. Pneumonia, together with cardiac 
arrhythmias, is known to be the most frequent cause of death in DM1.19 However, up until 
now, there has been no evidence of severe late stage dysphagia and pneumonia due to 
aspiration in DM2 patients as is the case in adult-onset DM1 patients.
Both abdominal pain and constipation were present in 62% of the DM2 patients. The mean 
constipation score of DM2 patients was 9.1, which was significantly higher than in the control 
group (6.1). This confirms the presence of constipation in DM2 patients, which is also 
supported by an increased colon transit time in 24% of the DM2 patients. Several procedures 
have been used to measure colonic transit time (CTT), and different upper limits of normal 
CTT have been described, varying from 4515 to 72 hours.17,18 We defined a delayed CTT as 
more than 72 hours, using the highest upper limit. For comparison, mean CTT among 73 
controls was 36 ± 4 hours described by Pemberton.18 In the literature, we found only one 
study of a PROMM family where constipation was earlier described.8 
A point of criticism can be the uneven sex distribution in this study, because 79% of DM2 
patients are female. However, we found no correlation between the outcome measures 
(dysphagia, abdominal pain, and constipation) and sex, and no correlation was found 
between the constipation score and sex in DM2 patients. Colon transit time was delayed in 
four DM2 patients (one man, three women). In summary, although the sex distribution is 
uneven in our DM2 group, the occurrence of gastrointestinal symptoms correlates to the 
existence of the DM2 mutation and not to sex.
Physicians can help most patients with constipation through lifestyle, dietary and 
pharmacological adjustments like osmotic laxative, along with supplementary fibres. All this 
to avoid obstructive symptoms as mega colon, which has been described in DM1 and can 
lead to death.20 As a treatment guideline for DM2, prescription of tramadol and other opiates 
has to be avoided because of the frequent negative side effects on gastrointestinal motility.
In conclusion, awareness of gastrointestinal dysfunction as part of the clinical picture of DM2 
may lead to early recognition of these symptoms, so adequate treatment can be provided. 
Further research on the pathophysiology of these gastrointestinal symptoms is warranted.
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Abstract
Background and aim
The phenotype of myotonic dystrophy type 2 (DM2) shows similarities as well as differences to that of 
myotonic dystrophy type 1 (DM1). Dysphagia, a predominant feature in DM1, has not yet been 
examined in DM2. In a recent nationwide questionnaire survey of gastrointestinal symptoms in DM2, 
12 out of 29 DM2 patients reported to have difficulty in swallowing for solid food. The aim of the study 
was to investigate the presence of dysphagia in patients with genetically proven DM2 who reported 
difficulty in swallowing for solid food at the questionnaire survey.
Methods
Swallowing function and fiberoptic endoscopic evaluation of swallowing (FEES) were examined by a 
speech therapist and otorhinolaryngologist, respectively.
Results
In DM2 patients who reported difficulty in swallowing the presence of dysphagia could be confirmed 
(clinically in 100%, by FEES in 88%). A correlation exists between DOSS score and age (p=0.05). 
None of the patients was underweight, and none of the patients had suffered aspiration pneumonia in 
the past.
Conclusion
Dysphagia is present among DM2 patients and is more severe in older patients. However, dysphagia 
is generally mild, and do not lead to weight loss, or aspiration pneumonia.
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Introduction
Myotonic dystrophy type 2 (DM2, OMIM 602668) is a dominantly inherited multisystem 
disorder characterised by progressive proximal muscle weakness, myotonia, cataracts, 
cardiac arrhythmia, and muscle pain. DM2, earlier known as proximal myotonic myopathy 
(PROMM) is caused by a CCTG expansion in intron 1 of the ZNF9 gene on chromosome 
3q21.1 The clinical picture of DM2 shows similarities as well as differences to that of 
myotonic dystrophy type 1 (DM1). Shared core features are autosomal dominant inheritance, 
muscle weakness, myotonia, cataracts, and multiorgan involvement with cardiac conduction 
defects, insulin resistance, and gonadal atrophy. Notably absent is a congenital form of DM2, 
and evidence of anticipation is less striking than in DM1, while muscle pain is more 
prominent in DM2.2
Dysphagia, a predominant and potentially life-threatening feature in DM1, has not yet been 
examined in DM2. Dysphagia has been described in a few scattered PROMM and DM2 case 
reports.3-5 We recently performed a nationwide study to explore the presence and 
characteristics of gastrointestinal dysfunction in DM2 patients.6 In that validated 
questionnaire survey 12 out of 29 patients reported to have swallowing difficulties for solid 
food. In this study, we set out to assess oropharyngeal swallowing in patients with genetically 
proven DM2 who reported difficulty in swallowing at the questionnaire survey in order to 
objectify this symptom.
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Patients and methods
Patients
In a recently performed nationwide survey genetically proven DM2 patients filled out the 
Dutch Gastrointestinal Symptoms Questionnaire (GSQ).6 This standardized questionnaire 
covers symptoms from all parts of the gastrointestinal tract and contains questions about the 
severity of gastrointestinal symptoms during the last 4 weeks.7 All DM2 patients who reported 
swallowing difficulties at the GSQ were recruited for this study. Exclusion criterion for 
participating was pregnancy because of its increased risk of pulmonary aspiration.
Patients were approached for additional information about their medical history and the body 
mass index (BMI) was calculated for all patients. The medical ethics committee approved the 
protocol and all patients gave written consent.
Methods
All DM2 patients were clinically investigated by an experienced speech therapist in 
neuromuscular disorders. Eight DM2 patients gave additional informed consent to fiberoptic 
endoscopic evaluation of swallowing (FEES).
Clinical investigation
An orofacial examination was performed as previously described in literature.8 In short, the 
clinical examination included:
- Assessment of the strength of the jaws, lips, and tongue; weakness was scored as 
mild, moderate or severe.
- Assessment of myotonia of the masseter muscles and tongue; myotonia was scored as 
absent or present.
- Observation while eating solid food (a biscuit).
- A timed test of swallowing.9
Fiberoptic endoscopic evaluation of swallowing
Fiberoptic endoscopic evaluation of swallowing (FEES) is a valid and exceptionally safe 
technique for assessing preswallow anatomy and physiology in order to objectively evaluate 
patients with dysphagia.10 Diagnosis of oropharyngeal dysphagia was determined by 
premature spillage, pharyngeal residue, laryngeal penetration and aspiration.
Dysphagia Outcome and Severity Scale
All symptoms were scored with the Dysphagia Outcome and Severity Scale (DOSS), a 
reliable scale developed to rate the functional severity of dysphagia based on objective 
assessment.11 Scores range from 1 (severe oropharyngeal dysphagia necessitating non-oral 
nutrition) to 7 (normal in all situations). Oropharyngeal dysphagia was diagnosed when a 
patient was scored on level 1 to 6.
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Statistical analysis
We used the Pearson partial correlation coefficient for calculating correlations, and 
considered p < 0.05 significant.
Results
Clinical investigation
Twelve DM2 patients complaining of swallowing difficulties were recruited. Ten (from eight 
DM2 families) of the 12 patients took part in the study, two patients refused to participate. 
Mean age was 58.0 years (SD 11.6) and mean age of disease onset was 26.7 years (SD 
13.0). Mean BMI in DM2 patients was 25.1 (SD 4.0), none of the patients was underweight 
(BMI <18.5). None of the patients had suffered aspiration pneumonia in the past.
Seven patients showed signs of weakness of the jaws, lips, or tongue. None of the patients 
showed myotonia of the jaws or tongue.
Evaluation of eating showed slowness in all DM2 patients, and frequent swallowing in nine. 
Six patients demonstrated adapting head position upon swallowing. Coughing and wet 
phonation, indicating possible residue, penetration or aspiration, were observed in five 
patients.
A timed test of swallowing showed the swallowing speed (average volume per swallow) to be 
too low, that is to say lower than normal, in four patients (patient 3, 4, 8 and 9). Five other 
patients (patient 1, 5, 6, 7, and 10) drank more slowly than the mean swallowing speed of 
age and sex matched healthy controls from literature, but still fell within normal values.12 
(Table 4.1)
Fiberoptic endoscopic evaluation of swallowing
One patient exhibited normal swallowing and seven (88%) exhibited dysphagia; residue of 
solid food in seven cases (88%), residue of milk in six cases (75%), and residue of saliva 
was observed in two cases (25%). Spillage of milk was revealed in two patients (25%); 
spillage of solid food was detected in one patient (13%). No penetration or aspiration of milk 
or solid food was detected. (Table 4.1)
Dysphagia Outcome and Severity Scale
DOSS score was found to be abnormal in all DM2 patients, ranging in severity from “mild­
moderate” (score 4) to “within functional limits” (score 6). DOSS score and age correlated in 
patients (rho -0.66, p=0.05), age at disease onset and swallowing speed correlated 
significantly (rho -0.68, p=0.04). There was no correlation between DOSS score and age at 
disease onset or disease duration.
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Table 4.1 Patient characteristics and results of clinical investigation (orofacial examination, timed test 
of swallowing and evaluation of eating), FEES and DOSS.
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt 10
Characteristic
Sex F F M M F F F F F F
Age, y 68 55 37 64 71 72 55 62 46 48
Age at disease onset, y 43 18 27 52 22 12 10 28 26 29
Orofacial examination
Weakness of jaws - - - - - ± - - - -
Weakness of lips - - - ± - ± - - ± -
Weakness of tongue ± ± - ± ± ± - ± - -
Timed test of swallowing
Swallowing speed in mL/s 8 14 16 11 11 12 11 4 8 9
Evaluation of eating
Slowness ++ + + + + + ++ ++ + ±
Frequent swallowing + + + + + + - + + +
Adapting head position + + + - - + - + - +
Coughing, wet phonation + - + - - + - - + +
FEES na na
Deviant anatomy - + - - - - - -
Residue of saliva - + - - - - - +
Spillage of milk + - - - + - - -
Spillage of biscuit + - - - - - - -
Residue of milk + + + + - + - +
Residue of biscuit + + + + + + - +
Penetration of milk - - - - - - - -
Penetration of biscuit - - - - - - - -
Aspiration of milk - - - - - - - -
Aspiration of biscuit - - - - - - - -
DOSS 4 4 5 4 4 4 5 4 6 4
- = absent; ± = minimal signs; + = clear signs; ++ = severe. na = not assessed
DOSS = Dysphagia Outcome and Severity Scale score11 (7 = normal, 6 = within functional limits, 5 =
mild, 4 = mild-moderate, 3 = moderate, 2 = moderate-severe, 1 = severe dysphagia)
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Discussion
In DM2 patients who reported difficulties in swallowing the presence of dysphagia could be 
confirmed (clinically in 100%, by FEES in 88%). Dysphagia was more pronounced in older 
DM2 patients. None of the 10 patients had suffered aspiration pneumonia in the past, and no 
patient was underweight or had significantly lost weight. These findings are in 
correspondence with the results that dysphagia is generally mild.
These results give little or no indication of the underlying pathology of swallowing difficulties. 
Weakness of the oropharyngeal muscles as well as subclinical myotonia may play a role. In 
DM1 both myopathic weakness and myotonia encountered in oropharyngeal muscles play an 
important part in the oral and the pharyngeal phases of swallowing dysfunction.13 In our 
group, minimal weakness of the orofacial muscles but no myotonia was observed clinically. 
Electrophysiological evaluation of swallowing is necessary to show the possible existence 
and frequency of subclinical electrophysiological abnormalities in oropharyngeal swallowing 
and may clarify the mechanisms of dysphagia.
Recognition of dysphagia may have implications for the management of DM2 patients and 
for recommendations regarding the prognosis. Firstly, DM2 patients with dysphagia may 
benefit from conservative interventions such as speech therapy and modification of food 
consistency. Secondly, since the major complication of dysphagia is aspiration, dysphagia 
may be a problem that can lead to pneumonia. We found, however, no evidence of severe 
late stage dysphagia and pneumonia due to aspiration in DM2 patients as is the case in 
adult-onset DM1 patients.
49
References
1. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum 
LP. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 
2001;293:864-7.
2. Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 
2000;23:1789-99.
3. Phillips MF, Rogers MT, Barnetson R, Braun C, Harley HG, Myring J, Stevens D, Wiles CM, 
Harper PS. PROMM: the expanding phenotype. A family with proximal myopathy, myotonia 
and deafness. Neuromuscul Disord 1998;8:439-46.
4. Day JW, Roelofs R, Leroy B, Pech I, Benzow K, Ranum LP. Clinical and genetic 
characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). 
Neuromuscul Disord 1999;9: 19-27.
5. Grewal RP, Zhang S, Ma W, Rosenberg M, Krahe R. Clinical and genetic analysis of a family 
with PROMM. J  Clin Neurosci2004;11:603-5.
6. Tieleman AA, van Vliet J, Jansen JB, van der Kooi AJ, Borm GF, van Engelen BG. 
Gastrointestinal involvement is frequent in myotonic dystrophy type 2. Neuromuscul Disord 
2008;18:646-9.
7. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, Jansen JB. 
Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis S c i2006;51:1509-15.
8. Wohlgemuth M, de Swart BJ, Kalf JG, Joosten FB, van der Vliet AM, Padberg GW. Dysphagia in 
facioscapulohumeral muscular dystrophy. Neurology 2006;66:1926-8.
9. Nathadwarawala KM, Nicklin J, Wiles CM. A timed test of swallowing capacity for 
neurological patients. J Neurol Neurosurg Psychiatry 1992;55:822-5.
10. Rees CJ. Flexible endoscopic evaluation of swallowing with sensory testing. Curr Opin 
Otolaryngol Head Neck Surg 2006;14:425-30.
11. O ’Neil KH, Purdy M, Falk J, Gallo L. The Dysphagia Outcome and Severity Scale. 
Dysphagia 1999 ;14:139-45.
12. Hughes TA, Wiles CM. Clinical measurement of swallowing in health and in neurogenic 
dysphagia. QJM  1996;89:109-16.
13. Ertekin C, Yuceyar N, Aydogdu, Karasoy H. Electrophysiological evaluation of oropharyngeal 
swallowing in myotonic dystrophy. J Neurol Neurosurg Psychiatry 2001 ;70:363-71.
50
S1
S2
¿5
&cc
- c
O
Poor sleep quality and fatigue but no 
excessive daytime sleepiness in 
myotonic dystrophy type 2
1 2  1 2  1 1 3AA Tieleman , H Knoop , A-E van de Logt , G Bleijenberg , BG van Engelen , S Overeem ’
J Neurol Neurosurg Psychiatry 2010;81:963-967
1 Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands
2 Expert Centre Chronic Fatigue, Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands
3 Centre for Sleep Medicine ‘Kempenhaeghe’, Heeze, The Netherlands
53
Abstract
Background and aim
In myotonic dystrophy type 1 (DM1), sleep disorders are common, with excessive daytime sleepiness 
(EDS) as a predominant feature. In myotonic dystrophy type 2 (DM2), the presence of sleep 
disturbances is unknown. The aim of the study was to investigate the frequency of EDS, poor sleep 
quality and fatigue in DM2.
Methods
We surveyed 29 genetically proven DM2 patients with the Epworth Sleepiness Scale (ESS), 
Pittsburgh Sleep Quality Index (PSQI) and Checklist Individual Strength (CIS). The results were 
compared with 29 adult-onset DM1 patients and 65 population controls, both matched for age and 
sex.
Results
Only 6.9% of DM2 patients had EDS compared with 44.8% of DM1 patients and 6.2% of population 
controls (DM2-DM1: p=0.001, DM2-controls: p=0.51). Sleep quality was poor (PSQI >5) in both DM2 
and DM1 groups, and differed significantly from population controls (DM2: 6.5 ± 3.0; DM1: 6.2 ± 3.7; 
controls 4.3 ± 3.0) (DM2-controls: p=0.002). Poor sleep quality was not explained by depression or 
other comorbidity but was mainly due to sleep disturbances as a result of nocturnal pain.
Comparable with the DM1 group, DM2 patients experienced severe fatigue (DM2: 38.7 ± 13.1; DM1: 
42.9 ± 8.5; controls: 21.1 ± 11.1; DM2-controls: p<0.001). Results were not confounded by abnormal 
thyroid function or medication use.
Conclusion
These results provide new insight into the phenotype of DM2 and have consequences for clinical 
treatment. In addition, the absence of EDS in DM2 is a new discriminative feature with adult-onset 
DM1.
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Introduction
The myotonic dystrophies (DM) are dominantly inherited multisystem diseases, with muscle 
weakness and myotonia as the main neuromuscular symptoms. Other organs are 
prominently involved, with frequent early-onset cataracts, cardiac conduction abnormalities, 
gastrointestinal symptoms, endocrine changes and central nervous system symptoms.1-3 
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults, 
with a prevalence of 5-12 per 100,00o.1’4 The phenotype and genetics of myotonic dystrophy 
type 2 (DM2) have been described only recently, and its prevalence has not yet been 
established.5,6 The molecular basis of both DM1 and DM2 is a repeat instability in a non­
coding part of a gene: a CTG-trinucleotide repeat in the DMPK gene on chromosome 19 
(DM1) and a CCTG-tetranucleotide repeat in the ZNF9 gene on chromosome 3 (DM2).67 The 
resulting disruption of mRNA metabolism alters nuclear functions, including the splicing 
machinery. This leads to abnormal transcripts in many other genes, explaining the 
multisystemic nature of the diseases.7
Interestingly, repeat instability in two unrelated genes causes comparable clinical 
phenotypes. In fact, DM2 was not recognized as a separate disorder until 1994.58 However, 
some recent studies suggest important differences in the clinical symptomatology of DM1 
and DM2. For example, the severe congenital form encountered in DM1 is absent in DM2, 
and there is no confirmed evidence of anticipation in DM2.
Sleep disorders are very common in DM1, and are in fact considered a core feature. Of 
these, excessive daytime sleepiness (EDS) is a predominant symptom.1,9-11 EDS in DM1 can 
be severe and has been described as resembling the sleepiness of primary hypersomnias 
such as narcolepsy. Besides daytime sleepiness, severe fatigue is present in up to 74% of 
adult-onset DM1 patients.12
In contrast with DM1, virtually nothing is known about sleep and fatigue in DM2. Some 
authors have suggested a comparable presence of daytime sleepiness in DM213,14 but 
systematic studies are lacking. We therefore performed a nationwide study into EDS, sleep 
quality and fatigue in a cohort of DM2 patients, and compared these symptoms with both a 
matched group of adult-onset DM1 patients and with population controls.
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Methods
Subjects
All known patients Dutch with DM2 (n=32) were approached to participate in the study. DM2 
patients, and sex- and age-matched DM1 patients were retrieved from CRAMP, the Dutch 
neuromuscular database.15 In addition, 65 sex- and age-matched population controls were 
surveyed. All DM patients were older than 18 years of age, were ambulatory and had a 
genetically confirmed diagnosis. Exclusion criteria concerned the use of central nervous 
system stimulant medication or assisted ventilation such as nocturnal continuous positive 
airway pressure. The presence of a neuromuscular disorder was the only exclusion criterion 
for the population controls. All subjects gave written informed consent to participate, and the 
study was approved by the local ethical committee.
Questionnaires
Sleep quality
Nocturnal sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI).16 The 
PSQI is a self-rated questionnaire that measures seven components of sleep over a 1 month 
time interval: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medication and daytime dysfunction. Each component 
score has a range of 0-3 points. In all cases, a score of ‘0’ indicates no difficulty, while a 
score of ‘3’ indicates severe difficulty. The sum of the seven component scores is expressed 
as a global score, with a range of 0-21 points. The normal threshold is 5; higher scores 
indicate poorer sleep quality.16
Excessive Daytime Sleepiness
Daytime sleepiness was measured with the Epworth Sleepiness Scale (ESS).17 The ESS 
measures the tendency to fall asleep during eight different situations that are commonly 
encountered in daily life, yielding a score range of 0-24. The upper limit of normal is 10, and 
ESS scores above 10 are generally taken to reflect abnormal daytime sleepiness.
Fatigue severity
The presence of fatigue was assessed using the subscale ‘fatigue severity’ of the Checklist 
Individual Strength (CIS).18 The CIS measures the experience of fatigue associated problems 
during the previous 2 weeks. The CIS-fatigue severity subscale contains eight items scored 
on a 7-point Likert scale. Scores can range between 8 and 56; higher scores indicate higher 
levels of fatigue and scores of 35 or more are considered to indicate severe fatigue.18
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Comorbidity and medication use
All participants filled out a standardised questionnaire regarding medication use. When 
available, thyroid function data were retrieved from the patients’ medical files. Symptoms of 
depression were scored using the Beck Depression Inventory for primary care (BDI-pc). This 
shortened version of the BDI has seven items and includes cognitive and affective 
symptoms.19 Somatic symptoms of depression have been removed, to avoid overlap when 
used for patients with, for example, neuromuscular disorders. A score of 4 or more is 
indicative of clinical depression.
Statistical analysis
Numerical variables are shown as mean ± SD (range). Categorical data are shown as a 
number (percentage of total). One-way ANOVAs were used to compare the three study 
populations. Differences between DM2 and DM1 patients and between DM2 patients and 
population controls were then tested using t-test or chi-square test. Correlations were 
calculated with the Pearson coefficient. A p-values < 0.05 was considered to be significant.
Results
Demographics
Of the 32 DM2 patients that were approached, 29 (91%) responded and completed the 
questionnaires a home. DM2 patients originated from 12 unrelated families. A total of 34 
matched DM1 patients were selected from the CRAMP database, 5 of whom were excluded 
because of the use of modafinil (n=4) or nocturnal continuous positive airway pressure (n=1). 
The demographic characteristics of both patients groups and the population controls are 
listed in Table 5.1.
The groups were well matched for age, sex and body mass index (BMI). Age at onset was 
identical for the DM groups. There were no differences between the three groups regarding 
use of beta-blockers or sleeping medication. One quarter of DM2 patients used pain 
medication, as did 14% of DM1 patients and 5% of population controls (DM2 vs controls 
p=0.005; DM2 vs DM1 p=0.32). Thyroid function data were available for 28 DM2 patients and 
14 DM1 patients; none of them suffered from thyroid dysfunction. Depression scores were 
higher in both DM groups compared with controls (BDI-pc score DM2: 2.2 ± 2.7; DM1: 2.3 ± 
3.1; controls: 0.9 ± 1.7) (DM2 vs DM1: p=0.86; DM2 vs controls: p=0.006).
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Table 5.1 Demographic data of DM2 patients, DM1 patients and normal controls.
DM2 DM1 Controls P-value
(DM2-DM1)
P-value
(DM2-Controls)
N 29 29 65
Females 20 (71%) 20 (71%) 42 (65%)
Age (yrs) 53.2 ± 12.1 (28-71) 52.8 ± 12.1 (28-72) 52.4 ± 13.7 (26-73)
BMI (kg/m2) 25.1 ± 3.8 (18.8-36.0) 25.6 ± 3.3 (16.5-30.9) 25.5 ± 4.0 (15.4-39.7) 0.613 0.662
Age of onset (yrs) 35.9 ± 13.4 (12-67) 37.3 ± 13.2 (15-61) - 0.695 -
Disease duration (yrs) 17.3 ± 15.0 (2-57) 15.7 ± 9.0 (1-38) - 0.612 -
Sleeping medication 3 (10%) 5 (17%) 8 (12%) 0.446 0.638
Pain medication 7 (24%) 4 (14%) 3 (5%) 0.315 0.005
Beta-blockers 3 (10%) 2 (7%) 6 (9%) 0.640 0.865
Data are shown as mean ± SD (range) or N (%). BMI = Body Mass Index.
Table 5.2 PSQI, ESS and CIS-fatigue score in DM2, DM1 and normal controls.
DM2 DM1
Controls P-value
(ANOVA)
P-value
(DM2-DM1)
P-value
(DM2-Controls)
N 29 29 65
PSQI 6.5 ± 3.0 6.2 ± 3.7 4.3 ± 3.0 0.003 0.785 0.002
PSQI > 5 19 (65.5%) 13 (44.8%) 17 (26.2%) 0.001 0.113 <0.001
ESS 4.3 ± 4.5 9.6 ± 4.1 5.4 ± 3.9 <0.001 <0.001 0.214
ESS > 10 2 (6.9%) 13 (44.8%) 4 (6.2%) <0.001 0.001 0.508
CIS-fatigue 38.7 ± 13.1 42.9 ± 8.5 21.1 ± 11.1 <0.001 0.149 <0.001
CIS-fatigue > 35 19 (65.5%) 25 (86.2%) 7 (10.8%) <0.001 0.066 <0.001
Data are shown as mean ± SD or N (%).
PSQI = Pittsburgh Sleep Quality Index, ESS = Epworth Sleepiness Scale, CIS-fatigue = Checklist Individual Strength-fatigue score.
Sleep quality
Both DM2 and DM1 patients had significantly higher PSQI global scores than population 
controls, indicating a decrease in sleep quality (Table 5.2, Figure 5.1). Sixty-six percent of 
the DM2 group showed a poor sleep quality (PSQI >5) compared with 45% in the DM1 group 
and 26% in controls. (DM2 vs controls: p < 0.001, DM2 vs DM1: p = 0.11).
DM2 patients showed the worst scores on the PSQI component subjective sleep quality, 
which differed significantly from population controls (see Table 5.3 for PSQI component 
scores). In addition, DM2 patients differed significantly from both DM1 patients and 
population controls regarding the PSQI component score sleep disturbances (Table 5.3). 
Pain was the most commonly reported cause for sleep disturbances in the DM2 group. Sixty- 
nine percent of DM2 patients reported pain as the cause of having had trouble sleeping 
during the past month, compared with 34% of DM1 patients and 17% of controls (DM2 vs 
DM1: p=0.009 and DM2 vs controls: p<0.001). The PSQI component score daytime 
dysfunction was significantly higher in both DM2 and DM1 patients compared with population 
controls. The component scores on sleep duration, sleep efficiency and the use of sleeping 
medication did not differ significantly between the three groups (Table 5.3).
Table 5.3 PSQI component subscores in DM2, DM1 and in normal controls.
PSQI component DM2 DM1 Controls P-value
(ANOVA)
P-value
(DM2-DM1)
P-value
(DM2-Controls)
Subjective sleep 
quality
1.1± 0.9 0.9± 0.7 0.7± 0.6 0.024 0.270 0.008
Sleep latency 1.5± 1.1 1.0± 1.1 0.8± 0.7 0.010 0.147 0.001
Sleep duration 0.3± 0.7 0.5± 0.7 0.4± 0.7 0.831 0.578 0.597
Sleep efficiency 0.8± 1.2 1.0± 1.2 0.4± 0.8 0.016 0.449 0.075
Sleep disturbances 1.4± 0.8 1.0± 0.7 1.1± 0.5 0.017 0.039 0.008
Use of sleeping 
medication
0.1± 0.4 0.6± 1.1 0.3± 0.8 0.104 0.050 0.383
Daytime dysfunction 1.2± 0.8 1.2± 0.9 0.7± 0.7 0.001 0.877 0.002
Data are shown as mean ± SD or N (%). 
PSQI = Pittsburgh Sleep Quality Index
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Sleep latency in the DM2 group (28.5 ± 26.1 minutes, range 2-120) was comparable with 
sleep latency in the DM1 group (25.1 ± 26.4 minutes, range 2-120, p=0.63), and both were 
significantly longer than in population controls (15.2 ± 12.6, range 3-60, p=0.001). Fifty-two 
percent of DM2 patients reported falling asleep within 30 minutes compared with 59% in the 
DM1 group and 83% in the population control group. Total sleep duration was not different in 
the three groups.
PSQI scores were not correlated with age, age at onset or disease duration. Furthermore, 
there was no association between depression or fatigue scores and PSQI total score in DM2 
patients (DM2: r=0.29, p=0.13; r=0.35, p=0.06, respectively). In DM1 patients and controls, 
small but significant associations were found between the BDI-pc and PSQI (DM1: r=0.53, 
p=0.003; controls: r=0.29, p=0.02).
Excessive daytime sleepiness
Patients with DM2 did not have elevated ESS scores compared with population controls, and 
the percentage of DM2 patients with EDS was also in the control range (Table 5.2). One 
DM2 patient had an ESS just above the cut-off (11) and another reported severe EDS, with 
an ESS of 20. This latter patient also had poor nocturnal sleep quality (PSQI 11), severe 
fatigue (CIS-fatigue 56) and symptoms of depression (BDI-pc 5). As expected, DM1 patients 
showed a significantly higher ESS score than population controls. Forty-five percent of DM1 
patients showed significant EDS (ESS >10) compared with 6% of the population controls 
(Table 5.2, Figure 5.1). Significant associations were found between depression scores and 
EDS in DM2 and controls (DM2: r=0.42, p=0.03; DM1: r=0.33, p=0.08; controls: r=0.42, 
p=0.001). ESS scores were not correlated with age, age at onset or disease duration.
Fatigue severity
DM2 patients experienced high levels of fatigue, with 66% reporting severe fatigue (Table 
5.2, Figure 5.1). This was also the case for DM1 patients with over 85% reporting severe 
fatigue (DM2 vs DM1: p = 0.066). Both DM groups had significantly higher CIS-fatigue scores 
than population controls (Table 5.2, Figure 5.1). As with daytime sleepiness, fatigue 
correlated with depression scores on the BDI-pc in DM2 and controls (DM2: r=0.47, p=0.01; 
DM1: r=0.21, p=0.27; controls: r=0.52, p<0.001). Other demographic variables were not 
associated with fatigue, except worsening of fatigue with age in DM1 (r=0.57, p=0.001).
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Figure 5.1 Individual scores on the PSQI, ESS and CIS-fatigue in DM2, DM1 and in normal controls. 
The cut-off for abnormal levels is indicated by a broken line.
Discussion
We estimated the prevalence of poor sleep quality, daytime sleepiness and fatigue in 
patients with DM2, and compared these with adult-onset DM1 patients and population 
controls. DM2 patients showed significantly worse sleep quality than population controls. 
DM2 patients showed significantly worse sleep quality than population controls. High levels 
of fatigue were equally present in both types of DM. In striking contrast with DM1 -  in which 
EDS is a predominant feature -  we found that daytime sleepiness was not part of the clinical 
picture of DM2.
DM2 and DM1 patients reported longer nocturnal sleep latencies than population controls. 
For DM1, this has been reported previously. Laberge et al. found that only 47% of DM1 
patients fell asleep within 30 minutes compared with 76% of healthy controls20 although 
recent polysomnographic data by this research group revealed a mean sleep latency of 
about 15 minutes in 43 DM1 patients.21 The reason for the sleep onset insomnia in DM2 is 
unknown, and no polysomnographic data for DM2 patients exist at the moment. It is likely 
that nocturnal myalgic pain is one of the influencing factors. Nocturnal sleep disturbances 
occurred significantly more often in DM2 than in DM1 or controls, and nocturnal pain was 
reported to be the most common cause. The prevalence of nocturnal awakenings because of 
pain was twice as high in DM2 compared with DM1. This high prevalence occurred despite 
the fact that almost 25% of DM2 patients received pain medication at the time of study, and 
10% used hypnotics. Previous studies reported musculoskeletal pain to be a frequent 
symptom of DM2, and in one-third of patients pain was even the most disabling symptom.22 
The major pain type associated with DM2 is exercise induced, with relief at rest. However,
62
besides episodic pain, pain does persist for more than 6 months in many patients, indicating 
chronic pain.22 This is compatible with our finding of significant and sleep disturbing nocturnal 
pain.
The mean ESS scores in patients with DM2 were identical to the population controls and 
comparable with previously reported normal values.17 Furthermore, the prevalence of EDS 
(ESS >10) in DM2 patients was equal to that in population controls. We confirmed the high 
prevalence of EDS in patients with DM1.21,23,24 We excluded DM1 patients who were using 
psychostimulants for sleepiness, perhaps selecting patients with a relatively mild sleepiness. 
Therefore, the difference in the prevalence of sleepiness in DM2 and DM1 may even be 
underestimated in our study. The reason for this difference remains unclear. It may be an 
indication of relatively minor involvement of the central nervous system in DM2, as has been 
suggested previously.3 Further study into the differential molecular pathophysiology of both 
disorders may also yield new insights into the pathogenesis of hypersomnia. It is unclear why 
the DM1 patients with EDS were not taking psychostimulants. As there was no obvious 
contraindication to the use of psychostimulants in the DM1 patient group, this may have 
reflected differences in clinical practice by the treating physician or patient decision.
The low prevalence of EDS, despite high levels of fatigue, underscores the fact that these 
are clearly different symptoms.24 DM2 patients demonstrated high levels of fatigue, 
comparable with DM1. The proportion of DM2 patients with severe fatigue (66%) was also 
similar to values reported for other neuromuscular disorders, such as facioscapulohumeral 
dystrophy (61%) or hereditary motor and sensory neuropathy type 1 (64%).12 Fatigue was not 
explained by medication use such as beta-blockers or abnormal thyroid function.
Depression scores in both DM2 and DM1 were higher than in population controls. This has 
been repeatedly reported by others in DM1.23,25,26 However, most of these studies were 
before the advent of DNA based diagnosis and probably included a number of DM2 patients. 
Meola et al. investigated both DM1 and DM2 patients and did not find a higher frequency of 
clinical depression in either.14 This difference may in part be explained by the smaller number 
of patients in their study and differences in study methodology (self-report versus structured 
interview). In the DM2 group as well as in the controls, there were correlations between 
depression, sleepiness and fatigue scores. This is likely to reflect the fact that small 
increases in the ESS may not be specific for hypersomnia. The much higher ESS scores in 
DM1 patients point to more severe hypersomnia related to central nervous system 
dysfunction, which may occur independently of depression or fatigue. Depression was 
associated with sleepiness and fatigue scores in the DM2 group, and should be included in 
the differential diagnosis when DM2 patients experience hypersomnia.
We approached all known Dutch DM2 patients from 12 families. The nationwide study 
combined with the high response rate of 91% makes the presence of selection bias in the 
DM2 group unlikely. Other strengths of this study are the DNA based diagnosis of DM2 and 
DM1, the use of validated questionnaires and consideration of comorbid depression and 
thyroid dysfunction. However, we were not informed about the range of CCTG- and CTG 
expansion on chromosomes 3 and 21. Laberge et al. found that DM1 patients with fatigue or 
EDS and fatigue had significantly longer CTG repeats than those with neither of these
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symptoms.10 In DM2 however, phenotypical influence of the size of the CCTG-expansion, 
which is in part due to the somatic instability of the repeat, has not yet been established.27 
In conclusion, the absence of EDS in DM2 is another clinical feature that differentiates DM2 
from DM1, in addition to absence of a severe congenital form and genetic anticipation. We 
have shown a decrease in the quality of sleep in patients with DM2. This poor sleep quality 
was not explained by depression or other comorbidity but was mainly due to increased sleep 
latency and sleep disturbances. Nocturnal awakenings due to pain were the most common 
symptom mentioned. Fatigue is another commonly experienced symptom in DM2, and is not 
correlated with the use of beta-blockers, thyroid dysfunction or poor sleep quality.
Future studies should assess the nature of the nocturnal sleep disruption in DM2 by 
polysomnographic assessment, for example to delineate the possible role of sleep related 
breathing disorders. Multiple sleep latency testing in DM2 patients would be less likely to 
demonstrate abnormalities in the absence of subjective daytime sleepiness on the ESS but 
may still be of value to perform as a more objective assessment. Future studies aiming to 
improve nocturnal sleep quality in DM2 may also assess the consequences on potential 
daytime sequalae such as depression, fatigue or health related quality of life.
Our findings may have important clinical consequences. In view of the negative impact of 
sleep disruption on the quality of life of DM2 patients, we would support a low threshold for 
screening for sleep disturbances -especially related to nocturnal myalgia- and for performing 
sleep studies. In view of the findings in the current study, pain management throughout the 
day and night may improve sleep and quality of life in DM2 patients.
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Abstract
Objective
To investigate health status in patients with myotonic dystrophy type 2 (DM2) and determine its 
relationship to pain and fatigue.
Methods
Data on health status (SF-36), pain (MPQ) and fatigue (CIS-fatigue) were collected for the Dutch DM2 
population (n=32). Results were compared with those of sex-and age- matched adult-onset myotonic 
dystrophy type 1 (DM1) patients. In addition, we compared the obtained scores on health status of the 
DM2 group with normative data of the Dutch general population (n=1742).
Results
Compared to DM1, the SF-36 score bodily pain was significantly lower in DM2, indicating more body 
pain in DM2. DM2 did not differ from DM1 on any other SF-36 scales. In comparison to the Dutch 
population, DM2 patients reported lower scores (indicating worse clinical condition) on the physical 
functioning, role functioning-physical, bodily pain, general health, vitality, social functioning, and role 
functioning-emotional scales (p<0.01 on all scales). The difference was most profound for the physical 
functioning scale. In the DM2 group the severity of pain was significantly correlated with SF-36 scores 
for bodily pain (p=0.003). Fatigue was significantly correlated with the SF-36 scores for role 
functioning-physical (p=0.001), general health (p=0.02), and vitality (p=0.02).
Conclusion
The impact of DM2 on a patients’ physical, psychological and social functioning is significant and as 
high as in adult-onset DM1 patients. From the perspective of health-related quality of life, DM2 should 
not be considered a benign disease. Management of DM2 patients should include screening for pain 
and fatigue. Symptomatic treatment of pain and fatigue may decrease disease impact and help 
improve health status in DM2, even if the disease itself can not be treated.
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Introduction
Myotonic dystrophy type 2 (DM2) is a dominantly inherited multisystem disease with muscle 
pain, weakness, myotonia, early-onset cataracts, and involvement of other organs, including 
the heart, brain, and gastrointestinal system.1-3 The genetic origin was clarified in 2001 and 
consists of a CCTG expansion repeat located in intron 1 of the zinc finger protein 9 (ZNF9) 
gene on chromosome 3q21.4
The phenotype and clinical course of DM2 are generally more favorable than myotonic 
dystrophy type 1 (DM1), the most common type of muscular dystrophy in adult life.5 The 
severe congenital form in DM1 is absent in DM2, and evidence of anticipation is less striking 
in DM2. Muscle pain is more common in DM2 than in DM1, however.6-8 In various 
neuromuscular disorders, including non-dystrophic myotonic syndromes, pain has been 
shown to be a prominent symptom related to health status.9,10 Fatigue, another dominant 
symptom in neuromuscular diseases, is correlated with lower health status in DM1 and non- 
dystrophic myotonic syndromes.10,11
Although DM2 is a chronic disorder, up to now no studies have assessed health status in 
DM2 patients, where health status is defined as the impact of a disease on a patients’ 
physical, psychological and social functioning.12 Likewise, no data are available about the 
contribution of pain and fatigue on DM2 patients’ health status.
In this nationwide study we investigated health status, as measured with the SF-36, in 
patients with genetically confirmed DM2. We chose the SF-36 because of its extensive use 
both in general population surveys and in patient studies, and its validated translation in 
Dutch.13,14 We also examined the presence of pain (McGill Pain Questionnaire) and fatigue 
(CIS-fatigue scale), and tested the hypothesis that both these two symptoms correlate with 
health status. Results were compared with those of sex-and age-matched adult-onset DM1 
patients, and with data on health status (SF-36 scores) for the Dutch general population.15
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Patients and methods
Patients
All known Dutch DM2 patients (n=32) were approached to participate and 29 (91%) 
responded and completed the questionnaires in their home. All Dutch districts were 
represented in the sample and patients were treated in various hospitals throughout The 
Netherlands. As disease controls, we included 29 sex- and age-matched patients with adult- 
onset DM1. Both DM2 and DM1 patient groups were retrieved from CRAMP, the Dutch 
neuromuscular database.16 Inclusion criteria were a genetically confirmed diagnosis of DM2 
or DM1 at least 1 year prior to this survey and an age of 18 years and older. There were no 
exclusion criteria. The study was approved by the local ethical committee and all patients 
provided written informed consent.
Data collection
SF-36
Health status was assessed using the Dutch version of the SF-36 health survey. The SF-36 
comprises four physical health scales (physical functioning, role limitations due to physical 
problems, bodily pain, and general health perception) and four mental health scales (vitality, 
social functioning, role limitations due to emotional problems, and mental health).17 Items are 
summed per scale and transformed into scores between 0 and 100, with higher scores 
indicating better function or less bodily pain.17 The SF-36 has been used to assess health 
status in many different conditions, including myotonic dystrophy type 1, inclusion body 
myositis and late-onset Pompe disease.11,18,19
MPQ
Pain intensity and analgesic use were assessed with the McGill Pain Questionnaire (MPQ). 
The MPQ is widely used, well validated and reliable.20,21 Pain intensity was scored on a 100 
mm horizontal visual analogue scale (VAS), where 0 indicates no pain and 100 indicates 
pain as bad as could be. The main outcome measure for pain was the magnitude of pain at 
the current moment.
CIS-fatigue
The presence and level of fatigue was assessed using the ‘fatigue severity’ subscale of the 
Checklist Individual Strength (CIS).22 The CIS measures the experience of fatigue-associated 
problems during the previous 2 weeks. The CIS-fatigue severity subscale contains eight 
items scored on a 7-point Likert scale. Scores can range between 8 and 56 with higher 
scores indicating higher levels of fatigue and scores of 35 or more are considered to indicate 
severe fatigue.22,23
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Original data on health status for the Dutch general population, including SF-36 scores, age 
and sex, were available for analysis (n = 1742).15 The clinimetric performance of the SF-36 in 
the Dutch general population has been reported previously.15 Differences in SF-36 scores 
between DM2 and the general population and between DM1 and the population were tested 
by analysis of covariance (ANCOVA) with adjustment for age and sex. Differences in SF-36 
scores between DM2 and DM1 patients were tested with t-tests. Pearson correlations were 
computed to measure the relationship between patient characteristics and SF-36 scales. P- 
values below 0.05 were considered to be significant. Numerical variables are reported as 
mean ± standard deviation (range). Categorical data are reported as number (percentage of 
total).
Statistical analysis
Results
Study population
Of the 32 DM2 patients invited to participate, 29 patients (91%) from 13 families participated 
in the study. Three DM2 patients did not consent and did not specify their reasons for non­
participation. The disease control group existed of 29 sex- and age-matched adult-onset 
DM1 patients from 25 families. There were no missing values in the patient groups. The 
percentage of missing values for each SF-36 scale in the Dutch general population group (n 
= 1742) was lowest for the social functioning and bodily pain scales (0.4%, n = 7, for each) 
and highest for the role functioning-emotional scale (2.9%, n = 51). Demographic 
characteristics of the three groups are listed in Table 6.1. Age, sex, age of onset, disease 
duration and BMI did not differ significantly between the two patient groups.
Table 6.1 Characteristics of patients with DM2 and DM1, and of the general population.
DM2 DM1 Dutch general population15
N 29 29 1742
Age, yrs 53.2 ± 12.1 (28-71) 52.8 ± 12.0 (28-72) 47.6 ± 18.0 (16-94)
Females 20 (69%) 20 (69%) 761 (44%)
BMI, kg/m2 25.1 ± 3.8 (18.8-36.0) 25.7 ± 3.5 (16.5-30.9) -
Age of onset, yrs 35.9 ± 13.4 (12-67) 37.2 ± 13.7 (15-61) -
Disease duration 17.3 ± 15.0 (2-57) 17.0 ± 9.9 (1-38) -
Data presented as mean ± standard deviation (range) or as N (%); BMI = Body Mass Index.
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Health status (SF-36)
Table 6.2 presents raw (unadjusted) group means on the SF-36 scales for DM2 and DM1 
patients. To compare the health status of DM2 and DM1 with the general population, SF-36 
scores were adjusted for age and sex. Figure 6.1 presents the adjusted mean SF-36 scores 
in DM2, DM1 and the general population.
DM2 and DM1 both scored significantly lower than the general population on physical 
functioning (p = 0.001, for both). DM2 reported a significantly lower score on the bodily pain 
scale (indicating a higher level of pain) than the population (p = 0.005), whereas DM1 did not 
differ from the population on the bodily pain scale (p = 0.97).
The scales role functioning-physical, general health, social functioning, role functioning- 
emotional, and vitality yielded a similar pattern of results. On each of these scales, DM2 
scored significantly lower than the population (p <0.01). Likewise, DM1 scored significantly 
lower than the population on each of these five scales (p <0.04). The DM2 score on the 
mental health scale did not differ significantly (p = 0.06) from the Dutch normative sample. 
Comparisons of SF-36 scales between the patient groups revealed that DM2 scored 
significantly lower than DM1 on bodily pain (p = 0.04), indicating a higher level of pain in 
DM2. There were no significant differences between the patient groups on the remaining SF- 
36 scales (p >0.10).
In DM2 age was not correlated with age of onset, SF-36 scores, pain (VAS momentary and 
VAS maximal) scores, and CIS-fatigue. Age of onset was correlated with SF-36 bodily pain 
score (r = 0.39, p = 0.04) in DM2.
In contrast, in DM1 age was correlated with age of onset (r = 0.71, p < 0.001), SF-36 scores 
physical functioning (r = -0.50, p = 0.006), social functioning (r = -0.51, p = 0.005), mental 
health (r = -0.43, p = 0.02), vitality (r = -0.39, p = 0.037), bodily pain (r = -0.39, p = 0.039), 
general health (r = -0.41, p = 0.027) and CIS-fatigue score (r = 0.48, p < 0.01). Furthermore, 
there was an association between age of onset and SF-36 social functioning (r = -0.41, p = 
0.03) and mental health scores (r = -0.41, p = 0.03).
Pain (MPQ)
Mean VAS momentary and maximum pain scores per patient group are shown in Table 6.2. 
Twenty-three out of the 29 DM2 patients (79%) reported pain complaints, 6 DM2 patients 
(21%) reported that they had no pain at all. Eight DM2 patients (28%) used analgesics, 
specifically opioids (3 patients, 10%), NSAIDs (2 patients, 7%), paracetamol (2 patients, 7%), 
and amitriptyline (1 patient, 3%).
Thirteen DM1 patients (45%) reported having pain, the other 16 DM1 patients (55%) reported 
that they had no pain at all. Seven DM1 patients (24%) used analgesics, specifically NSAIDs 
(2 patients, 7%), paracetamol (5 patients, 17%), and amitriptyline (1 patient, 3%).
DM2 scored significantly higher than DM1 on VAS maximum pain (t(56) = 3.07, p =0.003), 
indicating more pain in DM2. Although DM2 scored higher than DM1 on VAS momentary 
pain, this difference did not achieve significance (t(56) = 1.79, p =0.079).
74
Table 6.2 Mean scores of DM2 patients and DM1 patients on the outcome measures.
DM2 DM1 P-value DM2-DM1
Health status (SF-36)
Physical health
Physical functioning 38.4 (27.9) 50.7 (28.6) 0.11
Role functioning-physical 37.1 (35.7) 50.9 (41.4) 0.18
Bodily pain 57.6 (24.6) 73.1 (31.6) 0.04
General health 42.4 (23.1) 41.7 (19.7) 0.90
Mental health
Vitality 45.9 (23.0) 39.1 (16.0) 0.20
Social functioning 69.1 (29.5) 70.0 (24.7) 0.90
Role functioning-emotional 58.5 (44.3) 65.4 (43.2) 0.55
Mental health 69.7 (22.9) 68.0 (20.8) 0.77
Pain (MPQ)
Pain (%) 23 (79.3%) 13 (44.8%) 0.014
VAS-momentary pain (mm) 23.6 (22.5) 13.1 (21.8) 0.079
VAS-maximum pain (mm) 56.3 (34.9) 27.8 (36.0) 0.003
Fatigue (CIS)
Severe fatigue (%) 19 (65.5%) 25 (86.2%) 0.066
CIS-fatigue score 38.7 (13.1) 44.3 (8.7) 0.058
Data presented as mean (SD) or N (%).
In both DM2 and DM1 VAS momentary scores were correlated with VAS maximum (DM2: r = 
0.70, p <0.001, DM1: r = 0.81, p <0.001), SF-36 score bodily pain (DM2: r = -0.40, p = 0.03, 
DM1: r = -0.71, p < 0.01) and CIS-fatigue score (DM2: r = 0.39, p = 0.04, DM1: r = 0.43, p =
0.02). In DM1 VAS momentary scores also correlated with SF-36 score social functioning (r = 
-0.51, p <0.01) and role functioning emotional (r = -0.40, p = 0.03).
Fatigue (CIS-fatigue)
Mean fatigue scores per patient group are shown in Table 6.2. Nineteen of the 29 DM2 
patients (66%) and 25 out of the 29 DM1 patients (86%) reported severe fatigue. Although 
there was a higher average level of fatigue in DM1 patients in comparison to DM2, this 
difference did not achieve significance (p = 0.059).
In DM2 CIS-fatigue scores were correlated with SF-36 scores role functioning-physical (r = 
-0.58, p = 0.001), vitality (r = -0.44, p = 0.016) and general health (r = -0.42, p=0.02), as well 
as with VAS maximum (r = 0.70, p < 0.001) and VAS momentary scores (r = 0.39, p = 0.04). 
In DM1 CIS-fatigue scores were significantly correlated with all of the SF-36 scales except 
for the scale mental health (Table 6.3).
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Figure 6.1 Health status in Dutch myotonic dystrophy type 2 patients compared to the Dutch general 
population. Solid line: DM2 (n=29). Dotted line: DM1 (n=29). Dashed line: general population 
(n=1742). Values are mean scores for SF-36 scales, adjusted for age and sex. The center of the 
graph represents the lowest possible score on each scale. BP= bodily pain, PF=physical functioning, 
RP=role functioning-physical, GH=general health, VT=vitality, SF=social functioning, RE=role 
functioning-emotional, MH=mental health.
Discussion
In this nationwide study we found that DM2 patients scored significantly lower than the Dutch 
general population on seven of the eight physical and mental health scales of the SF-36. SF- 
36 scores in DM2 were comparable to those of adult-onset DM1 patients on all SF-36 scales 
except for bodily pain scale. DM2 scored significantly lower than DM1 on the bodily pain 
scale, indicating more body pain in DM2. These results demonstrate that DM2 has a high 
disease impact on physical as well as on mental health functioning. This impact is at least 
comparable to that of adult-onset DM1. Until now, DM2 was considered a benign disease, 
mainly because of the more favorable phenotype and clinical course of DM2 in comparison 
with DM1.5 However, this cross-sectional study clearly demonstrates that the symptoms of 
DM2 greatly impact patients’ self-reported health status.
Although DM2 and DM1 are usually considered neuromuscular disorders, the results of our 
study reflect their multisystem character. The low scores on both physical and mental health 
scales in the DM2 and DM1 patients in comparison to the general population are in contrast 
with results from previous studies on health status in more restricted neuromuscular 
disorders, including non-dystrophic myotonias, inclusion body myositis, late-onset Pompe 
disease, and immune-mediated polyneuropathies.10,18’19’24 In these neuromuscular diseases,
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although low scores were found on the physical health scales, mental health scores 
remained relatively high. Preserved high mental scores in chronic disorders have been 
explained by the fact that patients’ limitations in daily activities develop over a long period. 
Over time, patients may adapt to their situation and adjust their expectations, priorities and 
even redefine concepts related to mental health aspects of quality of life, leading to the so 
called response shift.25,26 It may well be possible that in DM2 and DM1, in which cognitive 
impairment such as frontal lobe dysfunction and an avoidant personality trait have been 
reported,27,28 adaptive coping behavior is reduced or even not present, in contrast to other 
disabling neuromuscular disorders.
Cognition in terms of overall intelligence does not seem to be impaired in DM2.29 The ability 
to complete this self report questionnaire in a reliable and valid manner was, therefore, 
present in DM2 patients. In addition, all DM2 and DM1 patients who participated in the 
current study had been diagnosed at least 1 year prior to the study, so it is unlikely that the 
observed lower scores on vitality, social functioning, and role limitations due to emotional 
problems could be attributed to a reactive depression. Our health status results in DM1 are 
corroborated by previous research in which health status was measured with the SF-36 in a 
group of 322 adult-onset DM1 patients.11 Aside from a difference in age between the present 
DM1 group and the one reported by Kalkman (mean age: 52.8 yrs versus 43.0 yrs 
respectively) results are comparable; all physical and mental health scores, except for the 
score bodily pain, were lower than those of the general population. Pain was not evaluated in 
that study, but fatigue was correlated with a lower reported health status in physical and 
social functioning.
Compared to the general population, the differences in SF-36 scores of DM2 patients was 
most profound for the physical functioning scale (adjusted mean score of DM2 patients 43.5 
(± 21.1) versus 82.6 (± 19.7) of the general population). The DM2 score on the mental health 
scale was the only SF-36 score not significantly (p=0.06) lower compared to the Dutch 
normative data (adjusted mean 69.9 (± 18.6) versus 76.4 (± 17.4) of the general population). 
However, the outcome in DM2 is comparable to SF-36 mental health scores of two other 
samples with clearly defined chronic health conditions, namely migraine and cancer patients 
(SF-36 mental health score 72.0 and 68.0 respectively).15
In DM2, age did not correlate with any of the SF-36 scales. This lack of correlation between 
age and health status may be an indication that the symptoms of DM2 are relatively stable 
over the lifespan. There was a positive correlation between age of onset and the bodily pain 
scale of the SF-36, indicating more bodily pain in patients whose symptoms began at a 
younger age and conversely, less bodily pain in patients whose symptoms began at an older 
age. This implies that there may be a tendency for pain to worsen over time in DM2. 
However, future research should investigate these associations in the context of a 
prospective design.
In contrast, in DM1, age was strongly associated with age of onset. This strong correlation, 
showing that older patients in this sample had a later age of onset and younger patients had 
an early age of onset, underscores the shortened life expectancy associated with DM1. Age 
in DM1 was highly associated with more impairments in functioning and more body pain (p <
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0.04 on six scales), underscoring the progressive nature of this disease. These DM1 results 
are corroborated by previous research of us and others. In the previously mentioned study 
on health status in DM1 patients, similar associations were found between age and SF-36 
scores.11 As also that study had a cross-sectional design, the need for future longitudinal 
research exits. In contrast, recent data in non-dystrophic myotonic syndromes showed no 
correlation between age and SF-36 scores, indicating that age did not appear to play a role 
in health status.10 Taken together, these results again underscore the progressive nature and 
shortened life expectancy in DM1 in comparison to DM2 and non-dystrophic myotonic 
syndromes.
In DM2, age did not correlate with pain, as measured with VAS, or fatigue, as measured with 
CIS, again indicating that the symptoms of DM2 may remain somewhat stable over the 
lifespan. There was a significant correlation in DM2 between increased pain and higher 
levels of fatigue. Also, fatigue was negatively correlated to the scales vitality, general health 
and role functioning-physical. Of course, one cannot infer causality on the basis of 
correlations alone. However, both pain and fatigue appear to be related to a decrease of 
health status in DM2. Pain is a chronic symptom in DM2 and the observed association 
between pain and fatigue underscores the need to identify and provide effective pain 
treatments for DM2 patients.6
Some mention should be made of potential limitations of this study. First, in eight families 
with DM2, several members were evaluated. Shared genetic cofactors or recognized 
behavioral biasing could have influenced pain, and data on physical, psychological and social 
functioning. Second, because DM2 is, in general, more likely to be under diagnosed than 
DM1, the participating DM2 patients may be more representative of the severe end of the 
DM2 disease spectrum, leading to lower physical and functional scores. Third, by studying 
the Dutch DM2 population, this study does not take potential cultural differences (e.g. The 
Netherlands versus United States) into account. However, evidence suggests that cultural 
differences do not play a role in health status in neuromuscular disorders.19,30 Fourth, despite 
the solidity of our nationwide findings, it should be noted that we did not evaluate the 
clinimetric properties of the SF-36 in these specific patient populations, an omission that 
future research in this area could address.
Despite these limitations, the comprehensiveness of the SF-36 may help to increase 
physicians’ awareness, by providing information on health status in patients with DM2, 
besides the traditional investigation of symptoms, signs and laboratory studies.
In summary, the current study shows the impact of DM2 on a patients’ physical, 
psychological and social functioning is significant and as high as in adult-onset DM1 patients. 
From the perspective of health-related quality of life, DM2 should, therefore, not be 
considered a benign disease. Pain and fatigue are correlated to a lower reported health 
status. Management of DM2 patients should include screening for pain and fatigue. 
Symptomatic treatment of these two symptoms may decrease disease impact and improve 
health status in DM2, even if the disease itself cannot be treated. There remains a need for 
prospective follow-up studies assessing the natural course of DM2 in relation to health 
status, fatigue and pain.
78
References
1. Harper PS, van Engelen BG, Eymard B, Wilcox DE. Myotonic Dystrophy: present 
management, future therapy. New York: Oxford University Press, 2004.
2. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 
2007;6:294-306.
3. Tieleman AA, van Vliet J, Jansen JB, van der Kooi AJ, Borm GF, van Engelen BG. 
Gastrointestinal involvement is frequent in myotonic dystrophy type 2. Neuromuscul Disord 
2008;18:646-9.
4. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP. 
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 
2001 ;293:864-7.
5. Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, Kress W, Schoser B, Moxley 
R. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other 
myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006;16:403-13.
6. George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal pain in patients 
with myotonic dystrophy type 2. Arch Neurol2004;61:1938-42.
7. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol 
Neurosurg Psychiatry 2010;81:358-67.
8. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM. Chronic pain in 
persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch Phys Med 
Rehabil 2008;89:320-8.
9. Jensen MP, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with 
neuromuscular disease. Arch Phys Med Rehabil2005;86:1155-63.
10. Trip J, de Vries J, Drost G, Ginjaar HB, van Engelen BG, Faber CG. Health status in non- 
dystrophic myotonias: close relation with pain and fatigue. J Neurol2009;256:939-47.
11. Kalkman JS, Schillings ML, van der Werf SP, Padberg GW, Zwarts MJ, van Engelen BG, 
Bleijenberg G. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, 
and HMSN-I. J Neurol Neurosurg Psychiatry 2005;76:1406-9.
12. De Vries J. Quality of life assessment. In: Vingerhoets AJJM, ed. Assessment in Behavioral 
Medicine. Hove: Brunner-Routledge, UK;2001:353-70.
13. Wagner AK, Gandek B, Aaronson NK, Acquadro C, Alonso J, Apolone G, Bullinger M, 
Bjorner J, Fukuhara S, Kaasa S, Leplege A, Sullivan M, Wood-Dauphinee S, Ware JE Jr. 
Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results 
from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 
1998;51:925-32.
14. Gandek B, Ware JE Jr. Methods for validating and norming translations of health status 
questionnaires: the IQOLA Project approach. International Quality of Life Assessment. J Clin 
Epidemiol 1998;51:953-9.
15. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers 
MA, te Velde A, Verrips E. Translation, validation, and norming of the Dutch language 
version of the SF-36 Health Survey in community and chronic disease populations. J Clin 
Epidemiol 1998;51:1055-68.
16. van Engelen BG, van Veenendaal H, van Doorn PA, Faber CG, van der Hoeven JH, 
Janssen NG, Notermans NC, van Schaik IN, Visser LH, Verschuuren JJ. The Dutch
79
neuromuscular database CRAMP (Computer Registry of All Myopathies and 
Polyneuropathies): development and preliminary data. Neuromuscul Disord 2007;17:33-7.
17. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 
Conceptual framework and item selection. Med Care 1992;30:473-83.
18. Sadjadi R, Rose MR, Muscle Study Group. What determines quality of life in inclusion body 
myositis? J Neurol Neurosurg Psychiatry 2010;81: 1164-6.
19. Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, Van Doorn PA, van der 
Ploeg AT. Late-onset Pompe disease primarily affects quality of life in physical health 
domains. Neurology 2004;63:1688-92.
20. Vanderiet K, Adriaensen H, Carton H, Vertommen H. The McGill Pain Questionnaire 
constructed for the Dutch language (MPQ-DV). Preliminary data concerning reliability and 
validity. Pain 1987;30:395-408.
21. Van der Kloot WA, Oostendorp RA, van der Meij J, van den Heuvel J. The Dutch version of 
the McGill pain questionnaire: a reliable pain questionnaire. Ned Tijdschr Geneeskd 
1995;139:669-73.
22. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. 
Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383-92.
23. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, van der Wilt GJ, 
Spinhoven P, van der Meer JW. Cognitive behavior therapy for chronic fatigue syndrome: a 
multicentre randomised controlled trial. Lancet 2001 ;17:841-7.
24. Merkies ISJ, Schmitz PIM, van der Meche FGA, Samijn JPA, van Doorn PA. Quality of life 
complements traditional outcome measures in immune-mediated polyneuropathies. 
Neurology 2002;59:84-91.
25. Carver CS, Scheier MF. Scaling back goals and recalibration of the affect system are 
processes in normal adaptive self-regulation: understanding ‘response shift’ phenomena. 
Soc Sci Med2000;50:1715-22.
26. Kempen GI, Ormel J, Brilman EI, Relyveld J. Adaptive responses among Dutch elderly: the 
impact of eight chronic medical conditions on health-related quality of life. Am J Public 
Health 1997;87:38-44.
27. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, Cattaneo E, Cotelli M, 
Gobbo C, Fazio F, Siciliano G, Mancuso M, Vitelli E, Zhang S, Krahe R, Moxley RT. 
Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and 
in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 2003;13:813-21.
28. Meola G, Sansone V, Perani D, Colleluori A, Cappa S, Cotelli M, Fazio F, Thornton CA, 
Moxley RT. Reduced cerebral blood flow and impaired visual-spatial function in proximal 
myotonic myopathy. Neurology 1999;53:1042-50.
29. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 
2007;36:294-306.
30. Jenkinson C. Comparison of UK and US methods for weighting and scoring the SF-36 
summary measures. J Public Health Med 1999;21:372-6.
80
81
82
iS
&cc
- c
O
Strong association between myotonic 
dystrophy type 2 and autoimmune diseases
AA Tieleman1, AA den Broeder2, A-E van de Logt1, BGM van Engelen1 
J Neurol Neurosurg Psychiatry 2009;80:1293-1295
1Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands
2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
83
Abstract
Background and aim
Myotonic dystrophy type 2 (DM2) is a dominantly inherited multisystem disorder, characterised by 
progressive proximal weakness, myotonia, cataracts and cardiac conduction abnormalities. Our 
clinical impression of an association between DM2 and autoimmune diseases or autoantibody 
formation has not been published previously. The aim of the present study was to investigate the 
frequency of autoimmune diseases and serum autoantibodies in patients with DM2 compared with 
patients with adult-onset myotonic dystrophy type 1 (DM1).
Methods
Twenty-eight genetically proven Dutch DM2 patients participated in the study and were compared with 
51 age and sex matched adult-onset DM1 patients. As the primary outcome measure, the presence of 
an autoantibody or autoreactive T cell associated autoimmune disorder was assessed. As a 
secondary outcome measure, the presence of autoantibodies in serum (nuclear and non-nuclear 
antibodies) was assessed in all patients.
Results
The frequency of autoimmune diseases (21% vs 2%) and the frequency of autoantibodies (25% vs 
2%) were both significantly (p <0.01) higher in DM2 patients compared with DM1 patients. Data on 
DM1 patients were comparable with the general population. Results were not confounded by smoking, 
medication use, familial clustering, age or sex.
Conclusion
The results provide new insight into the clinical picture of DM2. In addition, possible explanations for 
the association between DM2 and autoimmune diseases are proposed.
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Introduction
Myotonic dystrophy type 2 (DM2) is caused by a CCTG expansion in intron 1 of the ZNF9 
gene on chromosome 3q21.3.1 The clinical picture of DM2 shows similarities to as well as 
differences from that of myotonic dystrophy type 1 (DM1). Shared core features are 
autosomal dominant inheritance, muscle weakness, myotonia, cataracts, and multi organ 
involvement. Notably absent is a congenital form of DM2 while evidence of anticipation is 
less striking than in DM1, and muscle pain is more prominent in DM2.2 
In a recent observational study on gastrointestinal symptoms in DM2, an unexpectedly high 
frequency of autoimmune diseases was suggested in our DM2 patient group.3 An increased 
occurrence of autoimmune disorders was previously emphasised in one of the first large 
families, published as proximal myotonic dystrophy, buy later shown to be DM2.4 
A small study in 20 DM2 patients showed reduced serum levels of IgG and IgM but normal 
serum IgA levels, the same pattern that is seen in DM1.5 In that study, however, autoimmune 
diseases and autoantibody formation were not assessed.
In the current study, we set out to assess whether DM2 is indeed associated with a high 
frequency of autoantibody or autoreactive T cell associated autoimmune diseases compared 
with DM1 and whether this possible association is reflected in an increased frequency of 
autoantibodies in serum.
Patients and methods 
Patients
All known DM2 patients in The Netherlands were identified, using the Dutch neuromuscular 
database, and approached for participation in the study with the consent of their treating 
physician. A control group of sex and age matched adult-onset DM1 patients was identified 
and approached identically. Inclusion criteria were age > 18 years and confirmed diagnosis 
of DM1 and DM2 by genetic testing. There were no exclusion criteria.
Methods
The primary outcome measure -  the presence of an autoantibody or autoreactive T cell 
associated autoimmune disorder -  was assessed in all patients using a standardised 
questionnaire that examined medical history, symptoms and signs, and medication use. The 
diagnosis of an autoimmune disease was made based on classification criteria if possible, or 
otherwise based on the evaluation of a rheumatologist. In the case of a previously diagnosed 
autoimmune disease, the patient’s medical report was checked and verified regarding the 
accuracy of the diagnosis. A physical examination was done if this was necessary for the 
diagnosis.
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The following diseases were considered to be definite or probable autoantibody and/or 
autoreactive T cell related autoimmune diseases and were actively sought for:
• Rheumatological diseases: rheumatoid arthritis, systemic diseases (M Sjogren, 
systemic lupus erythematosus, antiphospholipid syndrome, mixed connective tissue 
disease), myositis, antineutrophil cytoplasmic antibody positive vasculitis (Churg- 
Strauss syndrome, Wegener’s granulomatosis, microscopic polyangiitis, systemic 
sclerosis), spondyloarthropathies (M Bechterew, enterogenic arthropathies, 
syndrome of Reiter, acute rheumatoid fever/post streptococci reactive arthritis), 
polymyalgia rheumatica, giant cell arteritis and juvenile rheumatoid arthritis 
(systemic, oligoarticular, polyarticular)
• Dermatological diseases (vitiligo, cutaneous lupus erythematosus)
• Ophthalmological diseases ((epi)scleritis, uveitis anterior)
• Gastrointestinal diseases (coeliac sprue, Crohn’s disease, ulcerative colitis)
• Neurological diseases (myasthenia gravis, multiple sclerosis)
• Haematological diseases (aplastic anaemia, vitamin B12 deficiency)
• Renal disease (antineutrophil cytoplasmic antibody associated glomerulonephritis)
• Liver diseases (autoimmune hepatitis, primary biliary cirrhosis, sclerosing 
cholangitis)
• Endocrine diseases (diabetes mellitus type 1, Addison’s disease, hypothyroidism 
and hyperthyroidism)
It can be argued for some endocrine diseases whether all cases constitute autoimmune 
disease. For example, hypothyroidism is considered an autoimmune phenomenon in more 
than 90% of cases, hyperthyroidism is autoimmune mediated in 70-80% of cases and 
pernicious anaemia (including antiparietal cell antibodies and/or antibodies against intrinsic 
factor) is the most common cause of vitamin B12 deficiency. A sensitivity analysis for the 
association between DM2 and autoimmune diseases was therefore also conducted based on 
a more lenient definition of autoimmune disease, including hypothyroidism, hyperthyroidism 
and vitamin B12 deficiency. For the secondary outcome measure, the following 
autoantibodies were assessed in the serum of all patients according to standardised 
methods: IgM rheumatoid factor6, anti-cyclic citrullinated peptide (CCP)7 and antinuclear 
antibodies (ANA).8 If ANA were found, then a further specification was done using line 
blotting or anti-dsDNA measurement, depending on the fluorescence pattern. Other 
autoantibodies were only measured if necessary for the classification of an autoimmune 
disorder.
Statistical analysis
A Fisher’s exact test was used to compare the frequencies of autoimmune diseases and auto 
antibodies in the DM2 population versus the control population. A power analysis was 
conducted on the basis of the following assumptions: 32 DM2 patients, a control group of 32 
DM1 patients (ratio=1), an expected frequency of autoimmune diseases in the DM1
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population of 5% (according to the prevalence in the Dutch general population)9, an expected 
prevalence of 30% in the DM2 population (based on the previously mentioned observations) 
and an alpha of 0.05 and the use of a one-tailed test. The analysis showed the power of this 
study to be 80%. All protocols and procedures were according to good clinical practice 
guidelines. The local ethics committee approved the study and written informed consent was 
obtained from all patients.
Results
Patient population
Twenty-eight of the 31 known Dutch patients with genetically proven DM2 participated in the 
study. They belonged to 10 different DM2 families. Two patients did not consent and one 
patient was not able to participate in the study because of psychological problems. The 
control group was enlarged to increase the accuracy of this study. Fifty-one DM1 patients, 
originating from 42 different DM1 families, matched for age (mean age 51 years) and sex 
(75% female) were enrolled (Table 7.1).
Table 7.1 Baseline characteristics of DM2 and DM1 patients.
Characteristic DM2 DM1
N 28 51
Female sex (n (%)) 22 (79) 38 (75)
Age (years) (mean (SD)) 55 (12) 51 (10)
Never smoked (%) 39 45
Currently smoking (%) 4 20
Autoimmune diseases
Rheumatoid arthritis (N) 2 0
M Sjögren (N) 1 0
Churg-Strauss syndrome (N) 1 0
Crohn’s disease (N) 0 1
Uveitis anterior (N) 1 0
Autoimmune hepatitis (N) 1 0
Aplastic anaemia (N) 1 0
Vitamin B12 deficiency (N) 7 2
Hypothyroidism (N) 2 1
Hyperthyroidism (N) 2 0
Total No of patients with > 1 
autoimmune diseases (N)*
12 4
*According to the more lenient definition
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Autoimmune diseases
The frequency of autoimmune diseases was significantly higher among DM2 patients than 
among DM1 patients (Table 7.2). The six DM2 patients (one man, five women) with an 
autoimmune disease belonged to five different DM2 families. One male in the DM1 
population was diagnosed with an autoimmune disorder (Crohn’s disease).
When hypothyroidism, hyperthyroidism and vitamin B12 deficiency were included as 
autoimmune diseases, the frequency of autoimmune diseases remained significantly higher 
in the DM2 group compared with the DM1 group. Compared with an expected frequency of 
autoimmune diseases (5%) in the general population,9 the frequency of autoimmune 
diseases in the DM2 group was significantly increased.
Autoantibodies
ANA were detected significantly more frequently in DM2 patients than in DM1 patients. The 
overall presence of autoantibodies was significantly more common in the DM2 population 
than in the DM1 population (Table 7.2).
Two of the five DM2 patients with ANA positivity were not diagnosed with an autoimmune 
disease. The cases of rheumatoid factor or anti-CCP positivity were associated with an 
autoimmune disease in the DM2 group.
Table 7.2 Frequency (proportion) of autoimmune diseases and autoantibodies in DM2 and DM1 
patients.
Outcome measure
DM2
(N=28)
95% CI
DM1
(N=51)
95% CI P2-1
value
Autoimmune diseases 6 (0.21) 0.06-0.37 1 (0.02) 0-0.06 0.007
Rheumatoid factor positive 4 (0.14) 0.007-0.28 1 (0.02) 0-0.06 0.06
Anti-CCP positive 2 (0.07) 0-0.17 0 (0%) - 0.13
ANA positive 5 (0.18) 0.03-0.33 0 (0%) - 0.005
No of patients with > 1 
autoantibodies positive
7 (0.25) 0.08-0.42 1 (0.02) 0-0.06 0.003
P2-1= P value difference DM2 and DM1.
Discussion
To our knowledge, this is the first report describing a significantly higher frequency of 
autoimmune diseases (21% vs 2%) and autoantibodies (25% vs 2%) in DM2 patients 
compared with DM1 patients and the general population.
The association between DM2 and increased frequency of autoimmune diseases has not 
been described in literature previously. However, one pedigree study in a large family, 
published as proximal myotonic dystrophy but later shown to be DM2, showed autoimmune
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susceptibility, with one patient suffering seropositive destructive rheumatoid arthritis and one 
patient having giant cell arteritis. Another patient was seropositive for rheumatoid factor 
without showing clinical symptoms.4 Several case reports have been published concerning 
the coexistence of DM1 and autoimmune diseases.10-13 Cases include autoimmune mediated 
hyperthyroidism, Addison’s disease, Hashimoto’s thyroiditis, thrombocytopenic idiopathic 
purpura and myasthenia gravis. Also, hypogammaglobulinaemia and increased frequency of 
autoantibody formation has been described in DM1 patients.14-20 To date, no cohort study 
has confirmed these sporadic observations and no mechanism of action has been elucidated 
conclusively. An increased frequency of autoimmune diseases was not found in the DM1 
population in our study.
The internal validity of this study seems adequate. The presence of a significant selection or 
observation bias seems unlikely, considering the non-selective inclusion and broad inclusion 
criteria, and the use of a nicely matched control group. However, other factors could have 
confounded the relation between DM2 and the high frequency of autoimmune diseases. 
Firstly, drug induced autoimmunity could play a role. Drugs that are known to induce 
autoreactivity include procainamide, hydralazine, sulfa drugs, anti-tumour necrosis factor 
agents (eg. infliximab, adalimumab, etanercept), minocycline, interferons and HMG coA 
reductase inhibitors.21 Of these drugs, however, only statins were used among DM1 and 
DM2 patients, and were not associated with the occurrence of autoimmune diseases or ANA 
production. The classical presentation of drug-induced lupus was not found in these patients. 
Secondly, family associated autoimmunity could have confounded the relation between DM2 
and the frequency of autoimmune diseases. However, the six DM2 patients with autoimmune 
diseases in our DM2 group belonged to five different DM2 families. Thirdly, smoking was 
considered as a candidate confounder. Cigarette smoking is considered a strong risk factor 
for the development of rheumatoid arthritis although this relation has not been described for 
other autoimmune diseases. No significant difference was seen in past or current smoking 
between the two groups.
Two possible explanations can be proposed for the most likely true association between 
DM2 and autoimmune diseases. The DM2 mutation may directly affect immune function 
through a RNA mediated disease process.22
Another possibility is genetic linkage as a cause for this association. The co-occurrence of 
autoimmune disorders could be explained by a genetic mutation in flanking genes in linkage 
disequilibrium with the DM2 expansion, conferring susceptibility for autoimmune disease.
The high frequency of autoimmune diseases and ANA in DM2 -  assuming good 
generalisation of these results -  has implications for clinical practice. Because DM2 is a 
multisystem disease that is treated via a multidisciplinary approach by a neurologist, an 
ophthalmologist, a cardiologist and a rehabilitation specialist, physicians working in all of 
these medical specialities need to be aware of the manifestations of immunological disease. 
This is especially important because symptoms of autoimmune disease may overlap with 
DM2 symptoms, thus hampering early detection. Apart from its clinical significance, this 
association is of interest for research into the genetic causes of autoimmune diseases.
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Abstract
Objective
The aim of the study was to determine the presence and extent of muscle changes in myotonic 
dystrophy type 2 (DM2) detected by muscle ultrasound. Results were compared to adult-onset 
myotonic dystrophy type 1 patients (DM1) and healthy controls. Furthermore, we tested the hypothesis 
that structural muscle changes correlate with age, quantitative muscle force and serum creatine 
kinase in both disorders.
Methods
Ultrasound examinations were performed on seven muscles (masseter muscle, elbow flexors and 
forearm flexors, rectus femoris and tibialis anterior muscle) in 31 patients with genetically confirmed 
DM2 and 31 age- and sex-matched DM1 patients.
Results
In DM2 all examined muscles showed significantly (p<0.001) increased echo intensities, indicating 
structural muscle changes. Atrophy of the masseter muscle and the rectus femoris were both found in 
23% of DM2 patients, and 19% of DM2 patients showed atrophy of the elbow flexors. Muscle 
thickness was significantly more decreased in the proximal arm muscles in DM2 compared to DM1. 
Echo intensity sum score correlated positively with age (DM2: r= 0.57, p= 0.001; DM1: r= 0.30, p=
0.10), and negatively with quantitatively measured muscle force (DM2: r= -0.36, p=0.048; DM1: r= 
-0.69, p<0.001) in both DM types.
Conclusions
All tested muscles are affected and structurally abnormal in patients with DM2. Proximal arm muscles 
are more affected in DM2 compared to DM1, which corresponds to clinical findings. Structural muscle 
changes increase with age in both DM types, which shows the progressive course of the disorders. 
Ultrasound is a sensitive technique for quantifying muscle changes and may also be useful in 
prospective studies measuring the natural disease course or the results of treatment strategies in DM 
types.
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Introduction
Myotonic dystrophy type 2 (DM2) is a dominantly inherited neuromuscular disease 
characterised by a multisystem phenotype with core features of progressive muscle 
weakness, muscle pain and myotonia.1,2 DM2 is caused by a CCTG repeat expansion in 
intron 1 of ZNF9 located on chromosome 3q21.3.3
Neuromuscular symptoms in DM2 show both similarities and differences with respect to 
myotonic dystrophy type 1 (DM1), the most common type of muscular dystrophy in adult life. 
Muscle pain is more prominent in DM2 in comparison to DM1,4,5 Weakness and muscle 
atrophy tend to be proximally predominant in DM2, in contrast to DM1, in which these are 
distally predominant.2 Myotonia measured by needle electromyography has been shown to 
be distally predominant in both types of DM.6
Literature on skeletal muscle imaging in DM2 reports of one MRI study comparing muscle 
changes in 14 DM2 and 15 DM1 patients.7 Fatty degeneration was found in only 36% of DM2 
patients. Since all DM2 patients with mild to moderate proximal muscle weakness (n=6) had 
normal MRI results, the authors concluded that MRI is not a reliable indicator for skeletal 
muscle involvement in mildly affected DM2 patients.
Muscle ultrasound is a non-invasive technique for detecting the presence and extent of 
changes in muscle structure and muscle thickness in various parts of the body.8,9 Muscles 
affected by a neuromuscular disease show increased echo intensity, i.e. the muscles appear 
whiter.10-13 This higher echo intensity is the result of increased intramuscular fibrous and fatty 
tissue.14,15 Furthermore, muscle thickness can be decreased, normal, or increased in the 
affected muscles.16,17 The purpose of this study was to determine the presence and extent of 
muscle changes in DM2 by ultrasound compared to adult-onset DM1 and healthy controls. In 
addition, we tested the hypothesis that structural muscle changes correlate with age, 
quantitatively measured muscle force and serum creatine kinase (CK) in both disorders.
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Patients and methods
Study population
DM2 and DM1 patients were recruited through the Dutch Patient Association for 
Neuromuscular Diseases (VSN) and by using the Dutch neuromuscular database.18 All 
known DM2 patients (n = 38) in The Netherlands and a control group of sex- and age- 
matched adult-onset DM1 patients were approached for participation in the study. Inclusion 
criteria were age above 18 years, genetically confirmed diagnosis of DM2, and genetically 
confirmed diagnosis of DM1 in the patient or at least one family member. The local medical 
ethics committee approved the study and each patient gave written informed consent.
Laboratory investigation
Creatine kinase was measured in all patients (normal values CK < 220 U/L for males and CK 
< 170 U/L for females).
Muscle force measurement
Muscle strength (score 0-5) was assessed manually according to the Medical Research 
Council (MRC) scale.19 Two proximal (elbow flexors and quadriceps femoris) and two distal 
muscle groups (forearm flexors and tibialis anterior muscle) were tested bilaterally, which 
resulted in a maximum MRC sum score of 40 (8x5). Muscle strength was defined as mildly 
reduced when the MRC sum score was 36 to 39, moderately reduced in case of a MRC sum 
score of 32 to 35, and severely reduced with a MRC sum score less than 32. Clinical 
impairment in DM1 patients was also categorized using the five-point Muscular Impairment 
Rating Scale (MIRS) for myotonic dystrophies.20
To quantify mild muscle weakness, we also measured muscle force with dynamometry (in 
Newton) performed in four muscle groups bilaterally (elbow flexion, three-point grip, knee 
extension and ankle dorsiflexion) in standardized positions using a handheld dynamometer 
(type CT 3001, C.I.T. Technics, Haren, The Netherlands, www.citec.nu). 21,22 All patients were 
tested by the same researcher (A.V.) to reduce variations in testing. The mean of two 
measurements of each muscle group on both sides was calculated and compared with the 
p50 and p5 value of previously reported healthy controls.22 The sum score of dynamometry 
was calculated by the sum of the muscle force of all muscles tested using dynamometry.
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Ultrasound examinations were performed on seven muscles (right masseter muscle, right 
and left elbow flexors (biceps brachii and brachialis muscle), right and left forearm flexors, 
right rectus femoris, and the left tibialis anterior muscle). The method of ultrasound scanning, 
measurement of echo intensity and muscle thickness were in accordance with our previous 
protocol.23, 24 A broad band linear 5-17 MHz transducer was used for each muscle, except for 
the rectus femoris, which was measured using a broad band linear 4-8 MHz transducer to 
ensure sufficient depth penetration (Philips IU 122; Philips Healthcare, Best, The 
Netherlands). Equipment settings were kept constant (gain 70dB, compression 55, focal 
zone 1-2.5 cm for the 5-17 MHz transducer, and gain 59dB, compression 55, focal zone 0-6 
cm for the 4-8 MHz transducer).
Echo intensity and muscle thickness are different for each muscle group and depend on age 
and sex.25,26 As we adhered to the protocol used in our earlier studies, we were able to use 
previously established normal values.24 Only the rectus femoris muscle was measured with a 
lower frequency probe for which normal values were established in a group of 54 healthy 
volunteers.27 The previously established normal values were converted with a linear 
regression equation because a new ultrasound device was used.28 To compare individual 
patients and muscles in this study, we transformed echo intensity and muscle thickness into 
z-scores. In effect, the z-score reflects the number of standard deviations (SD) that a certain 
measurement deviates from normal, given a certain age and sex.23,29 Abnormal echo 
intensity was defined as one muscle with z-score greater than 2. For muscle atrophy or 
hypertrophy, the same cut-off value was used (muscle thickness z-score <-2, respectively z- 
score >2). The sum score of echo intensity was calculated by adding up the z-scores of echo 
intensity for all of the examined muscles.
Data analysis
The data were analyzed using the SPSS package for Windows, version 16.0 (SPSS Inc, 
Chicago, IL, USA). A one-sample f-test was used to assess whether the patients showed a 
significant increase or decrease in echo intensity and muscle thickness z-scores compared 
with the healthy population. An independent-sample f-test was used to compare echo 
intensity, muscle thickness and muscle force values for DM1 and DM2. We ran a paired- 
sample f-test to compare the absolute values of echo intensity and muscle thickness of the 
dominant and non-dominant arm muscles. Correlations between the echo intensity sum 
score and age, quantitatively tested muscle force and CK were calculated using Pearson’s 
correlation coefficient. Statistical significance was defined as p-value <0.05.
Muscle ultrasound
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Results
Study population
Of the 38 DM2 patients, four did not consent without specifying their reasons and two were 
unable to participate due to transport problems. One DM2 patient was excluded because of 
comorbidity (hemiparesis due to a cerebrovascular accident). We thus included 31 DM2 
patients, from 12 unrelated families. The study also included 31 age and sex-matched DM1 
patients, from 27 different DM1 families. In the majority of DM1 patients paternal inheritance 
was found. There were no significant differences between the two groups regarding weight, 
length and handdominance, and all patients were ambulatory (Table 8.1).
Table 8.1 Demographic characteristics of DM2 and DM1 patients.
Characteristic DM2 DM1
N 31 31
Females 24 (77%) 24 (77%)
Age, yr 53.5 ± 12.2 (29-74) 52.8 ± 12.0 (23-70)
Weight, kg 74.7 ± 12.2 (55-103) 75.0 ± 11.0 (53-105)
Length, cm 172 ± 8 (158-192) 169 ± 9 (155-192)
Hand dominance right 28 (90%) 27 (87%)
Data are shown as mean ± SD (range) or N (%).
Laboratory investigation
Laboratory results in DM2 showed a slightly elevated serum CK; median CK was 376 U/L 
(range 56-1521) in women and 293 U/L (range 124-464) in men. Eighteen female and 5 male 
DM2 patients showed increased CK.
A normal to slightly elevated median serum CK was found in DM1 patients; 209 U/L (range 
66-636) in women and 160 U/L (range 73-273) in men. Twelve female and 3 male DM1 
patients showed increased CK.
Muscle force measurement
The mean MRC sum score was 36 (SD 2.8) in DM2; 13 (42%) and 12 (39%) of the DM2 
patients showed moderate and mild muscle weakness, respectively. One DM2 patient 
showed severe muscle weakness (MRC sum score 31) and five DM2 patients (16%) showed 
normal muscle strength.
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Table 8.2 The mean muscle force values in Newton (SD) for DM2 and DM1
Total Men Women
Muscle group DM2 DM1 p-value DM2 DM1 normal DM2 DM1 normal
(N=31) (N=31) DM2-DM1 (N=7) (N=7) value P5 (N=24) (N=24) value P5
Elbow flexors 80 (32) 105 (31) 0.003** 109 (39) 122 (40) 216 71 (24)** 100 (27)** 146
Three-point grip 77 (33) 49 (27) 0.001** 114 (33)* 60 (35)* 94 66 (25)** 46 (24)** 65
Knee extensors 93 (42) 113 (27) 0.02* 113 (65) 130 (27) >160 86 (32)* 109 (26)* >160
Foot dorsiflexors 54 (33) 56 (26) 0.81 75 (58) 62 (23) 232 48 (19) 54 (27) 164
The mean muscle force values in Newton (SD) for DM2 and DM1, for men and women separately, and the 5th centime values (P5) of normal men 
and women.
* = significant difference between DM2 and DM1 (p<0.05)
** = significant difference between DM2 and DM1 (p<0.01)
The mean MRC sum score was 35 (SD 2.4) in DM1; 19 (61%) and 10 (32%) of the DM1 
patients showed moderate and mild muscle weakness, respectively. One DM1 patient 
showed severe muscle weakness (MRC sum score 30) and one DM1 patient showed normal 
muscle strength. The mean MIRS-score was 3.8 (SD 0.6). Twenty-six (84%) and 3 (10%) of 
the DM1 patients had a MIRS-score of 4 and 3, respectively. Two (6%) DM1 patients were 
assigned to the lower score 2.
Results of muscle force measured by dynamometry are presented in Table 8.2. The mean 
force of all muscles tested bilaterally of DM2 and DM1 patients was below the p5 of normal 
values, except for the three-point grip in DM2 patients. In comparison to DM1, muscle force 
was significantly lower in the proximal muscles (elbow flexors (80N ± 32 versus 105N ± 31, 
p=0.003) and rectus femoris muscle (93N ± 42 versus 113N ± 27, p=0.02)) of DM2 patients. 
The three-point grip was significantly lower in DM1 patients compared to DM2 (49N ± 27 
versus 77N ± 33, p=0.001).
Muscle ultrasound
Ultrasound results of echo intensity and muscle thickness are listed in Table 8.3 and Table 
8.4. The measurement for one muscle (rectus femoris) in one DM2 patient was excluded 
from further analysis, because of a recent trauma to this muscle.
Echo intensify
In both DM2 and DM1 patients, mean echo intensity was significantly (p < 0.001) increased 
in all tested muscles compared to normal values, except for the rectus femoris in DM1 
patients (Table 8.3). Mean echo intensity of the rectus femoris was lowest (i.e. closest to 
normal) for both DM2 and DM1 patients. Mean echo intensity of distal limb muscles (forearm 
flexors and tibialis anterior muscle) was more increased than mean echo intensity of proximal 
limb muscles (elbow flexors and rectus femoris muscle) in both disorders.
The mean echo intensity of the elbow flexors in DM2 was more increased than in DM1, and 
showed statistical significance in the left elbow flexors (2.4 ± 1.4, and 1.7 ± 1.4 respectively, 
p=0.049). No significant differences between mean echo intensity of the dominant and non­
dominant arm muscles were found in DM2 or DM1.
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Table 8.3 Ultrasound results of echo intensity (EI) of the tested muscles for DM2 vs DM1 patients
Echo intensity DM2 Z > 2 SD DM1 Z > 2 SD
P-value EI 
DM2-DM1
Masseter r 2.1 (1.0) ▲ 42% 2.0 (1.3) A 52% 0.60
Elbow flexors r 2.4 (1.6) ▲ 61% 1.7 (1.3) A 42% 0.053
Elbow flexors l 2.4 (1.4) A 58% 1.7 (1.4)A 35% 0.049*
Forearm flexors r 3.4 (1.7) A 81% 3.2 (1.5) A 71% 0.50
Forearm flexors l 3.7 (2.0) A 68% 3.6 (1.6) A 74% 0.76
Rectus femoris r 0.9 (1.4) A 16% 0.5 (1.6) 19% 0.36
Tibialis anterior l 2.3 (1.3) A 55% 2.4 (1.2) A 61% 0.76
Ultrasound results: echo intensity (EI) of the tested muscles for DM2 versus DM1 patients in mean z- 
score (SD), and percentage DM2 and DM1 patients with EI z-score > 2 SD. 
r = right, l = left. SD = standard deviation.
▲= significantly increased compared to normal values (p<0.001)
* = significant difference between DM2 and DM1
Table 8.4 Ultrasound results of muscle thickness (MT) of the tested muscles for DM2 vs DM1 patients
Muscle thickness DM2
Z < -2 
SD
DM1
Z < -2 
SD
p-value MT 
DM2-DM1
Masseter r -1.6 (1.0) ** 23% -1.9 (1.1) ** 42% 0.16
Elbow flexors r -1.0 (1.4) ** 19% 0 (1.2) 3% 0.005*
Elbow flexors l -0.5 (1.3) 13% 0.6 (1.2)A 0% 0.001*
Forearm flexors r 0.8 (1.1) A 3% 0.2 (1.4) 3% 0.07
Forearm flexors l 0.5 (1.0)A 0% 0 (1.2) 0% 0.12
Rectus femoris r -1.0 (1.9) * 23% -0.7 (1.5) * 16% 0.51
Tibialis anterior l 0.1 (1.0) 3% 0 (1.0) 3% 0.86
Ultrasound results: muscle thickness (MT) of the tested muscles for DM2 versus DM1 patients in 
mean z-score (SD), and percentage DM2 and DM1 patients with MT z-score < 2 SD. 
r = right, l = left. SD = standard deviation.
** = significantly decreased compared to normal values (p<0.001)
* = significantly decreased compared to normal values (p<0.05)
A = significantly increased compared to normal values (p<0.05)
* = significant difference between DM2 and DM1 (p<0.01)
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Echo intensity sum score was positively correlated with age in DM2 (r= 0.57, p=0.001) but 
not in DM1 (r=0.30, p=0.10) (Figure 8.1). A significant negative correlation was found 
between echo intensity sum score and the sum of muscle force of all muscles as measured 
by dynamometry in both DM2 (r= -0.36, p=0.048) and DM1 (r= -0.69, p<0.001).
Echo intensity sum score did not correlate significantly with CK in either DM2 (r= -0.25, 
p=0.19) or DM1 (r= -0.14, p=0.44).
Correlations
Figure 8.1 Correlation between age and muscle EI z-scores in patients with DM2 and DM1.
Muscle thickness
Muscle thickness was significantly reduced in all tested muscles in DM2, except for the distal 
muscles (forearm flexors and tibialis anterior muscle). Seven (23%) DM2 patients showed 
atrophy of the masseter muscle, seven (23%) DM2 patients showed atrophy of the rectus 
femoris, and six DM2 patients (19%) revealed atrophy of the elbow flexors.
In DM1, mean muscle thickness was significantly reduced only in the masseter muscle and 
the rectus femoris. Thirteen (42%) and five (16%) of the DM1 patients showed atrophy of the 
masseter and rectus femoris muscle, respectively.
Muscle thickness was significantly (p<0.01) reduced in the right and left elbow flexors in DM2 
in comparison with DM1.
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Dominant versus non-dominant arm muscles
No significant differences between muscle thickness of the dominant and non-dominant 
upper arm muscles were found in DM2 (difference 0.02 cm, p=0.56) or DM1 (difference 0.01 
cm, p=0.86). The dominant forearm flexors of DM2 patients were thicker (difference 0.11 cm, 
p = 0.04) than the non-dominant forearm flexors. No significant difference was found 
between the thickness of the dominant and non-dominant forearm flexors (difference 0.09 
cm, p =0.06) in DM1. In healthy females, previous data show a comparable difference (0.12 
cm) between the dominant and non-dominant forearm flexors as in DM2.24 
Although significant muscle hypertrophy was found for two muscles in DM2 patients and for 
one muscle in DM1 patients, individual z-scores exceed 2 SD in only 5 DM2 patients and 5 
DM1 patients (data not shown).
Figure 8.2 Ultrasound image of the elbow flexors of a 46-year-old healthy male control (left panel) 
and a same age DM2 male patient (right panel). The echo intensity of the biceps brachii muscle (and 
the brachialis muscle) is severely increased and muscle thickness of the elbow flexors is decreased in 
the DM2 patient.
H = humerus; Bi = biceps brachii muscle; Br = brachialis muscle; X = calipers for measuring muscle 
thickness.
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Figure 8.3 Transverse ultrasound image of the quadriceps muscle. Left panel: normal appearance, 
51-year-old healthy control. Middle panel: 56-year-old DM2 patient; muscle thickness is decreased 
and echo intensity of the rectus femoris is increased. Right panel: 57-year-old DM1 patient; muscle 
thickness is decreased, echo intensity of the rectus femoris is normal.
RF = rectus femoris, VI= vastus intermedius; F = femur; X = calipers for measuring muscle thickness; 
double arrow = subcutaneous tissue.
Discussion
This quantitative muscle ultrasound study shows that all tested muscles are affected and 
structurally abnormal in patients with DM2, as muscle echo intensity was significantly 
increased. Atrophy of both the masseter and the rectus femoris muscles is found in 23% of 
DM2 patients, and 19% of DM2 patients show atrophy of the elbow flexors. The degree of 
abnormality (z-score) of echo intensities increases with age, which shows the progressive 
course of the disease. As expected, the clinical parameter muscle force was negatively 
correlated with muscle echo intensity in both types of DM. Compared with DM1, the proximal 
arm muscles are more often and more severely affected in DM2, with a strong significant 
decrease of muscle thickness in the elbow flexors in DM2.
Our study is the first to demonstrate structural muscle changes in the masseter muscle and 
in the forearm flexors in DM2 patients. We found the rectus femoris muscle to be the least 
structurally affected muscle in DM2, as noted by other researchers. A recently performed 
MRI study on skeletal muscles showed that the rectus femoris was spared in all 14 DM2 
patients, even in patients in whom the vastii medialis, intermedius and lateralis were 
affected.7 This observation has been previously described in other imaging and needle 
biopsy studies on myotonic dystrophy, muscular dystrophies and non-dystrophic myotonia.30- 
32 The pathophysiological mechanism behind this selective muscle involvement within the 
quadriceps muscle has not yet been elucidated. In both DM types the rectus femoris muscle 
may thus not be representative for the whole quadriceps muscle.
104
Previous studies have shown that muscle echo intensity is strongly correlated with structural 
changes in the muscle biopsy.14,15 Our data are compatible with the pathological data 
obtained by muscle biopsies in DM2 patients. Increased fiber size variability, pyknotic 
nuclear clumps and type 2 fiber predominance were observed in muscles, besides necrosis, 
connective tissue proliferation and an increase of fat cells.33
Until recently, muscle MRI has been regarded as the most sensitive method in the detection 
of dystrophic and non-dystrophic abnormalities within striated muscles.34 Duchenne muscular 
dystrophy, spinal muscular atrophy, limb girdle muscular dystrophies, congenital muscular 
dystrophies, emery dreifuss muscular dystrophy and congenital myopathies all reveal 
characteristic findings and specific patterns of muscle involvement on MRI. However, a 
recent whole-body MRI study on skeletal muscles in DM2 showed that mild to moderate 
muscle weakness was not reflected by MRI signal alterations. The rectus femoris muscle 
was considered to be normal in all patients.7 In our study we found a higher degree of 
structural muscle abnormalities than in the previous MRI study, with also a significant 
increase of echo intensity in the rectus femoris muscle. Sixteen percent of the patients 
showed a rectus femoris muscle with a z-score of more than 2 SD. Furthermore, recent 
whole-body 3-Tesla muscle MRI did not demonstrate fatty degeneration or skeletal muscle 
edema in severe recessive myotonia congenita patients.35 Significant morphologic skeletal 
muscle changes were thus not present or not strong enough to be visualized on MRI. 
However, a recent muscle ultrasound study into chloride and sodium channelopathies did 
show structural changes in most of the tested muscles, and muscle echo intensities were 
correlated to functional muscle parameters.17 In combination with this relative inexpensive 
and easily accessible technique muscle ultrasound appears to be an important imaging tool 
for in vivo assessment of muscle changes in patients with myotonic disorders.
In our DM1 group, the distal limb muscles (forearm flexors, tibialis anterior muscle) and 
masseter muscle showed the highest echo intensity, and were each abnormal in more than 
50% of the individual patients. These muscle ultrasound results are in concordance with 
previous results from imaging studies, although all of these studies were carried out before 
the era of DNA-based diagnosis of DM, so they may have included a number of DM2 
patients. Previously, the highest echo intensities were found in the tibialis anterior and 
brachioradialis muscle.36 In the masseter muscle ultrasound measurements showed obvious 
signs of fatty degeneration and atrophy of this muscle in most of the 16 DM patients 
compared to healthy controls.37 In addition, MRI study of the masticatory muscles (masseter, 
temporalis, pterygoids) showed fatty infiltration and volumetric reduction of muscles in 87% 
of DM patients.38 In our DM1 group, the distribution and severity of muscle involvement 
corresponds to the phenotype of DM1, with facial weakness, including jaw and temporal 
wasting, and distal weakness as the first muscular signs in the disease.
Because DM2, in general, is more likely to be under diagnosed compared to DM1, the 
participating DM2 patients may be on the more severe end of the DM2 disease spectrum. 
Due to age-matching with the DM2 group, the mean age of our DM1 patients is 53 years. 
However, life expectancy is greatly reduced in DM1 patients: the DM1 adult-phenotype mean 
age at death is 55.4 years.39 Thus the participating DM1 patients reflect a phenotype on the
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less severe end of the spectrum. This is illustrated by the mean MIRS-score of 3.8 in our 
DM1 patient group.7 This slight selection bias should be taken into account when interpreting 
the results.
The results of this ultrasound study may contribute to increased recognition of muscle 
involvement of masticatory, proximal as well as distal limb muscles in the multisystem 
disorder DM2, which is important for diagnosis. Particularly in myotonic dystrophy patients, 
for whom a MRI may not even be suitable because of the presence of a cardiac pacemaker 
or severe pulmonary problems, muscle ultrasound is an excellent tool for quantifying muscle 
changes. Furthermore, muscle ultrasound may also be useful in prospective studies 
measuring changes in skeletal muscle, whether these muscle changes reflect the natural 
disease course or are the results of new treatment strategies in myotonic dystrophies.
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Abstract
Myotonic dystrophy type 2 (DM2) is a progressive multisystem disease with muscle weakness and 
myotonia as main characteristics. The disease is caused by a repeat expansion in the zinc finger 
protein 9 (ZNF9) gene on chromosome 3q21. Several reports show that patients from European 
ancestry share an identical haplotype surrounding the ZNF9 gene. In this study we investigated 
whether the Dutch DM2 population carries the same founder haplotype. Forty Dutch DM2 patients 
from 16 families were genotyped for 8 short tandem repeat markers surrounding the ZNF9 gene. In 
addition, the single nucleotide polymorphism rs1871922 located in the first intron of DM2 was 
genotyped. Results were compared with previously published haplotypes from unrelated Caucasian 
patients. The repeat lengths identified in this study were in agreement with existing literature. In 36 
patients of our population we identified three common haplotypes. One patient showed overlap with 
the common haplotype for only one marker closest to the ZNF9 gene. The haplotype from a family 
originating from Morocco showed overlap with that of the patients of European descent for a region of 
222kb. All patients carried at least one C allele of SNP rs1871922 indicating that all patients carry the 
European founder haplotype. We conclude that DM2 patients from The Netherlands, including a 
North-African family, harbour a common haplotype surrounding the ZNF9 gene. This data show that 
the Dutch patients carry the common founder haplotype and strongly suggest that DM2 mutations in 
Europe and North-Africa originate from a single ancestral founder.
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Introduction
Myotonic dystrophy type 2 (DM2, OMIM 602668) is an autosomal dominant, multisystem 
disease, characterised by progressive muscle weakness, myotonia, cataracts, and 
multiorgan involvement with cardiac conduction defects, gastrointestinal involvement and 
endocrine disorders.1,2 In 2001, the mutation causing DM2 was identified as a CCTG 
expansion in intron 1 of the zinc finger protein 9 (ZNF9) gene located on chromosome 
3q21.3.3,4 Expanded DM2 alleles show unprecedented somatic instability, with significant 
increases in length over time (e.g. 2,000 base pairs / 3 years). The number of CCTG repeats 
in healthy individuals is below 30 and can be up to 11,000 in patients, the shortest reported 
expansion associated with DM2 is (CCTG)75.
Two groups independently showed that European DM2 patients share a common ancestor.5,6 
Liquori et al. investigated 71 families with DM2, of which 70 families were of Northern 
European descent and one family from Afghanistan.3 The majority of the families carried one 
of the three consensus haplotypes. The haplotype of an Afghan family showed great 
similarity to the core haplotype, suggesting that the mutation was introduced via the settling 
of Aryan tribes of Indo-European descent in ancient Afghanistan. Bachinski et al. studied 17 
kindreds from geographically separate populations of European origin; the presence of a 
single founder mutation in European DM2 patients was indicated in this study as well.6 Based 
on their data, the authors estimated the age of the DM2 mutation at 4,000 - 11,000 years. 
Neither the study of Liquori, nor the study of Bachinski included patients from The 
Netherlands. Recently, a Japanese group identified the first Japanese patient with DM2; this 
patient carried a haplotype that differs from the haplotype associated with DM2 in the 
European population.7
In the current study, we set out to assess whether Dutch DM2 patients, including a North- 
African family, carry the common European founder haplotype.
Methods
Patients
All known DM2 patients in The Netherlands were identified using the Dutch neuromuscular 
database and approached for participation in the study.8 A total of 42 potentially eligible DM2 
patients were recruited. One DM2 patient did not consent without specifying the reason, and 
one registered DM2 patient was found to be deceased. We included 40 DM2 patients from 
16 unrelated families in the study (see Supplementary Table 9.1). All of the patients were 
Caucasian, with one family ethnically originating from Morocco. The regional ethics review 
board approved the study and all patients had given written informed consent.
113
Molecular analysis
All molecular analyses were performed in a CCKL (Co-ordination Committee for the 
promotion of Quality Control with regard to Laboratory research, www.cckl.nl); accredited 
laboratory at the Department of Human Genetics at the Radboud University Nijmegen 
Medical Centre in Nijmegen, The Netherlands.
Genetic confirmation of DM2
Affected individuals were identified as DM2 patients using southern blotting according to the 
protocol as previously described.3,4 All patients harboured a repeat expansion in the ZNF9 
gene.
Microsatellite analysis
Molecular analysis was performed in 40 patients. DNA samples from the study of Liquori et 
al. were included to allow direct comparison of our data with the previously published 
haplotypes. Three trio’s (2 affected individuals per trio) each representing one haplotype 
were analysed. Genomic DNA was extracted from blood lymphocytes using standard 
procedures.9 Eight short tandem repeat (STR) markers as previously described by Liquori et 
al. were selected for haplotype analysis (CL3N122, CL3N99, CL3N83, CL3N59, CL3N117, 
CL3N119, CL3N19 and CL3N23).5 Primers were ordered from Applied Biosystems 
(Nieuwerkerk aan den IJssel, The Netherlands). The forward primer had a fluorescent dye 
label (6-FAM, NED, or VIC), while the reverse primer contained a proprietary tail that helps 
stabilize the amplified product. Semi-automated fluorescent genotyping was carried out using 
the following protocol. Genomic DNA (50 ng) was amplified in a 10 ^  reaction using 
AmpliTaq Gold DNA Polymerase (0.4 U, Applied Biosystems), AmpliTaq PCR Buffer II 
(Applied Biosystems), dNTPs (250 ^M each), Magnesium (1.25 or 2.5 mM, depending on the 
primers), and the marker-specific primers (0.5 ^M). Amplification was performed using the 
following protocol: 95°C for 12 min. followed by 10 cycles of denaturation for 30 sec. at 94°C, 
annealing at 62°C, and primer extension at 72°C for 1 min.. A subsequent 22 cycles were 
performed with 30 sec. heating at 89°C, 30 sec. annealing at 62°C and primer extension at 
72°C, followed by a final extension at 72°C for 10 min. 1 ul of each amplified STR marker 
was pooled for each patient, and combined with size standard (LIZ-500) before being 
analyzed on an ABI3730 (Applied Biosystems). GeneMapper v4.0 (Applied Biosystems) was 
used to analyze the raw results from the ABI3730; a genotype was not considered final until 
two persons had independently checked the GeneMapper results and both individuals were 
in agreement.
SNP genotyping
SNP rs1871922 (TSC0873597) was genotyped according to the method described 
previously by Vallo et al., with the following adaptations.10 For restriction fragment length 
polymorphism (RFLP) analysis, the PCR products were purified using the NucleoFat 96 PCR 
plate (BIOKE, Leiden, NL) and incubated overnight at 37°C with 5U of HaeIII enzyme (New
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England Biolabs UK, Ltd). One sample of each genotype was sequenced using a 3730 DNA 
Analyzer (Applied Biosystems) as quality control.
Haplotype construction
Affected haplotypes were established by determining which alleles co-segregated in the 
families. In case only a proband was available we assigned the haplotype present in other 
DM2 patients as the affected haplotype.
Results
Haplotype analysis
We were unable to obtain a PCR product for marker CL3N83. As this marker was not 
obligatory to determine if our patients carried similar haplotypes as presented by Liquori et 
al., we excluded this marker from the study.5 DNA of 40 patients was analyzed for the 
remaining seven microsatellite markers surrounding the DM2 gene ZNF9. The results of the 
analysis are shown in Table 9.1. The lengths of the repeats that we found were in the same 
range as those reported by Liquori et al.5 The flanking marker CL3N23 and marker CL3N99 
showed more variability in repeat length compared to the other markers, which is in 
agreement with the data of Liquori et al. We were able to assign 90% of the patients to the 
three previously published haplotypes (Table 9.1: patients 1-36). Our analysis shows that 
patients with haplotype C carry different repeat lengths of the markers centromeric from 
CL3N59 than the previously reported lengths.5
Patient one could be assigned under two haplotypes; based on marker CL3N59 and 
CL3N119 the patients fit with haplotype A. However based on the length of markers 
CL3N119, CL3N19 and CL3N23 the patient shares part of the haplotype C group. As the 
length of CL3N59 is unique for haplotype A we decided to fit the patient under this haplotype.
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Table 9.1 Haplotypes of 40 DM2 patients. The markers span 761 kb surrounding the CCTG expansion causing DM2.
marker CL3N122 CL3N99 CL3N59 rs1871922 CL3N117 CL3N119 CL3N19 CL3N23
location kb from  CCTG  repeat 396 348 119 11 103 216 292 365
Patientnum ber -- fam ilynum ber
Haplotype A  from  Liquori 216 185 157 241 232/236 208 n.a.
1 -  I 214/218 169/175 148/157 AC 241/245 236/240 190/210 226/234
2 -  II 216/218 179/185 146/157 AC 241/245 236/238 208 226/234
3 -  III 216 175/185 148/157 AC 241/245 234/236 208 226/234
4 -  III 216 175/185 148/157 AC 241/245 234/236 208 226/234
5 -  IV 214/216 179/185 146/157 AC 241/245 236/238 204/208 234
6 -  V 216 185 157 AC 241/245 236 208 234
<
CD
d
O
CL
Cfl
X
7 -  V 216 185 157 AC 241/245 236 208 234
8 -  V 216 185 157 CC 241/245 236 208 234
9 -  VI 216 185 157 CC 241/245 236/238 208 230
10 -  VI 216 185 157 CC 241/245 236/238 208 230
11 -  VII 216 189 157 AC 241 236 208 230
12 -  VII 216 189 157 AC 241 236 208 230
13 -  VII 216 189 157 CC 241 236 208 230
14 -  VII 216 189 157 AC 241 236 208 230
15 -  VII 216 189 157 AC 241 236 208 230
16 -  VII 216 189 157 AC 241 236 208 230
Haplotype B from  Liquori 216 181 148/157 241/245 240 190 238
17 -  VIII 216/218 175/181 148/157 z
O
co
z
<
Q .
X
LU
O
H
O
O
AC 241/245 240/246 190/198 222/234
18 -  IX 216 173/177 148/157 AC 241/245 234/240 190/214 230/234 co
CD
d
O
CL
Cfl
X
19 -  X 216 181 157 AC 241/245 236/240 190/210 230/234
20 -  X 216 181 157 AC 241/245 236/240 190/210 230/234
21 -  X 216 181 157 AC 241/245 236/240 190/210 230/234
22 -  XI 216/218 181 157 CC 241 240 190 234
23 -  XI 216/218 181 157 AC 241 240 190 234
24 -  XII 216 173/181 148/155 CC 241/245 234/246 204/210 222/238
Haplotype C from  Liquori 218 175 150 241 240 190 226/238
25 -  XIII 214 192 150 CC 241 240 190 226
26 -  XIII 214 192 150 AC 241 240 190 226
27 -  XIII 214 192 150 CC 241 240 190 226
28 -  XIII 214 192 150 CC 241 240 190 226 o
CDd
O
d
cfl
X
29 -  XIII 214 192 150 CC 241 240 190 226
30 -  XIII 214 192 150 CC 241 240 190 226
31 -  XIV 214 192 150 CC 241/245 240 190 226
32 -  XIV 214 192 150 AC 241/245 240 190 226
33 -  XIV 214 192 150 CC 241/245 240 190 226
34 -  XIV 214 192 150 CC 241/245 240 190 226
35 -  XIV 214 192 150 AC 241/245 240 190 226
36 -  XIV 214 192 150 AC 241/245 240 190 226
37 -  XV 210 194 150 AC 241 238 186 234
38 -  XV 210 194 150 CC 241 238 186 234
VX-93 210 194 150 CC 241 238 186 234
40 -  XVI 216/218 173/175 137/143 CC 241/245 238/246 204/206 214/222
The length of the analyzed markers is expressed in basepairs. The first row of each haplotype denotes repeat lengths from the analysis of the unrelated individuals from 
Liquori. The patients have been assigned to a haplotype based on the repeat lengths observed. Only the repeat lengths of the disease causing haplotype are shown. For some 
patients it was not possible to determine the disease causing allele with 100% certainty, in those cases the repeat lengths of both alleles are indicated. n.a. not analysed. 
CL3N122, CL3N99 and CL3N59 are located centromeric from the expansion. The other markers investigated and SNP rs1871922 are located telomeric from the expansion.
One patient born in the United States of America (patient 40) showed a haplotype that differs 
from the common haplotypes identified in the Dutch patient population. The haplotype of the 
three patients (number 37, 38 and 39) from Morocco was comparable to haplotype C, but 
only for a region of 222 kb surrounding the ZNF9 gene.
SNP genotyping
SNP rs1871922 is located in intron one of the DM2 gene, located 11 kb telomeric from the 
expansion. The C allele of this SNP is linked to the European founder mutation and was 
therefore used to investigate if patients carry this mutation.6,7,10 SNP genotyping showed that 
all patients carried at least one C allele.
Discussion
In this study we show that Dutch DM2 patients share a common haplotype surrounding the 
DM2 locus, which is the same as the European founder haplotype. The three family 
members originating from Morocco also carried part of the common European haplotype. 
Genotype analysis of SNP rs1871922 showed that all patients carried the C allele which 
strongly indicates that also these patients carry the common European founder mutation.6 
Although we designed similar primers for the repeat length analysis as Liquori and 
colleagues we did observe different fragment sizes than those found in the previous study.5 
This can probably be attributed to the primer design (our primers carried a poly-A tail for 
stability) and difference in the machines used for the estimation of the fragment lengths. Due 
to the inclusion of samples with known repeat lengths we were able to compare our results 
directly with the previously published haplotypes. 88% of the patients carried one of the three 
haplotypes known to be associated with DM2. However patients carrying haplotype C 
showed a fragment length 214 bp for marker CL3N122 (expected length 218 bp) and 192 bp 
for marker CL3N99 (expected length 175 bp). Based on this we can conclude that a 
recombination occurred between marker CL3N99 and CL3N59 in the Dutch population 
compared to the patients analysed in the study by Liquori.5
Recently, the first DM2 patient from an East-Asian population was described.7 This patient is 
the first patient reported with a haplotype different from the European founder haplotype. 
Three non-European patients originating from Morocco (37-39) were part of our study, the 
data presented show that these patients carry part of haplotype C (222kb surrounding the 
ZNF9 expansion). This is the second non-European family described that carries one of the 
common founder haplotypes.5,6 The disease linked haplotype is however different from the 
one described for the family from Afghanistan.5 As Morocco is part of the Mediterranean 
basin and has had strong historic ties to the Roman Empire and other European colonial 
powers we cannot exclude that the presence of the European founder haplotype is a result of 
genetic admixture.
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Patient 40 carried only the small common region shared by all patients (from the CCTG 
expansion to CL3N117). Therefore the patient could not be assigned to one of the three 
common haplotypes. This can be attributed to the ethnicity of the patient. The patient 
originated from America and his great grandparents originated from Germany and Russia.
In conclusion, our data show that Dutch patients carry the common founder haplotype and 
strongly suggest that European and North-African DM2 patients share an identical haplotype. 
Further studies in African and other non-European DM2 patients are required to confirm this 
latter result. It may be worthwhile at least for counselling patients to investigate whether DM2 
patients of different ethnic backgrounds who share an identical haplotype have a comparable 
phenotype.
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Supplementary Table 9.1 Overview of the family structure of the Dutch DM2 patients.
family patientnumber sex family
birth
year
I 1 F 1941
II 2 F 1939
III 3 F 1946
4 F sister of 3 1952
IV 5 M 1956
V 6 F 1942
7 F daughter of 6 1978
8 F cousin of 6 1952
VI 9 F 1932
10 F daughter of 9 1963
VII 11 F 1944
12 F sister of 11 1948
13 M son of 12 1974
14 M brother of 11 1951
15 F sister of 11 1953
16 F second cousin of 11 1953
VIII 17 F 1963
IX 18 F 1945
X 19 M 1942
20 F sister of 19 1952
21 M son of 20 1975
XI 22 F 1935
23 M brother of 22 1941
XII 24 F 1953
XIII 25 F 1932
26 F daughter of 25 1959
27 F sister of 25 1935
28 F daughter of 27 1958
29 F daughter of 27 1961
30 M son of 27 1964
XIV 31 F 1935
32 F daughter of 31 1961
33 M brother of 31 1942
34 F sister of 31 1952
35 F daughter of 34 1980
36 F cousin of 31 1952
XV 37 F 1945
38 M son of 37 1964
39 F daughter of 37 1972
XVI 40 M 1969
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Summary, discussion and future perspectives
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General discussion and future perspectives
Myotonic dystrophy type 2 is an autosomal dominant multisystem disorder, characterised by 
muscle dysfunction (weakness, atrophy, muscle pain, and stiffness), myotonia, early-onset 
cataracts, and cardiac conduction defects.
In 1994 Ricker reported on a group of 15 patients from 3 families and Thornton reported on 3 
patients from 2 families with a comparable clinical picture that was dominated by the 
presence of stiffness, proximal muscle weakness, myotonia, cataracts, and autosomal 
dominant inheritance. Ricker called this new disorder proximal myotonic myopathy 
(PROMM).1 The genetic defect of this new disease was elucidated in 2001 and turned out to 
be a CCTG repeat in the intron of the ZNF9 gene on chromosome 3q21.2 After the 
verification of the mutation, the term myotonic dystrophy type 2 was preferred. In 2003 the 
first Dutch DM2 patient was diagnosed at the outpatient clinic of the Neuromuscular Centre 
Nijmegen, UMC St Radboud.
All clinical studies presented in this thesis have been conducted based on a bottom-up 
design. In business development, a bottom-up approach means that the adviser takes the 
wants and needs of the would-be entrepreneur as the starting point. One of the advantages 
of this approach is the motivating experience of any member of the group to be responsible. 
In opting for this strategy to process information and structure knowledge, we took the 
individual symptoms and signs mentioned by DM2 patients as the starting point of our 
research. The high response rate in the DM2 group -  83% to 91% in every study described 
in this thesis -  may be due to this approach, resulting in a relatively low selection bias.
The clinical spectrum
The initial description of the phenotype of PROMM is nowadays still applicable to most 
patients with DM2. Over the years, additional clinical characteristics have been recognized. 
Several studies in this thesis (Chapters 3, 4 and 5) expanded the clinical spectrum of DM2. 
Additional clinical features that have been recognized in a large proportion of DM2 patients 
are gastrointestinal symptoms (Chapter 3), in particular abdominal pain, constipation and 
less frequently dysphagia. In addition, severe fatigue and sleep problems are common and 
prominent in DM2 (Chapter 5). These clinical symptoms are of diagnostic value and they 
might offer clues in clarifying the pathophysiology of DM2. Besides, these symptoms may 
considerably affect health-related quality of life, as is demonstrated for fatigue (Chapter 6). In 
addition, knowledge on the clinical signs and symptoms is a starting point for symptomatic 
management. For a summary of the phenotypical features see Table 10.1.
We found a strong association between DM2 and auto-immune disorders and antinuclear 
antibodies in the Dutch population (Chapter 7). The presence of autoimmune susceptibility, 
namely giant cell arteritis, and seropositive rheumatoid arthritis, has already been noted in 
one of the first large families, which turned out to be linked to the DM2 locus. As our study is
124
small, the association cannot be viewed as being definitive. However, if our results are 
confirmed in other DM2 populations, then this study may in turn offer an explanation for the 
frequent complaint of pain in DM2 patients.
It took only seven years between the first description of DM2 and the discovery of the DNA- 
defect that causes the multisystem disease. Ranum et al. demonstrated that DM2 is caused 
by CCTG expansion in intron 1 of the ZNF9 gene on chromosome 3q21.2 The discovery that 
a CCTG repeat expansion that is expressed at the RNA but not the protein level causes 
DM2, and the observation that CCUG repeat-containing foci accumulate in affected muscle 
nuclei suggests that a gain-of-function RNA mechanism underlies the clinical features.3 
Clarifications of the pathophysiological pathways may ultimately lead to therapeutic actions. 
We were able to demonstrate that DM2 patients in The Netherlands and North-Africa carry 
the same haplotype (Chapter 9). This finding essentially confirms two previously published 
results4,5 for more diverse, ‘non-European’ DM2 populations in the Dutch population, and 
suggests that DM2 mutations in patients of European and North-African descent originate 
from a single ancestral founder.
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Table 10.1 Clinical similarities and differences between DM1 en DM2.
DM1 DM2
Core features
muscle weakness + +
myotonia + +
cataracts + +
Localization of muscle weakness
facial weakness, jaw muscles ++ +
distal limb muscle weakness ++ +
proximal leg muscle weakness +/- ++
Muscle symptoms
muscular atrophy ++ +
muscle pain +/- ++
CK elevation + +
Heart
cardiac arrhythmias ++ +
Gastrointestinal symptoms
dysphagia ++ +
abdominal pain + +
constipation + +
Liver
Y-GT elevation + +
Endocrine
diabetes mellitus / insulin resistance + +
hypogonadism + +
thyroid dysfunction + +/-
Brain
cognitive dysfunction ++ +/-
mental retardation + -
excessive daytime sleepiness ++ -
Genetics
congenital form + -
anticipation + +/-
++ finding is present and prominent, + finding is present, +/- finding is 
present but only to a minor degree, - finding is not present.
Adapted from http://neuromuscular.wustl.edu.
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Remarks on the occurrence of the DM2 mutation and on the frequency of 
the disease
An initial conclusion that can be drawn on the basis of the research presented in this thesis is 
that DM2 is a newly diagnosed disease in The Netherlands with an increasing frequency 
(Chapter 2, Chapter 9). To date, seven years after the publication of the first Dutch DM2 
patient, a total of 51 affected individuals from 23 families have been shown to carry the DM2 
mutation, detected in the genetic laboratories in Nijmegen, Utrecht and Maastricht.
The frequency of the disease and of the DM2 mutation seems to be increasing fast. At the 
time of the last International Congress on Neuromuscular Diseases (XII ICNMD, Naples 
2010), the overall frequency of DM2 mutations in the Finnish population was approximately 1 
in 2,250 for the DM2 mutations, comparable to that of the DM1 mutation.6 These results 
suggest that the DM2 mutation occurs more frequently than previously suspected, and also 
means that DM2 is not a rare disease anymore in Finland. At the ENMC (European 
Neuromuscular Centre) International Workshop in December 2010 Dr. S. Vohanka presented 
that DM2 is even more frequent than DM1 in the Czech population.
In contrast, it is not unlikely that the prevalence in DM1 will decline in the coming years, due 
to different reasons. First, infertility of male patients with adult-onset DM1 will lead to the 
elimination of the DM1 gene. Second, the severity in anticipation of the disease will lead to 
mentally handicapped children after five to six generations, who will not procreate.7 Third, 
genetic counseling and prenatal diagnostic testing is resulting in a declining prevalence of 
DM1 (Höweler, personal comment).8
In summary, there is sufficient ratio to believe that DM2 will become a common 
neuromuscular disorder in most European populations, and an even more frequent disease 
than DM1, which is presently still the most common form of adult-onset muscular dystrophy. 
Research in the epidemiological field will evolve enormously over the coming decade.
We know that more than 60% of our patients was first diagnosed with a different disorder 
before it became clear that they suffered from DM2. What we have learned from working with 
patients with DM2 is that the most important clue to the diagnosis is to think of DM2 even in 
those cases without prominent neuromuscular features or obvious phenotype, e.g. early- 
onset cataracts (< 50 years), isolated elevated CK- and Y-glutamyltransferase levels, or 
dilatative cardiomyopathy. Fibromyalgia in particular shows a high overlap in the clinical 
presentation with DM2. Recent research showed that DM2 was found in two of sixty-three 
persons (3.2%) diagnosed as having fibromyalgia in Finland.9 When translated to the local 
situation, this suggests that in the Sint Maartenskliniek Nijmegen -  with a population of about 
900 fibromyalgia patients -  approximately 30 patients carry the DM2 mutation. It will be of 
relevance to investigate the presence of the DM2 mutation in patients who have been 
previously diagnosed as having fibromyalgia, and from now on DM2 should be in the 
differential diagnosis of fibromyalgia. Ongoing efforts should be made to improve the 
recognition of DM2 by neurologists, cardiologists, ophthalmologists, rheumatologists, and 
also pediatricians.
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Future perspectives
Clinical studies
Now that it is possible to identify DM2 patients with certainty using molecular genetic 
analysis, we should use the knowledge that we have of the phenotype to define clinically 
relevant outcome measures (clinical, biochemical and imaging techniques) for longitudinal 
and intervention studies.
We demonstrated that muscle ultrasound as imaging technique is an excellent tool for 
quantifying muscle changes in DM2 and DM1 (Chapter 8). Muscle ultrasound can also be 
useful as an outcome measure in clinical studies. The validity of this easily applicable 
imaging tool as an outcome measure in prospective studies in myotonic dystrophies must 
therefore be evaluated.
New rating scales should be developed for certain outcome measures. For instance, a 
disease specific rating scale for clinical muscular impairment in DM2 patients would be a 
priority to study the natural history of the disease, to monitor major stages of DM2 
progression, and to identify homogeneous groups of patients for clinical trials.
No literature currently exists on the natural history of DM2. Now that we have found 
dysphagia present in DM2, which symptom is a risk for aspiration pneumonia, it will be even 
more necessary to gain insight into the natural course of the disease, to assess whether or 
not life expectancy is shortened, and what the causes of death are in DM2.
The results described in Chapter 7 revealed an association between DM2 and auto-immune 
diseases and serum auto antibodies. This study should be and will be further explored. A 
copy of our study will start simultaneously in Finland and in Italy, to see if the results in 
regions with a different prevalence for auto-immune disorders can confirm the relationship 
between DM2 and auto-immune diseases. If so, then the search for the underlying 
pathophysiology will be a huge challenge.
Other important clinical questions remain. The absolute cardiac risk in DM2 is recently 
investigated in a cross-sectional trial, and showed that left ventricular dysfunction and 
cardiac arrhythmias are frequent in myotonic dystrophy type 2.10 An international survey into 
cardiac conduction abnormalities, frequency of ECG and cardiac ultrasound abnormalities, 
and arrhythmias in DM2 is under investigation.
There is evidence from neuropsychological test scores, psychiatric interviews, neuroimaging 
and neuropathological data that brain involvement is present in DM2. However, all DM2 
studies on cognition are limited by a small number of patients, and contrary findings are 
found with respect to lexical verbal fluency. Further cognitive studies are necessary to clarify 
the degree as well as the clinical relevance of brain involvement in DM2.
There also remain questions to be answered in terms of genetics. Whether or not the 
parental sex plays a role in determining the level of intergenerational instability -as in DM1, 
where an increase of CTG-repeat units on average is higher by maternal transmission 
compared to paternal transmission- is still an open question in this important topic.
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As can be said of many rare disorders, adequate treatment is yet to be developed. We found 
that fatigue is a prominent symptom in DM2 and deserves more attention (Chapter 5). 
Clinical trials on managing fatigue as well as on pain are required for DM2 patients in order 
to evaluate the efficacy of specific treatment and exercise programs and to improve health- 
related quality of life, even if the disease itself cannot be treated yet. The TREAT-NMD 
neuromuscular network has been creating ‘tools’ for trial-readiness in the neuromuscular 
field, by patient registries, by defining outcome measures, and standardization of animal 
models. This tool-building approach addresses areas worldwide that would not get 
considered in normal research projects.
The recent development of animal models for DM2 -the DM2-ZNF9ki-189 mouse, the DM2- 
HSAth-121 mouse, and the DM2 Drosophila fly - could greatly improve the research 
possibilities. New therapeutic strategies should follow from these studies, for instance 
chemical screens to identify drugs which can rescue DM2, and antisense strategies based 
on selective recognition of the repeat can be performed. The ultimate goal in development of 
new therapies is reversal of the disease phenotype.
Research on rare disorders
In Europe, a disease is called rare if it affects no more than 5 in 10,000 inhabitants of the 
member states of the European Union.11 If, according to previously estimated frequency, the 
frequency of DM2 is 1 in 100,000, it is clearly a rare disorder.12 For rare diseases, patient 
registries make it possible to collect information on a large number of patients from different 
geographic regions. Clinical databases or disease registries are ongoing listings of 
observational data, collected on patients who meet specific criteria.13 The power of such 
databases lies in the number of patients included and the more or less comprehensive 
coverage of the patient population.14 In The Netherlands, the clinical database in which 
information is stored on patient characteristics and diagnoses with respect to for 
neuromuscular diseases is named CRAMP (Computer Registry of All Myopathies and 
Polyneuropathies). All Dutch physicians who treat DM2 patients are encouraged to submit 
the diagnosis and patient characteristics to the neuromuscular disease registry 
(a.tieleman@neuro.umcn.nl or b.vanengelen@neuro.umcn.nl).
Concluding remarks
This thesis is the result of a nationwide, bottom-up designed research into the clinical picture 
of genetically identified patients with myotonic dystrophy type 2, including the patients’ 
perspective in the assessment of the impact of the disorder. Continued and structured follow- 
up of DM2 patients is necessary to expand our knowledge of the natural course of the 
disease, to obtain solid epidemiological data, and to start and evaluate treatment 
possibilities. This requires physicians’ awareness of the disease, which we hope to have 
stimulated by the studies described in this thesis, strong patient organisations that promote 
and fund research, and patient registries. The final determinant of success in rare diseases 
such as DM2 is strong partnership between patient organisations, industry, health insurance 
companies and research centres.
Therapy and pathophysiological studies
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Summary
This thesis describes the results of a nationwide study into the phenotype, genetics, muscle 
ultrasound imaging and health status of patients with myotonic dystrophy type 2. The study 
was started in 2007 with the aim to accurately map out the clinical picture in greater detail, 
after the identification of the first Dutch DM2 family and the possibility to genetically confirm 
the disease.
In Chapter 1 an introduction and a historical background concerning myotonic dystrophy 
(DM) is described. The milestones in DM research are given, including the discovery of the 
related genes for DM1 and DM2 in respectively 1992, and 2001. The pathophysiology, the 
differential diagnosis and treatment of DM2 is described.
In Chapter 2 the first reported Dutch DM2 family is described.
In Chapter 3 we describe the results of a cross-sectional study of twenty-nine genetically 
proven DM2 patients who filled out two standardized questionnaires about gastrointestinal 
symptoms; most important outcome measures were answers to questions about dysphagia, 
abdominal pain, and constipation. The results were compared to those of 29 adult-onset 
DM1 patients, and to 87 age- and sex-matched healthy controls. Radiological measurement 
of colon transit time was investigated in 18 DM2 patients. The results show that dysphagia 
for liquids (38%) and solid food (41%), abdominal pain (62%), and constipation (62%) were 
all significantly more common among DM2 patients than among healthy controls, and 
comparable to their occurrence in DM1. Colon transit time was increased in 24% of the DM2 
patients. In conclusion our results show that gastrointestinal symptoms are highly prevalent 
in DM2 patients. Gastrointestinal dysfunction may be attributed to any part of the 
gastrointestinal tract. The results provide new insight into the clinical picture of DM2.
Chapter 4 describes a study in follow-up to the outcomes of Chapter 3. Twelve out of 29 
DM2 patients reported to have difficulty in swallowing for solid food. The aim of this study 
was to investigate the presence of dysphagia in patients with genetically proven DM2 who 
previously reported difficulty in swallowing for solid food. Swallowing function and fiberoptic 
endoscopic evaluation of swallowing (FEES) were examined by a speech therapist and 
otorhinolaryngologist respectively. In DM2 patients who reported difficulty in swallowing the 
presence of dysphagia could be confirmed (clinically in 100%, by FEES in 88%). A 
correlation exists between DOSS-score and age. None of the patients was underweight, and 
none of the patients had suffered aspiration pneumonia in the past. Dysphagia is present 
among DM2 patients and is more severe in older patients. However, dysphagia is generally 
mild, and do not lead to weight loss, or aspiration pneumonia.
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In Chapter 5 we investigated the frequency of excessive daytime sleepiness (EDS), poor 
sleep quality and fatigue in DM2. We surveyed 29 genetically proven DM2 patients with the 
Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI) and Checklist 
Individual Strength (CIS). The results were compared with 29 adult-onset DM1 patients and 
65 population controls, both matched for age and sex. Only 6.9% of DM2 patients had EDS 
compared to 44.8% of DM1 patients and 6.2% of population controls. Sleep quality was poor 
in both the DM2 and DM1 group, and differed significantly from population controls. Poor 
sleep quality was not explained by depression or other comorbidity, but mainly due to sleep 
disturbances as a result of nocturnal pain. Comparable to the DM1 group, DM2 patients 
experienced severe fatigue. Results were not confounded by abnormal thyroid function or 
medication use. These results provide new insight into the phenotype of DM2, and have 
consequences for clinical treatment. In addition, the absence of EDS in DM2 is a new 
discriminative feature with adult-onset DM1.
In Chapter 6 data on health status (SF-36), pain (MPQ) and fatigue (CIS-fatigue) were 
collected for the Dutch DM2 population (n=32). Results were compared with those of sex-and 
age matched adult-onset myotonic dystrophy type 1 (DM1) patients. In addition, we 
compared the obtained scores on health status of the DM2 group with normative data of the 
Dutch general population. Compared to DM1, the SF-36 score bodily pain was significantly 
lower in DM2, indicating more body pain in DM2. DM2 did not differ from DM1 on any other 
SF-36 scales. In comparison to the Dutch population, DM2 patients reported lower scores 
(indicating worse clinical condition) on the physical functioning, role functioning-physical, 
bodily pain, general health, vitality, social functioning, and role functioning-emotional scales. 
The difference was most profound for the physical functioning scale. In the DM2 group the 
severity of pain was significantly correlated with SF-36 scores for bodily pain and fatigue. 
Fatigue was significantly correlated with the SF-36 scores for role functioning-physical, 
general health, and vitality. The impact of DM2 on a patients’ physical, psychological and 
social functioning is significant and as high as in adult-onset DM1 patients. From the 
perspective of health-related quality of life, DM2 should not be considered a benign disease. 
Management of DM2 patients should include screening for pain and fatigue. Symptomatic 
treatment of pain and fatigue may decrease disease impact and improve health status in 
DM2.
In the observational study on gastrointestinal symptoms in DM2, an unexpectedly high 
frequency of autoimmune diseases was suggested in our DM2 patient group. In Chapter 7, 
we set out to assess whether DM2 is indeed associated with a high frequency of 
autoantibody or auto reactive T cell associated autoimmune diseases compared to DM1 and 
whether this possible association is reflected in an increased frequency of autoantibodies in 
serum. The aim of the study was to investigate the frequency of autoimmune diseases and 
serum autoantibodies in patients with DM2 compared to adult-onset myotonic dystrophy type 
1 (DM1) patients. Twenty-eight genetically proven Dutch DM2 patients participated in the 
study and were compared with 51 age and sex matched adult-onset DM1 patients. As the 
primary outcome measure, the presence of an autoantibody or auto reactive T cell
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associated autoimmune disorder was assessed. As a secondary outcome measure, the 
presence of autoantibodies in serum (nuclear and non-nuclear antibodies) was assessed in 
all patients. The frequency of autoimmune diseases (21% versus 2%) and the frequency of 
autoantibodies (25% versus 2%) were both significantly (p <0.01) higher in DM2 patients 
compared with DM1 patients. Data on DM1 patients were comparable with the general 
population. Results were not confounded by smoking, medication use, familial clustering, age 
or sex. The results provide new insight into the clinical picture of DM2. In addition, possible 
explanations for the association between DM2 and autoimmune diseases are proposed.
Imaging of skeletal muscles in DM2 was before this thesis only assessed in one MRI study 
with 14 DM2 patients. The authors of the study concluded that MRI is not a reliable indicator 
for skeletal muscle involvement in mildly affected DM2 patients (Kornblum et al., 2006). In 
Chapter 8 the aim of the study was to determine the presence and extent of muscle changes 
in myotonic dystrophy type 2 (DM2) detected by muscle ultrasound. Results were compared 
to adult-onset myotonic dystrophy type 1 patients (DM1) and healthy controls. Furthermore, 
we tested the hypothesis that structural muscle changes correlate with age, quantitative 
muscle force and serum creatine kinase in both disorders. Ultrasound examinations were 
performed on seven muscles (masseter muscle, both elbow flexors (biceps brachii and 
brachialis), both forearm flexors, rectus femoris and tibialis anterior muscle) in 31 patients 
with genetically confirmed DM2 and 31 age- and sex-matched DM1 patients. In DM2 all 
examined muscles showed significantly increased echo intensities, indicating structural 
muscle changes. Atrophy of the masseter muscle and the rectus femoris were both found in 
23% of DM2 patients, and 19% of DM2 patients showed atrophy of the elbow flexors. Muscle 
thickness was significantly more decreased in the proximal arm muscles in DM2 compared to 
DM1. Echo intensity sum score correlated positively with age, and negatively with 
quantitatively measured muscle force in both DM types. All tested muscles are affected and 
structurally abnormal in patients with DM2. Proximal arm muscles are more affected in DM2 
compared to DM1, which corresponds to clinical findings. Structural muscle changes 
increase with age in both DM types, which shows the progressive course of the disorders. 
Ultrasound is a sensitive technique for quantifying muscle changes in DM and may also be 
useful in prospective studies measuring the natural disease course or the results of treatment 
strategies in DM types.
In Chapter 9 we describe the results of a study investigating whether the Dutch DM2 
population, including a North-African family, carry the common European founder haplotype. 
Forty Dutch DM2 patients from 16 families were genotyped for 8 short tandem repeat 
markers surrounding the ZNF9 gene. In addition, the single nucleotide polymorphism 
rs1871922 located in the first intron of DM2 was genotyped. Results were compared with 
previously published haplotypes from unrelated Caucasian patients. The repeat lengths 
identified in this study were in agreement with existing literature. In 36 patients of our 
population we identified three common haplotypes. The haplotype from a family originating 
from Morocco showed overlap with that of the patients of European descent for a region of
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222kb. All patients carried at least one C allele of SNP rs1871922 indicating that all patients 
carry the European founder haplotype. We conclude that DM2 patients from The 
Netherlands, including a North-African family, harbour a common haplotype surrounding the 
ZNF9 gene. This data show that the Dutch patients carry the common founder haplotype and 
strongly suggest that DM2 mutations in Europe and North-Africa originate from a single 
ancestral founder.
Finally, in Chapter 10 we describe the main findings and study limitations and we give 
suggestions for future research. The importance of a patient registry is underlined. We pay 
attention to the expecting increase in the amount of DM2 patients. There is enough ratio to 
believe that the incidence and prevalence of DM2 will strongly increase in the coming 
decade. We cannot exclude that DM2 will even become a more frequent disease than DM1 
in Europe.
To get answers on the remaining questions concerning the natural course of the disorder, 
anticipation, the unequal distribution of men and women unless the fact that DM2 is an 
autosomal dominant disorder, and therapeutic approaches of the disease, the discussion 
between basal and clinical researchers, as well as between researchers of different medical 
specialties, can be started.
134
Samenvatting
In dit proefschrift worden de resultaten van een nationale studie beschreven waarin we 
nieuwe klinische kenmerken, de genetica, spierecho-waarden en de gezondheidsstatus van 
volwassen patiënten met myotone dystrofie type 2 (DM2) hebben bestudeerd. De studie 
werd in 2007 gestart met als hoofddoel het fenotype van DM2 gedetailleerd te beschrijven, 
nadat in 2003 de eerste Nederlandse familie met DM2 werd gediagnosticeerd en genetische 
bevestiging van de aandoening mogelijk was.
In hoofdstuk 1 wordt een introductie en een historisch perspectief betreffende myotone 
dystrofieën (DM) gegeven. De hoogtepunten uit de ontdekkingsgeschiedenis van DM worden 
beschreven, waaronder de ontdekking van de verantwoordelijke genen voor DM1 en DM2 in 
respectievelijk 1992, en 2001. De pathofysiologie, de differentiaal diagnose en de 
behandeling van DM2 wordt besproken.
Hoofdstuk 2 beschrijft de eerste gediagnosticeerde Nederlandse familie met DM2.
In hoofdstuk 3 beschrijven we de resultaten van een cross-sectionele studie waarin door 29 
DM2 patiënten gestandaardiseerde vragenlijsten werden ingevuld betreffende symptomen 
van het gastro-intestinale systeem; als belangrijkste uitkomstmaten werden dysfagie, 
buikpijn, en obstipatie gekozen. We vergelijken de resultaten met deze van DM1 patiënten 
(klassieke type) en gezonde controle personen. Van de onderzochte groep DM2 patiënten 
rapporteerde 41% dysfagie voor vast voedsel, 38% dysfagie voor dranken, 62% buikpijn en 
eveneens 62% gaf aan last te hebben van obstipatie. Dit is veel vaker dan de gezonde 
controle populatie meldde, en vergelijkbaar met de uitkomsten van DM1 patiënten. 
Daarnaast werd bij 18 DM2 patiënten een markerstudie naar de passagesnelheid van de 
ontlasting in het colon uitgevoerd. De colonpassagetijd was toegenomen in 24% van de DM2 
patiënten. Concluderend toont de studie aan dat gastro-intestinale symptomen vaak 
voorkomen bij DM2 patiënten, ziekte-gerelateerd zijn, en kunnen optreden in elk deel van het 
maag- en darmstelsel.
Hoofdstuk 4 beschrijft de vervolgstudie op hoofdstuk 3. Van de 12 DM2 patiënten die 
slikklachten rapporteerden op de vragenlijst betreffende symptomen van het gastro­
intestinale systeem namen 10 patiënten deel aan het onderzoek. Doel was om de 
aanwezigheid van slikklachten in DM2 objectief te onderzoeken. De score op de Dysphagia 
Outcome and Severity Scale (DOSS) werd als uitkomstmaat gekozen (uitkomst 1-7). De 
uitkomst was gebaseerd op orofaciaal onderzoek uitgevoerd door een logopedist 
gespecialiseerd in neuromusculaire ziekten, en analyse van het slikken middels 
fiberoptische endoscopische evaluatie van de slikfunctie. De DOSS score van de patiënten 
varieerde van 4 (milde-matige dysfagie) tot 6 (dysfagie binnen functionele grens). Een 
correlatie tussen de ernst van de slikklachten en de leeftijd werd gevonden. Geen van de
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patiënten had ondergewicht, en geen van hen had een aspiratiepneumonie doorgemaakt in 
het verleden. We concludeerden dat dysfagie voorkomt in DM2, en ernstiger aanwezig is bij 
oudere patiënten. Over het algemeen zijn slikstoornissen in DM2 in milde mate aanwezig, en 
leiden niet tot gewichtsverlies of tot een aspiratiepneumonie.
In hoofdstuk 5 werd de kwaliteit van slaap, en de symptomen vermoeidheid, en overmatige 
slaperigheid overdag gemeten bij DM2 patiënten, DM1 patiënten (klassieke type) en in de 
algemene bevolking. We gebruikten de PSQI, de ESS en de CIS-fatigue als 
meetinstrumenten. Overmatige slaperigheid kwam slechts in 6.9% van de DM2 patiënten 
voor, vergelijkbaar met de uitkomst in de algemene bevolking (6.2%), tegenover 44.8% in de 
DM1 groep. De kwaliteit van slaap was laag in zowel de DM2 als DM1 groep, terwijl deze 
onder de algemene bevolking normaal was. De verminderde slaapkwaliteit in DM2 was 
grotendeels te verklaren door problemen met slapen tengevolge van pijn, en kon niet 
verklaard worden door depressie of andere comorbiditeit. In vergelijkbare ernst met de DM1 
groep ervaarden DM2 patiënten extreme vermoeidheid. Deze uitkomsten werden niet 
beinvloed door schildklierpathologie of door medicatiegebruik in deze groepen. We 
concludeerden dat door de herkenning van vermoeidheid en slaapstoornissen het fenotype 
van DM2 uitbreidt, en dat de afwezigheid van overmatige slaperigheid overdag een nieuw 
discriminatief kenmerk is tussen DM2 en DM1.
In hoofdstuk 6 werd onder 29 DM2 patiënten de gezondheidsstatus gemeten, waarbij 
gezondheidsstatus wordt gedefinieerd als de impact van een ziekte op het gebied van fysiek, 
psychologisch en sociaal functioneren. Dit gebeurde met de SF-36 als meetinstrument. Deze 
vragenlijst meet kwaliteit van leven op 8 gebieden: fysiek functioneren, rolbeperkingen door 
fysieke gezondheidsproblemen, lichamelijke pijn, ervaren gezondheid, vitaliteit, sociaal 
functioneren, rolbeperkingen door emotionele problemen en geestelijke gezondheid. De 
scores werden vergeleken met die van 29 DM1 patiënten (klassieke type) en met die van de 
algemene bevolking. Daarnaast bepaalden we de relatie tussen gezondheidsstatus en pijn 
(gemeten middels de MPQ) en vermoeidheid (gemeten middels de CIS-fatigue). De 
resultaten toonden dat DM2 patiënten significant lager scoorden op 7 van de 8 gebieden van 
de SF-36 ten opzichte van de algemene bevolking. SF-36 scores in DM2 waren vergelijkbaar 
met deze van DM1 patiënten voor alle gebieden, met uitzondering van lichamelijke pijn; hier 
scoorden DM2 patiënten lager op, wat duidt op meer pijn in DM2. De ernst van de pijn in de 
DM2 groep correleerde met de SF-36 score lichamelijke pijn en met vermoeidheid. 
Vermoeidheid correleerde met fysiek functioneren, ervaren gezondheid, en vitaliteit. We 
concludeerden dat de impact van DM2 op het gebied van fysiek, psychologisch en sociaal 
functioneren aanzienlijk is en tenminste vergeleken kan worden met deze van DM1 
patiënten. Symptomatische behandeling van pijn en vermoeidheid kunnen mogelijk de 
gezondheidsstatus in DM2 verbeteren.
Hoofdstuk 7 is een uiteenzetting naar aanleiding van onze klinische impressie ontstaan 
tijdens de eerdere studies dat er een verband leek te bestaan tussen DM2 en het optreden
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van autoimmuunziekten. Om deze hypothese nader te onderzoeken werd een cross- 
sectionele cohort studie opgezet. We onderzochten 28 DM2 patiënten, afkomstig van 10 
families, en 51 DM1 patiënten (klassieke type) van 42 families. Doel van de studie was de 
frequentie van autoimmuunziekten en serum autoantilichamen te onderzoeken, in 
vergelijking met het voorkomen in DM1. Als primaire uitkomstmaat werd de aanwezigheid 
van een autoantilichaam of autoreactieve T cell geassocieerde autoimmuunziekte genomen. 
Als tweede uitkomstmaat werd de aanwezigheid van serum autoantilichamen (nucleair en 
non-nucleair) onderzocht in alle patiënten. Het voorkomen van autoimmuunziekten (21% 
versus 2%) en autoantilichamen (25% versus 2%) waren beiden significant hoger in DM2 
patiënten vergeleken met DM1. De resultaten werden niet beinvloed door familiaire 
clustering, medicatiegebruik, roken, leeftijd of geslacht. Mogelijke verklaringen voor de 
gevonden associatie tussen DM2 en autoimmuunziekten worden besproken.
Beeldvormend onderzoek van skeletmusculatuur in DM2 was voor de verschijning van dit 
proefschrift verricht in één MRI-studie, waarin 14 DM2 patiënten deelnamen. De conclusie 
van de studie luidde dat MRI geen betrouwbare indicator is voor het meten van de 
betrokkenheid van skeletspieren in mild-aangedane DM2 patiënten (Kornblum et al., 2006). 
In hoofdstuk 8 beschrijven we een studie waarin middels spierechografie de echo-intensiteit 
en spierdikte werd onderzocht van een zevental skeletspieren (m. masseter, 
bovenarmflexoren (m. biceps brachii en m. brachialis) en onderarmflexoren beiderzijds, m. 
rectus femoris en m. tibialis anterior) van 31 DM2 patiënten en 31 DM1 patiënten (klassieke 
type). Daarnaast werd gekeken of de echo-intensiteit correleerde met de leeftijd, met 
kwantitatief gemeten spierkracht en met het spierenzym (CK). De belangrijkste 
studiebevinding in de DM2 groep betreft een verhoogde spierecho-intensiteit, welke in de 
literatuur gecorreleerd is aan spierfibrose en / of vervetting van de spier, in alle onderzochte 
spieren. De spierdikte was significant afgenomen in de proximale armspieren in DM2 in 
vergelijking met de DM1 groep, wat correleert met de klinische bevindingen. Atrofie werd 
gemeten in een deel van de DM2 patiënten in de m. masseter (23%), de m. rectus femoris 
(23%) en in de m. biceps brachii (19%). De somscore van de echo-intensiteit in DM2 
correleert negatief met de gemeten spierkracht, en correleert positief met de leeftijd, wat het 
progressieve beloop van de aandoening ondersteunt. Spierechografisch onderzoek blijkt 
een betrouwbare techniek voor kwantitatieve bepaling van de echo-intensiteit en spierdikte in 
myotone dystrofieën, en kan mogelijk in de toekomst ook worden ingezet in prospectieve 
studies naar het natuurlijk beloop van myotone dystrofieën en de resultaten van 
behandelingsstrategieën.
In hoofdstuk 9 worden de resultaten van de genetisch analyse van 40 Nederlandse DM2 
patiënten afkomstig van 16 families beschreven. Doel van de studie was om te onderzoeken 
of de Nederlandse DM2 populatie, inclusief een familie welke oorspronkelijk afkomstig is uit 
Marokko, hetzelfde haplotype draagt als het bekende Europese haplotype. De resultaten 
werden vergeleken met eerder gepubliceerde haplotypes van niet-gerelateerde Caucasische 
DM2 patiënten. De repeatlengte van acht ‘short tandem repeat markers’ rondom het ZNF9
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gen geidentificeerd in de Nederlandse populatie kwam overeen met de repeatlengte eerder 
in de literatuur beschreven. Daarnaast werd het ‘single nucleotide polymorphism‘ (SNP) rs 
1871922 welke gelokaliseerd is in intron 1 gegenotypeerd. In 36 patiënten identificeerden we 
de bekende haplotypes A, B en C. Het haplotype van de familie van Marokkaanse afkomst 
toonde overlap met het haplotype van patiënten van Europese afkomst voor een regio van 
222kb. Alle 40 patiënten droegen tenminste één C allel van het SNP rs 1871922, wat 
aanduidt dat alle DM2 patiënten het bekende Europese haplotype dragen. We 
concludeerden dat Nederlandse DM2 patiënten, inclusief een Noord-Afrikaanse familie, 
hetzelfde haplotype rondom het ZNF9 gen dragen, wat er sterk op wijst dat de DM2 mutaties 
in Europa en in Noord-Afrika van eenzelfde oorsprong zijn.
Tenslotte worden in hoofdstuk 10 de belangrijkste bevindingen en enkele beperkingen 
besproken en er worden suggesties gedaan voor toekomstig onderzoek. Het belang van een 
goede organisatie middels een patiëntregister wordt onderstreept en is in Nederland gelukkig 
verwezenlijkt in de CRAMP database. De te verwachten toename van het aantal 
gediagnosticeerde DM2 patiënten wordt onder de aandacht gebracht. Er is voldoende ratio 
om aan te nemen dat de incidentie en de prevalentie van DM2 de komende decade sterk 
gaan stijgen, waarbij het niet uit te sluiten is dat DM2 zelfs een meer frequente aandoening 
zal worden dan DM1 in Europa.
Om antwoorden te krijgen op de openstaande vragen met betrekking tot het natuurlijk beloop 
van de ziekte, anticipatie van de aandoening, de ongelijke man -  vrouw verhouding ondanks 
het gegeven dat DM2 een autosomaal dominante aandoening is, en therapeutische 
benaderingen van de ziekte, kan de discussie worden geopend tussen basale en klinische 
onderzoekers, alsook tussen onderzoekers van verschillende medische specialismen.
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Abbreviations
ALAT alanine aminotransferase
ANA anti-nuclear antibodies
ANCOVA analysis of covariance
ANOVA analysis of variance
ASAT aspartate aminotransferase
BDI-pc Beck depression inventory for primary care
BMI body mass index
C cytosine
CCP anti-cyclic citrullinated peptide
CI confidence interval
CIS checklist individual strength
CK creatine kinase
CNS central nervous system
CRAMP computer registry of all myopathies and polyneuropathies
CT computed tomography
CTT colon transit time
DM1 myotonic dystrophy type 1
DM2 myotonic dystrophy type 2
DMPK dystrophica myotonica protein kinase
DNA deoxyribonucleic acid
DOSS dysphagia outcome and severity scale
ECG electrocardiogram
EDS excessive daytime sleepiness
EMG electromyography
ENMC European neuromuscular centre
ESS Epworth sleepiness scale
FEES fiberoptic endoscopic evaluation of swallowing
G guanosine
GSQ gastrointestinal symptoms questionnaire
y-g t Y-glutamyltransferase
LDH lactate dehydrogenase
MIRS muscular impairment rating scale
MPQ McGill pain questionnaire
MRC medical research council
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
OMIM online mendelian inheritance in man
PCR polymerase chain reaction
PMD proximal myotonic dystrophy
PROMM proximal myotonic myopathy
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PSQI Pittsburgh sleep quality index
SD standard deviation
SF-36 36 item short form health survey
SNP single nucleotide polymorphism
T thymine
U uracil
US ultrasound
VAS visual analogue scale
VSN vereniging spierziekten Nederland
ZNF9 zinc finger protein 9
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Geographic distribution of PROMM / DM2 patients throughout the world as reported in literature. Relevant countries 
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Slovakia, France, Italy, Spain, Morocco, Algeria, Lebanon, Afghanistan, Sri Lanka and Japan).
14
2
List of publications
Tieleman AA, Vinke A, van Alfen N, van Dijk HP, Pillen S, van Engelen BG. Skeletal muscle 
involvement in myotonic dystrophy type 2. A comparative muscle ultrasound study. Submitted
Tieleman AA, Jenks KM, Kalkman JS, Borm G, van Engelen BG. High disease impact of 
myotonic dystrophy type 2 on physical and mental functioning. J Neurol 2011;doi: 
10.1007/s00415-011-6027-8.
Coenen MJ, Tieleman AA, Schijvenaars MM, Leferink M, Ranum LP, Scheffer H, van 
Engelen BG. Dutch myotonic dystrophy type 2 patients and a North-African DM2 family carry 
the common European founder haplotype. Eur J Hum Genet 2011;19:567-70.
Tieleman AA, Knoop H, van de Logt AE, Bleijenberg G, van Engelen BG, Overeem S. Poor 
sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. 
J Neurol Neurosurg Psychiatry 2010;81:963-7.
Tieleman AA, den Broeder AA, van de Logt AE, van Engelen BG. Strong association 
between myotonic dystrophy type 2 and autoimmune diseases. J Neurol Neurosurg 
Psychiatry 2009;80:1293-5.
Tieleman AA, Knuijt S, van Vliet J, de Swart BJ, Ensink R, van Engelen BG. Dysphagia is 
present but mild in myotonic dystrophy type 2. Neuromuscul Disord 2009;19:196-8.
Tieleman AA, van Vliet J, Jansen JB, van der Kooi AJ, Borm GF, van Engelen BG. 
Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. Neuromuscul Disord 
2008;18:646-9.
Tieleman AA, van der Vliet TA, Vos PE. Two first-degree relatives with perimesencephalic 
nonaneurysmal hemorrhage. Neurology 2006;67:535-6.
Tieleman AA, van der Velden MP, Visser MC, Wokke JH, Scheffer H, van Engelen BG.
8. Four family members with proximal myotonic myopathy. Ned Tijdschr Geneeskd 
2004;148:948-52.
Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4- 
phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic 
axons in aged mice. Brain Res 1998;783:109-14.
143
Dankwoord
Mijn dank gaat in de eerste plaats uit naar de mensen met de aandoening myotone dystrofie 
type 2. Het samenwerken met jullie bracht voortdurend nieuwe onderzoeksvragen naar 
boven. Ik heb veel van jullie geleerd, en hoop op deze wijze iets terug te kunnen doen als 
dank voor de inzet en vastberadenheid die jullie toonden.
Naast de manuscriptcommissie en mijn mede-auteurs bedank ik graag iedereen die me de 
afgelopen jaren op diverse manieren heeft geholpen met het onderzoek. Een paar personen 
wil ik graag met name noemen.
George Padberg, mijn opleider. Ik wil u bedanken voor de vrijheid die u me gaf als 
beginnend wetenschapper.
Baziel van Engelen, mijn promotor. ‘Geen onderzoekstijd, geen onderzoeksgeld, en 100 
andere belangrijke zaken’, en na elk overleg met jou ging ik weer enthousiast verder.
Beste Baziel, ik bewonder je talent voor coaching ! Dank voor de geslaagde samenwerking, 
waarvan dit proefschrift het resultaat is.
Nens van Alfen. Nens, je had een belangrijke rol bij de start van mijn onderzoek. Dank je 
wel voor je luisterend oor en sterke vragen die altijd tot nadenken stemden.
George Borm. George, het filosoferen over de statistiek heb ik als verrassend leuk aspect 
van onderzoek doen ervaren. Dank voor je beschikbaarheid.
Ik wil de studenten met wie ik onderzoek deed of nog steeds doe hartelijk bedanken voor 
hun hulp en inzet; Judith van Vliet, Anne-Els van de Logt en Anita Vinke. Judith, ik vind het 
leuk dat je nu mijn paranimf wilt zijn. Ik kijk uit naar het vervolgonderzoek in de nabije 
toekomst.
Mijn collega’s in het Maasziekenhuis Petra Poels, Dirk Pröpper en Raymond Roebroek wil ik 
bedanken; jullie maakten het me mogelijk dit proefschrift af te ronden.
Beste Rijnsmeiden, we leven niet meer zo zorgeloos en onbezonnen als in onze 
studentenjaren, maar het plezier samen en de verwondering blijft. Ann, Hannes, A3, Wieny 
en Daan, veel dank voor jullie aanwezigheid in mijn leventje. Ik verkeer in goed gezelschap 
bij jullie.
Elske, je creativiteit en levensplezier blijven goed doen, ook in de taaie tijden. Dank dat je 
me ook vandaag bijstaat, als paranimf.
144
Lieve Henny, wat een Geluk dat jij op ons Nijmeegse pad kwam. Dank voor alle goede 
zorgen voor ieder van ons vijf. En....het beste komt nog !
Lieve pap en mam, jullie hebben ons kinderen altijd met veel aandacht, interesse en 
vertrouwen opgevoed, en zijn met hart en ziel beschikbaar. Veel dank hiervoor. Deze tijdloze 
kwaliteiten geven Floris en ik graag weer door aan ónze kinderen.
‘Mam, wordt dit je proefschrift?
Moet je dan alles weer opnieuw typen? (Lauke, december 2010)
Lieve Maxim, Jolijn en Lauke. Het boekje is klaar ! Dat betekent extra tijd voor ‘Dummie de 
mummie’, quatre-mains, schaatsen, muffins bakken, wandelen en kamperen. Heerlijk ! 
Pakken jullie de tentjes alvast?
Lieve Floris, heel veel dank, voor nabijheid en ruimte, liefde en strijd, maar bovenal voor je 
krachtige en liefdevolle steun. Ik vind het een zegen en feest mijn leven met je te delen.
Voor nu: op naar hoge bergen en koele m eren .
145
146
Curriculum vitae
Alide Annette Tieleman was born on July 15th, 1968 in Oegstgeest. She attended secondary 
school at the Visser ’t Hooft College in Leiden. She studied physical therapy from 1987 to 
1991 at the Hogeschool Leiden. She subsequently started working as a physical therapist in 
'Sandhaeghe', a paediatric institute for physically and mentally handicapped children, in 
addition to working in a private practice. She studied medicine from 1992 to 1999 at the 
University of Leiden. As part of her medical studies, she did internships at the Queen 
Elizabeth Hospital, Barbados, University of the West Indies and at the Parirenyatwa Hospital 
and St. Michaels Mission Hospital in Zimbabwe. She participated as a student in research 
projects supervised by Prof. dr. M.D. Ferrari, department of Neurology, Leiden. The main 
focus of her work was on the clinical efficacy and pharmacology of acute antimigraine drugs. 
She left The Netherlands in 1996 to work as a research-physician at the University of 
California, San Diego, department of Neurosciences. The project in which she participated 
focussed on the effect of Coenzyme Q10 on 6-hydroxydopamine-induced Parkinsonism in 
mature rats. She obtained her medical degree in February 1999.
In that same year, she started her neurology training at the department of Neurology at the 
Radboud University Medical Centre Nijmegen (Prof. dr. G.W.A.M. Padberg and Prof. dr. M. 
J. Zwarts). Registration as a neurologist took place in 2007. The PhD studentship on 
myotonic dystrophy type 2 that resulted in this thesis started in that same year. Part of the 
research was awarded with the Elseviers Award of the World Muscle Society.
She has worked as a neurologist at the Maasziekenhuis, Beugen since 2009 and as a guest 
lecturer at the Hogeschool Arnhem Nijmegen since 2006. In addition, she is engaged in the 
supervision of scientific research into myotonic dystrophy type 2 at the Radboud University 
Medical Centre Nijmegen.
Alide is married to Floris van Delft and their lives are enriched with three children: Maxim, 
Jolijn and Lauke. Family life is extended by lovely (grand)parents and friends.
147
148
How often people speak of art and science as though they were two entirely different 
things, with no interconnection.
An artist is emotional, they think, and uses only his intuition;
He sees all at once and has no need of reason.
A scientist is cold, they think, and uses only his reason;
He argues carefully step by step, and needs no imagination.
That is all wrong.
The true artist is quite rational as well as imaginative and knows what he is doing; 
if he does not, his art suffers.
The true scientist is quite imaginative as well as rational, and sometimes leaps to 
solutions where reason can follow only slowly; if he does not, his science suffers.
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